user_input,reference_contexts,reference,synthesizer_name,answer,source_content,source_document_info
"Whats the neuro status of the pashent with systmic murmer at RUSB, especaily ther alertness and cranial nerve intactness?","['0070a23b-dc9f-483f-a66d-a8d84a4b995b\n\nCARDIOVASCULAR: Regular rate and rhythm with late ___ systolic\nmurmur at RUSB, no rubs or gallops\nLUNGS: clear to auscultation bilaterally without rhonchi,\nwheezes, or crackles\nGI: soft, nontender, without rebounding or guarding, \nnondistended\nwith normal active bowel sounds, no hepatomegaly\nEXTREMITIES: no clubbing, cyanosis, or edema\nGU: no foley\nSKIN: no rashes, petechia, lesions, or echymoses; warm to\npalpation\nNEURO: Alert and interactive to person, ___ (daughters\nstated that this is a hospital before pt named it), ___, but\nthinks that it is ___, cranial nerves II-XII intact, strength \nis\n___ in RUE, RLE, LLE, ___ in LUE elbow flexion/extension and\nhand grip. Gait is WNL, negative Romberg, negative pronator\ndrift.\nPSYCH: normal mood and affect\nDISCHARGE EXAM\nVS: 97.9 PO 151 / 65 64 18 99 RA \nGEN: Alert and interactive, comfortable, no acute distress\nHEENT: PERRL, anicteric, conjunctiva pink, oropharynx without\nlesion or exudate, moist mucus membranes, ears without lesions \nor', '688ac351-3658-4804-8bb2-2bd5b3e5aaac\n\nEXTREMITIES: 2+ pitting edema bilaterally in lower extremities.\nPulses 2+ bilaterally. \nNEURO: Alert & oriented x3. Non-focal neuro exam.\nDISCHARGE PHYSICAL EXAMINATION:  \n===============================\n24 HR Data (last updated ___ @ 809)\n    Temp: 98.1 (Tm 99.0), BP: 168/75 (142-168/69-79), HR: 88\n(87-95), RR: 18 (___), O2 sat: 97% (94-97)  \n___ Total Intake: 720ml PO Amt: 720ml \n___ Total Output: 1100ml Urine Amt: 1100ml \nFluid balance: -380\n___ Total Intake: 180ml PO Amt: 180ml \n___ Total Output: 900ml Urine Amt: 900ml \nFluid balance: -720\nGENERAL: Sitting up comfortably at edge of bed, in NAD\nHEENT: NC/AT\nNECK: Supple. unable to appreciate JVD at 90 degrees\nCARDIAC: RRR, no rubs/gallops\nLUNGS: Faint bibasilar crackles on auscultation\nABDOMEN: Soft, NTND\nEXTREMITIES: 2+ pitting edema bilaterally to knees in ___. Pulses\n2+ bilaterally. WARM']","The patient is Alert and interactive to person, with some memory or recognition issues (as indicated by the patient initially not naming the hospital correctly but later doing so). The patient thinks it is a different time/frame than actual (exact details not specified). Cranial nerves II-XII are intact. Strength is noted as being 5/5 in Right Upper Extremity (RUE), Right Lower Extremity (RLE), Left Lower Extremity (LLE), and 4/5 in Left Upper Extremity (LUE) for elbow flexion/extension and hand grip. Gait is Within Normal Limits (WNL), with a negative Romberg and negative pronator drift.",custom_multi_hop_query_synthesizer,"Based on the provided documents, here's the answer to the question about the neuro status of the patient, focusing on alertness and cranial nerve intactness, particularly in relation to the systolic murmur mentioned (note: the murmur's location is mentioned as ""RRR, systolic murmur, normal S1, S2"" in Document 1, without specifying ""RUSB"", which might be a typographical error in the question since ""RUSB"" is not a standard abbreviation for heart sound locations):

### Answer to Neuro Status Question:

- **Patient/Subject ID:** 13180007 (Consistent across all documents: Document 1, Document 2, Document 3, Document 4, Document 5)
- **Alertness:**
  - **Document 1 (ED Assessment):** ""Neuro-A&O x3"" indicates the patient is Alert and Oriented to person, place, and time.
  - **Document 2 (Discharge Physical Exam) and Document 3 (Admission Physical Exam):** Both mention ""Mood, affect appropriate"" and in Document 3, ""Oriented x3"", reinforcing the patient's alertness.
- **Cranial Nerve (CN) Intactness:**
  - **Document 1 (ED Assessment):** ""CN ___ intact"" - Unfortunately, the specific cranial nerves checked are not listed, but it indicates intactness of the ones examined.
  - **Document 2 and Document 3:** Do not provide specific details on cranial nerve examination in the provided snippets.

### Additional Relevant Information:

- **Systolic Murmur Location:** Not explicitly stated as ""RUSB"" in any document; Document 1 mentions a systolic murmur without specifying location beyond ""CV- RRR, systolic murmur, normal S1, S2"".
- **Consistency of IDs:** The Patient/Subject ID, Note ID, and Admission ID are consistent across all provided documents, indicating they pertain to the same patient event.

### Limitations in Answering:

- The question's reference to ""RUSB"" for the murmur's location does not match any standard medical abbreviation for heart sound locations (e.g., RUSB is not a recognized location like ""PMI - Point of Maximum Impulse"").
- Specific cranial nerve examination details are not fully provided in the documents, limiting a detailed response on CN intactness.","['In the ED:  \nInitial VS: T 98.5, HR 102, BP 178/76, RR 22, SpO2 98% RA \n \nExam:\nGeneral- NAD\nHEENT- PERRL, EOMI, normal oropharynx\nLungs- Non-labored breathing, CTAB\nCV- RRR, systolic murmur, normal S', 'DISCHARGE PHYSICAL EXAM\n=======================\nGENERAL: NAD. Mood, affect appropriate.  \nHEENT: Normocephalic atraumatic. Sclera anicteric. EOMI.\nConjunctiva were pink. No pallor or cyanosis of the o', 'Social History:\n___\nFamily History:\nHis parents have heart disease.  Mother is ___ with heart \nproblems\nand diabetes.  Father, ___, with diabetes.  He has 16 brothers \nand\nsisters.  There is no known ', '___ 09:01AM BLOOD WBC-4.8 RBC-2.88* Hgb-7.4* Hct-24.0* \nMCV-83 MCH-25.7* MCHC-30.8* RDW-16.1* RDWSD-48.5* Plt ___\n___ 09:01AM BLOOD Neuts-78.5* Lymphs-12.1* Monos-7.5 \nEos-1.3 Baso-0.4 Im ___ AbsNeut-', 'Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
What were the initial presentation and immediate interventions for the patient with acute Heart Failure with preserved Ejection Fraction (HFpEF) exacerbation in the Emergency Department (ED)?,"['595bbed3-a542-444b-b48a-e6edf79ac096\n\nHistory of Present Illness:\n___ year old man with numerous cardiac risk factors, prior CVA\npresented with sudden onset worsening of subacute dyspnea found\nto have flash pulmonary edema admitted for acute HFpEF\nexacerbation. \n Per EMS and confirmed with family, patient was found on the\ncouch by his family was minimally responsive. Patient described\nsubacute shortness of breath over the last two weeks (e.g.,\nhaving to sit down multiple times when going to grocery store or\nup steps at home).  He has also had a cough, rhinorrhea but no\nfever, no sputum.  This worsened acutely this morning when he\nwoke-up struggling to breath.  EMS was called, SBP to 176 per ED\ndocumentation, patient was given nitro x2 and started on CPAP. \n In the ED, he was started on bipap diuresed with OV Lasix,\nstarted on home BP medications and then transferred to floor. \n - Initial vitals: HR 109 BP 176/67 RR 26 ___ 90, patient was\ntachypneic, unable to speak in full sentences, crackles L>R, no\nfocal deficits\n - EKG:  not commented upon\n - Labs/studies notable for: Patient was given: NG x2. Lasix IV\n40mg (at 4:30am), Zosyn/Vanc  \n Amlodipine 10mg, Carvedilol 25mg, Lisinopril 2.5mg,\nlevothyroxine, insulin 10U regular,  \n - Vitals on transfer:  ___ 1040 Temp: 98.4 PO BP: 115/45 R', ""a6e734ef-1c30-4cb6-ba6d-41227251d4d0\n\nWhen he came home to ___, he apparently thought that he was\nstill in ___, confused his wife for his daughter. On\n___ morning, he fell again. He was confused about the\nconfiguration of the bathroom (no tub in bathroom in PR), so he\ntripped and fell, called his daughter in tears (he often gets\nemotional since his CVA). She booked an appointment for same \nday,\nat which his FSBG>500, HbA1c (point of care, not in OMR) was\n15.0%. He declined to be transferred to the ED. Daughter ___\nwas on vacation from work, and so was able to check on him\nregularly. During these visits, she again established that he is\nnot taking prescribed medications. On the morning of\npresentation, pt's wife called daughter ___, concerned that \npt\nwas increasingly confused. FSBG was >500, and administered\nTresiba 50u at about 8 am. Pt called ___ about 15 minutes\nlater, at which time she again noted confusion and slurred\nspeech, which has intermittently been present since his CVA.\nDecision was made to bring him to the ED. \nOf note, during his last hospitalization ___, he had an\nepisode of dysarthria with confusion and mild expressive and\nreceptive aphasia for which code stroke was called. MRI/MRA \nbrain\nand EEG were unrevealing, with chronic changes and EEG slowing\nonly. He was continued on ASA and atorvastatin.""]","The patient, a man with numerous cardiac risk factors and a prior CVA, presented to the ED with sudden onset worsening of subacute dyspnea, leading to flash pulmonary edema. Initial vitals in the ED showed HR 109, BP 176/67, RR 26, with the patient being tachypneic. Immediate interventions included administration of nitro x2 by EMS, initiation of CPAP, which was later switched to BiPAP in the ED, diuresis with IV Lasix (40mg), and the continuation of home BP medications (Amlodipine 10mg, Carvedilol 25mg, Lisinopril 2.5mg).",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Patient Identification:**
* **Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, Document 2, Document 3, Document 4, Document 5)
* **Note ID:** 13180007-DS-19 (consistent across all documents)
* **Admission ID:** 20774429 (consistent across all documents)

**Initial Presentation in the ED (Extracted from Document 5):**
* **Chief Complaint (from Document 3 for context, but primarily answering from Document 5):** Dyspnea and chest pain (Document 3 mentions ""dyspnea on exertion and chest discomfort on exertion"")
* **Initial Vital Signs (VS) in the ED (Document 5):**
	+ Temperature (T): 98.5
	+ Heart Rate (HR): 102
	+ Blood Pressure (BP): 178/76
	+ Respiratory Rate (RR): 22
	+ Oxygen Saturation (SpO2): 98% on Room Air (RA)
* **Notable Initial Exam Findings (Document 5):**
	+ General: NAD (No Acute Distress)
	+ Lungs: Non-labored breathing, Clear To Auscultation Bilaterally (CTAB)
	+ CV: Regular Rate and Rhythm (RRR), systolic murmur, normal S1, S2
	+ Msk: 2+ edema
* **Notable Initial Labs and Studies (Document 5):**
	+ Hemoglobin (Hgb): 7.4
	+ Chemistry: Blood Urea Nitrogen (BUN) 39, Creatinine (Cr) 2.6
	+ proBNP: 784
	+ Troponin (TropT): 0.03
	+ EKG: T-wave inversion (TWI) in lateral leads
	+ CXR: Mild pulmonary vascular congestion with small bilateral pleural effusions, left greater than right

**Immediate Interventions in the ED (Extracted from Document 5):**
* **Medications Administered:** IV Lasix 80mg
* **Vitals on Transfer (post-intervention, Document 5):**
	+ T: 97.3
	+ HR: 88
	+ BP: 120/54
	+ RR: 18
	+ SpO2: 98% RA","['ACUTE PROBLEMS\n==============\n# Acute on chronic HFpEF: \nPatient presented with dyspnea and lower extremity edema and\nfound to be volume overloaded on exam. Warm and wet on exam.\nTrigger for HF exacer', 'DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'In the ED:  \nInitial VS: T 98.5, HR 102, BP 178/76, RR 22, SpO2 98% RA \n \nExam:\nGeneral- NAD\nHEENT- PERRL, EOMI, normal oropharynx\nLungs- Non-labored breathing, CTAB\nCV- RRR, systolic murmur, normal S']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
"Whats the relevent med list for DM managment in a pateint with Hx of CAD, ischemic CVA, CKD, and Hypothyroidism, with med speling dont mater?","['8c0badb1-fe3b-4585-8010-1ef4ba8fdd98\n\n================\n# Hx of CAD \n# Hx of ischemic CVA\nStress test in ___ with area of inducible ischemia in LCx \ndistribution. Trop peaked at 0.06 (iso CKD) and then \ndowntrended. No EKG changes seen. Continued home carvedilol, ASA \nand high dose atorvastatin. \n# CKD: Cr at presentation close to baseline. Underlying etiology \nlikely combination of HTN, DM. \n# Hypothyroidism: Continued home levothyroxine 100 mcg daily\n \nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Furosemide 40 mg PO 3X/WEEK (___) \n2. sevelamer CARBONATE 800 mg PO TID W/MEALS \n3. Minoxidil 2.5 mg PO DAILY \n4. Levothyroxine Sodium 100 mcg PO DAILY \n5. CARVedilol 37.5 mg PO BID \n6. amLODIPine 10 mg PO DAILY \n7. Albuterol Inhaler 2 PUFF IH Q6H \n8. Jardiance (empagliflozin) 10 mg oral DAILY \n9. Victoza 3-Pak (liraglutide) 1.2 mg subcutaneous DAILY', '8d31665e-700b-4b64-8af5-51456ad55ff5\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-140 \nK-4.6 Cl-99 HCO3-25 AnGap-16\n___ 06:35AM BLOOD Calcium-8.4 Phos-6.0* Mg-2.1\n \nBrief Hospital Course:\nSUMMARY\n=======\n___ male with history of HFpEF (EF 55-60% in ___,\nprior CVA, CKD, DM, hypertension, and carotid artery disease\nwho presented with 1 day of dyspnea and discomfort, and was\nadmitted for HF exacerbation. The trigger was unclear, possible \nmedication non-compliance. He was diuresed with several doses of \nIV Lasix 80 and by time of discharge symptoms had improved. He \nwas still slightly volume up on exam, with JVP ~12 and 1+ edema \nto ankles.\nTRANSITIONAL ISSUES\n===================\n[ ] At discharge his symptoms associated with volume overload \nhad subsided, but he was still slightly volume up on exam with \n1+ edema to ankles bilaterally and JVP of 12cm. He is being \ndischarged on torsemide 100 daily for active diuresis, with \nabout 3lb of fluid still left to lose.']","Based on the provided context, for a patient with a history of CAD, ischemic CVA, CKD, Hypothyroidism, and specifically focusing on Diabetes Mellitus (DM) management, the relevant medications from the admission list are:  1. **Jardiance (empagliflozin) 10 mg oral DAILY** - an SGLT2 inhibitor used in the treatment of type 2 diabetes. 2. **Victoza 3-Pak (liraglutide) 1.2 mg subcutaneous DAILY** - a GLP-1 receptor agonist used for type 2 diabetes management. Additionally, medications indirectly beneficial for DM management due to their effects on related conditions include: - **CARVedilol 37.5 mg PO BID** and **amLODIPine 10 mg PO DAILY** for hypertension, a common comorbidity with DM. - **sevelamer CARBONATE 800 mg PO TID W/MEALS** for CKD, which can be influenced by DM management.",custom_multi_hop_query_synthesizer,"Based on the provided documents, I'll answer the question following the instructions:

**Relevant Med List for DM Management in a Patient with:**

* **Hx of CAD:** Not explicitly confirmed (Document 4 suggests no known history of CAD, but risk factors are mentioned)
* **Ischemic CVA (History of CVA):** Confirmed (Documents 1, 2)
* **CKD (Chronic Kidney Disease):** Confirmed (Document 4)
* **Hypothyroidism:** Confirmed (Documents 1, 2)

**Patient/Subject ID:** `13180007` (consistent across all documents: **Document 1**, **Document 2**, **Document 3**, **Document 4**, **Document 5**)

**Relevant Medications for Diabetes Management (DM) from the Provided Documents:**

1. **Insulin:**
	* **70/30 Insulin:**
		+ 30 Units with Breakfast (Documents 1, 3)
		+ 10 Units with Lunch (Documents 1, 3)
	* **Lantus 30u:** Mentioned as given on the night of admission (Document 2), but not listed in discharge medications.
2. **Other Diabetes-Related Medications:**
	* **Victoza (Liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) subcutaneous DAILY:** (Documents 1, 3)

**Medications Relevant to Comorbid Conditions (not exclusively for DM but important for overall management):**

1. **For Hypothyroidism:**
	* **Levothyroxine Sodium 100 mcg PO DAILY** (Documents 1, 2, 3)
2. **For CKD (and other conditions):**
	* **Sevelamer CARBONATE 800 mg PO TID W/MEALS** (Documents 1, 3)
3. **For History of CVA and CAD Risk Factors:**
	* **Aspirin 81 mg PO DAILY** (Documents 1, 3, 4)
	* **Atorvastatin 80 mg PO QPM** (Documents 1, 3, 4)

**Note on Medication Spelling:** As per your instruction, medication spelling variations were not a concern for this response. All medications are listed as they appeared in the documents.","['CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', '# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n', 'Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
Whats the comon complictions of uncontrolld DM2 in patiants with exsisting CVA and HTN?,"['2574c42a-a6ef-418e-ac90-a21855611d18\n\npulmonary edema. No pneumonia, no pneumothorax.  The lateral \nradiograph shows mild flattening of the hemidiaphragms, \npotentially as a consequence of functional obstruction.\n___ CT HEAD -\n1. No evidence of acute intracranial abnormality.\n2. Unchanged appearance of chronic infarcts within the right \nfrontal lobe and left occipital lobe.\n3. Chronic lacunar infarcts within the right basal ganglia.\n4. Re-demonstration of few calcifications within the pons, \nfindings which are unchanged in appearance and likely sequela of \nprior ischemic or inflammatory process.\nMICRO:\n___ 3:38 pm URINE\n                            **FINAL REPORT ___\n   URINE CULTURE (Final ___:    < 10,000 CFU/mL. \n \nBrief Hospital Course:\nMr. ___ is a ___ ___ speaking male with a \nPMH of prior CVA ___, residual emotional lability, \ndysarthria), HFpEF, uncontrolled DM2, HTN, CAD, CKD, \n?hypothyroidism, asthma, mild cognitive impairment who presented', 'e2f22eea-f842-4b4c-8542-dfd4f8a519ce\n\n___ yo M with IDDM, HTN, CVA, asthma who presents to the ED after\nvomiting multiple times last night. He notes he ate taco bell at\n5, then at 6pm ate dinner and vomited all his rice at that time.\nContinued to vomit multiple times and decided to come to the ED.\nNon bilious non bloody. Doesn\'t have vomiting often. Denies any\nproblems with bowel movements. \nHe notes that he has been having problems with his BPs at home.\nNotes compliance and uses a pill box that his wife helps him\nfill. Notes that he tries to eat healthy (although he did have\ntacobell last night around 5pm). He also notes feeling ""off\nbalance"" when his BPs are raised but doesn\'t check them often at\nhome. Has been trying to check blood sugars more recently.\nDoesn\'t have a log here. \nNotes he sometimes has chest pain. Currently without chest pain.\nNotes that he doesn\'t get it with walking unless walking long\ndistance. Can walk up about 20 steps without stopping. \n \nPast Medical History:\n- DM2\n- Diabetic Retinopathy\n- Hypothyroidism\n- CKD Stage IIIa\n- HLD\n- HTN']","Based on the provided context, common complications or associated conditions with uncontrolled DM2 (Diabetes Mellitus Type 2) in patients with existing CVA (Cerebrovascular Accident) and HTN (Hypertension) include:               - **Chronic Infarcts**: As seen in the CT HEAD results, indicating potential previous brain tissue damage due to lack of blood supply.              - **Cognitive Impairment**: Mentioned in the brief hospital course, suggesting a decline in cognitive function.              - **Chronic Lacunar Infarcts**: Within the basal ganglia, indicative of small vessel disease, common in diabetes and hypertension.              - **CKD (Chronic Kidney Disease)**: Stage IIIa noted in the past medical history, a known complication of long-standing diabetes and hypertension.              - **Diabetic Retinopathy**: Listed in the past medical history, a common complication of diabetes affecting the eyes.              - **Emotional Lability and Dysarthria**: Residual effects from the CVA, potentially exacerbated by the metabolic and vascular stress of uncontrolled DM2 and HTN.",custom_multi_hop_query_synthesizer,"**Answering the Question with Available Data**

Given the patient's profile across the provided documents, we'll address the question about common complications of uncontrolled Diabetes Mellitus Type 2 (DM2) in patients with existing Cerebrovascular Accident (CVA) and Hypertension (HTN), using the patient's data as a reference point.

**Patient's Relevant Medical History (from Documents):**

- **Patient/Subject ID:** 13180007 (consistent across all documents)
- **Existing Conditions:**
	1. **Diabetes Mellitus Type 2 (DM2)**: Mentioned in Document 2 and implied in Document 3 (history of HFpEF, CKD, DM) and Document 5 (Discharge Diagnosis: type 2 diabetes mellitus).
	2. **Cerebrovascular Accident (CVA)**: Document 1 (#History of CVA), Document 2 (Cerebrovascular disease, status post CVA), and Document 3 (prior CVA).
	3. **Hypertension (HTN)**: Document 2 (Hypertension), Document 3 (hypertension), and implied through medication (e.g., amLODIPine in Documents 1 and 5).

**Common Complications of Uncontrolled DM2 in Patients with Existing CVA and HTN:**

While the documents provide a comprehensive view of the patient's health status, they don't directly list complications of uncontrolled DM2 in the context of CVA and HTN. However, based on medical knowledge, here are common complications that could arise in such patients:

1. **Increased Risk of Further CVA or Transient Ischemic Attacks (TIAs)**: Uncontrolled DM2 and HTN can exacerbate atherosclerosis, increasing the risk of subsequent strokes.
2. **Cardiovascular Diseases**: Exacerbation of conditions like Heart Failure with preserved Ejection Fraction (HFpEF), as mentioned in Document 3, due to increased strain on the heart.
3. **Chronic Kidney Disease (CKD) Progression**: Uncontrolled DM2 is a leading cause of CKD. The presence of HTN further accelerates kidney damage. (CKD is mentioned in Document 3.)
4. **Diabetic Nephropathy**: A specific complication of DM2 leading to kidney failure, potentially exacerbated by HTN.
5. **Retinopathy and Vision Loss**: Uncontrolled DM2 can lead to diabetic retinopathy, potentially worsened by HTN.
6. **Neuropathy**: DM2 can cause peripheral neuropathy, with HTN possibly contributing to autonomic neuropathy.
7. **Increased Risk of Infections and Poor Wound Healing**: Elevated blood glucose levels impair immune response and wound healing.
8. **Cognitive Decline**: There's evidence suggesting a link between uncontrolled DM2, HTN, and increased risk of cognitive decline or dementia, potentially exacerbated by a history of CVA.

**Metadata Consistency:**
- **Patient/Subject ID:** Consistently listed as 13180007 across all documents.
- **Note ID, Admission ID, Chart Time, and Store Time:** Also consistent across all documents, indicating these documents pertain to the same patient encounter. 

**Limitation:**
The provided documents, while comprehensive, do not explicitly outline the complications of uncontrolled DM2 in the context of CVA and HTN for this patient. The complications listed above are based on general medical knowledge and may not reflect the patient's current or specific situation without further clinical evaluation.","['CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver', 'Social History:\n___\nFamily History:\nHis parents have heart disease.  Mother is ___ with heart \nproblems\nand diabetes.  Father, ___, with diabetes.  He has 16 brothers \nand\nsisters.  There is no known ', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
"Whats the perscribd dose of Aspirin for a patiant with NSTEMI and hypertension, and whats its role in ther care plan?","['5afc91e0-6481-46b3-aa3c-473b2c2e6895\n\n#Community acquired pneumonia\nCough, worsened SOB, hypoxemia (although alternate explanation) \nbut no leukocytosis or fevers; influenza negative. Legionella \nand strep were negative. Patient was given a 5-day course of \nceftriaxone and azithromycin. \n#Hypertension\nGoal <130/80. As patient is on several anti-hypertensives with \nstill an elevated blood pressure, he underwent a secondary \nhypertension workup. His last renal ultrasound in ___ was \nwithin normal limits. He was placed on continuous O2 monitoring \novernight, and patient did not desaturate. His aldosterone to \nrenin ratio was 0.13, indicating no primary hyperaldosteronism. \n24 hour urine metanephrines and catecholamines were within \nnormal limits.\n#CAD w/ inducible ischemia\n#NSTEMI\nTroponin peaked at 0.02, thought to be type 2 due to volume \noverload. Continued aspirin, atorvastatin, carvedilol. The \ndecision was made to hold off on coronary angiogram due to \nkidney function and the suspicion that this was type 2.\n#H/o CVA\nPatient had an episode while in hospital with dysarthria,', '784a4f17-941d-40ee-a5aa-7471e6a5f600\n\n70/30 10 Units Lunch \n3.  Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath  \n4.  amLODIPine 10 mg PO DAILY  \n5.  Aspirin 81 mg PO DAILY  \n6.  Atorvastatin 80 mg PO QPM  \n7.  CARVedilol 50 mg PO BID  \n8.  Levothyroxine Sodium 100 mcg PO DAILY  \n9.  Minoxidil 10 mg PO DAILY  \n10.  Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine  \n11.  sevelamer CARBONATE 800 mg PO TID W/MEALS  \n12.  Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY  \n13.  Vitamin D 1000 UNIT PO DAILY  \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPrimary Diagnosis:\n-Acute on chronic diastolic heart failure exacerbation\nSecondary Diagnosis:']","For a patient with NSTEMI and hypertension, as observed in the provided medical context, the prescribed dose of Aspirin is 81 mg PO DAILY. The role of Aspirin in this care plan is consistent with managing Non-ST Elevation Myocardial Infarction (NSTEMI), where Aspirin is standard for its antiplatelet effects to reduce the risk of further cardiac events. Additionally, its anti-inflammatory properties may indirectly support the management of the patient's overall cardiovascular health, including hypertension, although its primary role in this context is related to the patient's CAD with inducible ischemia and NSTEMI rather than directly lowering blood pressure.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, I'll address the question to the best of my abilities. However, please note the following:

1. **Condition Context**: The question specifies ""NSTEMI"" (Non-ST Elevation Myocardial Infarction), but the documents provided do not explicitly mention NSTEMI. Instead, they refer to conditions like ""Acute on chronic diastolic heart failure exacerbation,"" ""History of CVA"" (Cerebrovascular Accident), hypertension, and others. The response will focus on the provided conditions, assuming a broader cardiovascular and hypertension context.

2. **Aspirin Dosage for Hypertension and Post-CVA Care**:
    - **Dosage**: According to **Document 1 (Medications on Admission)** and **Document 2 (Discharge Medications)**, the prescribed dose of Aspirin for this patient is **81 mg PO DAILY**. This dosage is commonly used for long-term antiplatelet therapy in patients with a history of CVA (stroke) and for cardiovascular protection, aligning with guidelines for secondary prevention in such cases.

    - **Role in Care Plan**: Aspirin plays a crucial role in the patient's care plan for several reasons:
        1. **Antiplatelet Therapy Post-CVA**: To reduce the risk of another stroke or cardiovascular event by inhibiting platelet aggregation.
        2. **Cardiovascular Protection**: Given the patient's history of heart disease (implied by ""History of CVA,"" heart failure, and hypertension), aspirin helps in reducing the overall cardiovascular risk.
        3. **Management of Hypertension-Related Cardiovascular Risk**: While primarily treated with other medications (e.g., amlodipine, minoxidil, and carvedilol as per the documents), aspirin contributes to mitigating the increased cardiovascular risk associated with hypertension.

**Metadata Relevance**:
- **Patient/Subject ID**: Consistently **13180007** across all documents.
- **Note ID, Admission ID, Chart Time, and Store Time** are also consistent across documents, indicating these entries are part of the same patient encounter.

**Answer Summary**:
- **Prescribed Aspirin Dose**: 81 mg PO DAILY
- **Role in Care Plan**: Antiplatelet therapy post-CVA, cardiovascular protection, and management of hypertension-related cardiovascular risk.","['CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'Social History:\n___\nFamily History:\nHis parents have heart disease.  Mother is ___ with heart \nproblems\nand diabetes.  Father, ___, with diabetes.  He has 16 brothers \nand\nsisters.  There is no known ', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
"What specific insulin regimen should a discharged patient, who was hospitalized for worsening shortness of breath and leg swelling, continue to follow as part of their post-discharge care, considering their pre-admission insulin schedule?","['cd30826d-ad9e-4a08-8b63-15e1e3bbfe0c\n\nYou were admitted to the hospital because:\n================================\n-You had worsening shortness of breath, with increased leg \nswelling and weight gain.\nDuring your stay:\n============\n-You had too much volume onboard so you were given IV diuretic \nmedications,. You improved significantly.\nAfter your discharge:\n================\n-Please continue taking all medications as prescribed (see \nbelow).\n-Please stop taking Lisinopril and metoprolol.\n-Please continue taking insulin according to the regimen you \nwere following before this admission.\n-New medications:\n  - Aspirin 81mg once daily\n  - Carvedilol 25mg twice daily\n  - Furosemide 40mg twice daily\n  - Hydralazine 100mg three times daily\n-Please attend any upcoming outpatient appointments you have \n(see below).\nWe wish you the very best!', ""fd49a2e0-9612-4cbf-91c3-bbfc765fb300\n\n[ ] Changed medications: Insulin (lantus 40 qam and 10 qpm w/ \nNovolog ___ w/ SSI with meals; discharged w/ insulin pens), \ncoreg was increased to 37.5 mg BID. Amlodipine was switched from \nqod to everyday.\n[ ] Please monitor BP as an outpatient and consider starting \nimdur.\n[ ] HFpEF - Consider initiation of spironolactone once Cr is \ndowntrending.\n[ ] ?COPD - Consider PFTs to see if patient has COPD. Started on \nadvair as an inpatient.\n[ ] DM: Please monitor his blood glucose as an outpatient as his \nblood glucoses ran elevated as an inpatient. He should follow-up \nwith ___ as an outpatient.\n[ ] Lung cancer screening - Given patient's smoking history, \nconsider outpatient CT Chest.\n[ ] Hyperlipidemia - Per prior cardiology note, patient approved \nfor PCSK9 inhibitor.\n[ ] Iron deficiency anemia: Will need a colonoscopy as an \noutpatient\n[ ] CKD - Anticipate he may need dialysis in the future. K on \ndischarge was 4.8 and Cr on discharge was 3.7.\n[ ] Labs: Please recheck a BMP at his next follow-up appointment \nto monitor K and Cr.\n[ ] Discharge weight: 72.7 kg\n==============""]","The patient should continue taking insulin according to the regimen they were following before this admission, which specifically includes: Insulin (Lantus 40 qam and 10 qpm with Novolog, with Sliding Scale Insulin (SSI) adjustments with meals), now discharged with insulin pens for administration.",custom_multi_hop_query_synthesizer,"Based on the provided documents, here's the answer to the question about the specific insulin regimen for the discharged patient:

**Answer:**
The patient should continue with the following insulin regimen as part of their post-discharge care, which is an adjustment from their pre-admission schedule:

* **70/30 Insulin:**
	+ 30 Units with Breakfast
	+ 10 Units with Lunch

**Rationale:**
This information is directly obtained from:

1. **Document 2: Discharge Medications** (under CONTENT)
2. **Document 3: Medications on Admission** (under CONTENT) - For comparison with pre-admission insulin schedule.
3. **Document 5: #IDDM** (under CONTENT) - Mentions the transition to home insulin from an inpatient insulin schedule (Lantus), but specifically refers to the **70/30** insulin regimen with dosages as detailed in Document 2.

**Pre-Admission vs. Post-Discharge Insulin Schedule:**
- **Pre-Admission (Document 3):** 70/30 30 Units Breakfast, 70/30 10 Units Lunch (No change noted in the provided documents, so assuming this was the pre-admission schedule based on the medications list accuracy statement in Document 3)
- **Post-Discharge (Document 2 & confirmed in Document 5):** Same as pre-admission, **70/30** - 30 Units with Breakfast, 10 Units with Lunch. No change in the insulin type or dosage for this specific regimen is noted across the documents.

**Metadata Relevance for this Question:**
- **Patient/Subject ID:** Consistently **13180007** across all documents, confirming all information pertains to the same patient.
- **Note ID, Admission ID, Chart Time, and Store Time:** While consistent across documents, these are not directly relevant to answering the insulin regimen question.","['DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'TRANSITIONAL ISSUES\n===================\n[ ] At discharge his symptoms associated with volume overload \nhad subsided, but he was still slightly volume up on exam with \n1+ edema to ankles bilaterally an', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
"What ar the commen causis of Congestive Heart Failure (CHF) exaserbation in pashents with a history of hypertension and diabetis, and how do sympoms like shortness of breath and lower extremity edema relait to the condishun?","['6ca6759d-052d-4b9a-b47d-014a869a41be\n\nechocardiographic evidence of tamponade.\nIMPRESSION: Mild symmetric biventricular hypetrophy with \npreserved biventricular systolic function. No clinically \nsignificant valvular disease. Small, predominantly anterior \npericardial effusion\nwithout echocardiographic evidence of tamponade.\n \nBrief Hospital Course:\n___ M w/ PMH significant for HTN, HLD, T2DM, and CVA in ___ \nwho presents w/ increased SOB and volume retention, concerning \nfor CHF exacerbation. \nACTIVE ISSUES: \n==============\n#Acute HF exacerbation (preserved EF 65% on stress echo in ___, \nunknown current EF)\n#Hypertension\nPatient presented with worsening shortness of breath, lower \nextremity edema and was hypervolemic on exam w/ diffuse rhonchi \non lung auscultation, as well as elevated BNP, all concerning \nfor CHF exacerbation. Stress echo in ___ showed \npreserved EF. Etiology could be either uncontrolled hypertension \nvs ischemia (especially given history of positive stress echo). \nExacerbation could be due to medication/dietary non-compliance.', 'e0673342-03d7-4e47-9dd2-f1d0eaafa133\n\n___ (PORTABLE AP)\nIMPRESSION: \nIn comparison with the study of earlier in this date, the \nendotracheal tube\nhas been pulled back so that the tip now lies approximately 5 cm \nabove the\ncarina.  Cardiomediastinal silhouette is stable.  The vascular \ncongestion\nsuggested previously is no longer appreciated.\n \nBrief Hospital Course:\n___ year old male w history of diastolic CHF, diabetes type 2 \nrecent admission for CHF exacerbation, re-admitted ___ \nwith hyperglycemia and respiratory distress requiring \nintubation, status post treatment of acute diastolic CHF, \nsubsequently optimizing glucose control, able to be discharged \nhome with ___ for medication assistance.  \nTRANSITIONAL ISSUES:\n====================\n[ ] Will need repeat Cr at his ___ appointment on ___, \n___, to ensure stability.\n[ ] Repeat CMP within 1 week of discharge, to ensure stability \nin electrolytes \n[ ] Patient has now had multiple presentations the hospital with']","Based on the provided context, CHF exacerbation in patients with a history of hypertension and diabetes can be attributed to two main etiologies: **1. Uncontrolled Hypertension** and **2. Ischemia** (especially in patients with a history of positive stress echo). Symptoms such as **worsening shortness of breath (SOB)**, **lower extremity edema**, and being **hypervolemic on exam** along with **diffuse rhonchi on lung auscultation** and **elevated BNP**, are all concerning for CHF exacerbation. Additionally, **medication/dietary non-compliance** can also contribute to the exacerbation of CHF. In patients with diastolic CHF, optimizing glucose control (for those with diabetes) and managing the underlying causes are crucial for stabilization and discharge.",custom_multi_hop_query_synthesizer,"**Answering the Question**

**Common Causes of Congestive Heart Failure (CHF) Exacerbation in Patients with a History of Hypertension and Diabetes:**

While the provided documents do not explicitly list common causes of CHF exacerbation, based on medical knowledge, common triggers for patients with a history of hypertension and diabetes include:

1. **Medication Non-Compliance**: As hinted in Document 3, not adhering to prescribed medications (e.g., diuretics, ACE inhibitors, beta-blockers) can lead to fluid buildup and worsening heart failure.
2. **Dietary Indiscretion**: Consuming high-sodium foods can lead to fluid retention, exacerbating CHF. (No evidence of dietary indiscretion was found in the provided documents, as per Document 3.)
3. **Infections**: Respiratory or urinary tract infections can increase the body's fluid demand and worsen heart failure symptoms.
4. **Worsening of Underlying Conditions**: Progression of hypertension or diabetes can directly impact heart function.
5. **Arrhythmias**: New-onset or worsening arrhythmias can reduce the heart's efficiency, leading to exacerbation.

**Relationship Between Symptoms (Shortness of Breath and Lower Extremity Edema) and CHF Exacerbation:**

1. **Shortness of Breath (Dyspnea)**: In CHF, the heart's reduced ability to pump blood efficiently can lead to fluid buildup in the lungs (pulmonary congestion), causing shortness of breath. This is evident in:
	* Document 1: ""dyspnea on exertion""
	* Document 2: Improved with IV Lasix, indicating fluid reduction alleviated symptoms
	* Document 3: ""Acute on chronic HFpEF"" with symptoms of dyspnea
2. **Lower Extremity Edema**: Fluid buildup due to the heart's inability to effectively pump blood can cause fluid to leak into body tissues, leading to swelling, particularly in the lower extremities due to gravity. This is noted in:
	* Document 1: ""worsening lower extremity edema""
	* Document 3: ""volume overloaded on exam"" with edema
	* Document 4: ""1+ edema to ankles"" at discharge, indicating some residual fluid retention

**Metadata Observations (as per instructions):**

* **Patient/Subject ID**: Consistently listed as **13180007** across all documents (1 through 5).
* **Note ID**: Identical across all documents as **13180007-DS-19**.
* **Admission ID**: Uniformly **20774429** in all provided documents.
* **Chart Time** and **Store Time**: Same for all documents, **20/06/62 0:00** and **21/06/62 9:56**, respectively.","['Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver', 'Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n', 'ACUTE PROBLEMS\n==============\n# Acute on chronic HFpEF: \nPatient presented with dyspnea and lower extremity edema and\nfound to be volume overloaded on exam. Warm and wet on exam.\nTrigger for HF exacer', 'DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
Whats the perscribed dose of CARVedilol for the patient with Hx of CAD and CKD stage III?,"['4b3d7a96-6534-434e-8295-b8356c5ca64d\n\nbasal/bolus four times daily regimen. However, this is not a \nsustainable regimen for patient on discharge. Discussed \npossibility of switching to 70/30 mix BID, however currently \npatient cannot be guaranteed to eat regular meal after each \ninsulin injection therefore currently not a tenable plan. In the \nfuture, if patient able to be placed in a day program, \npotentially could switch to this but for now will we continued \nhis prior home regimen (EXCEPT for Jardiance, which was \ndiscontinued due to contraindication with chronic kidney \ndisease) on discharge, with very close ___ follow-up and ___ \nservices to help increase compliance. With regards to his more \nsubacute mental status decompensation, would benefit from \nreferral for outpatient neurocognitive evaluation.\n# Hx of CAD: \n# Hx of ischemic CVA:\nStress test in ___ with area of inducible ischemia in LCx \ndistribution, in setting of multiple risk factors. Has been \nmedically optimized by prescribed medications, but as above it \nseems that pt has been taking these medications. TnT 0.04->0.02 \nin setting of CKD stage III-IV. Continued home aspirin, \natorvastatin, and carvedilol. Note that he was once on \nlisinopril (most recently filled in ___ for 2.5mg dose) \nhowever seems that this has since been discontinued.\n# CKD stage III:', 'dc9c33c0-6523-4835-a02f-162ecaa61776\n\n2. amLODIPine 10 mg PO DAILY \n3. Atorvastatin 80 mg PO QPM \n4. Minoxidil 10 mg PO DAILY \n5. CARVedilol 50 mg PO BID \n6. Levothyroxine Sodium 100 mcg PO DAILY \n7. Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine \n8. sevelamer CARBONATE 800 mg PO TID W/MEALS \n9. Vitamin D 1000 UNIT PO DAILY \n10. Torsemide 100 mg PO DAILY \n11. Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY \n12. 70/30 30 Units Breakfast\n70/30 10 Units Lunch\n13. Aspirin 81 mg PO DAILY \n \nDischarge Medications:\n1.  Acetaminophen 650 mg PO Q6H:PRN Pain - Mild/Fever  \n2.  70/30 30 Units Breakfast\n70/30 20 Units Dinner \n3.  Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath  \n4.  amLODIPine 10 mg PO DAILY  \n5.  Aspirin 81 mg PO DAILY  \n6.  Atorvastatin 80 mg PO QPM  \n7.  CARVedilol 50 mg PO BID']","The prescribed dose of CARVedilol for the patient is 50 mg PO BID (twice a day). This is part of the patient's medically optimized regimen for CAD, alongside other medications such as aspirin, atorvastatin, and with careful management due to CKD stage III-IV.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, here's the answer to the question:

**Question:** What's the prescribed dose of CARVedilol for the patient with Hx of CAD and CKD stage III?

**Answer Breakdown:**

1. **Patient Context**:
	* **Patient/Subject ID**: 13180007 (consistent across all documents)
	* **History of CAD**: Not explicitly mentioned in the documents, but a history of CVA (Cerebrovascular Accident) is noted, and risk factors for ischemia are mentioned in Document 5. However, CAD (Coronary Artery Disease) itself is not highlighted.
	* **CKD Stage III**: Not explicitly stated; Document 5 mentions CKD (Chronic Kidney Disease) with elevated Cr levels, but the stage is not specified.
2. **CARVedilol Dosage**:
	* **Document 1 (Discharge Medications)**: CARVedilol 50 mg PO BID
	* **Document 2 (Medications on Admission)**: CARVedilol 50 mg PO BID

**Answer**: The prescribed dose of CARVedilol for the patient (with the noted medical history, though CAD and CKD stage III are not explicitly confirmed as requested) is **50 mg PO BID**. This dosage is consistent across both the discharge medications (Document 1) and the medications on admission (Document 2).

**Metadata Consistency for Patient ID**:
- The **Patient/Subject ID** (13180007) is consistent across all documents (Document 1, Document 2, Document 3, Document 4, and Document 5).","['Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver', 'ACUTE PROBLEMS\n==============\n# Acute on chronic HFpEF: \nPatient presented with dyspnea and lower extremity edema and\nfound to be volume overloaded on exam. Warm and wet on exam.\nTrigger for HF exacer', '# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
"What is the standard dosage of Levothyroxine for a patient with Hypothyroidism in the context of multiple comorbidities (e.g., Hypertension, IDDM, CKD) as observed in clinical care coordination?","['08e7114b-32bf-470b-a3c6-d919c6de4e69\n\n# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n# Acute on chronic anemia:\nHb on admission was 7.4. No evidence of bleeding per history or \nexam. Possibly related to worsening of his renal function vs \ndilutional iso heart failure. His Hb was 7.6 on discharge. He \nreceived 3 doses of ferric gluconate 250 mg IV on ___.\n#IDDM\nPoorly controlled. A1c 14.4 in ___ in ___ at ___. \nRepeat A1C ___ was 11.4%. He was given Lantus 30u night of \nadmission, then transitioned to home insulin ___ with 70/30 \n30u with breakfast and 20u with lunch. He was also on ISS while \ninpatient.\nCHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.', '8c0badb1-fe3b-4585-8010-1ef4ba8fdd98\n\n================\n# Hx of CAD \n# Hx of ischemic CVA\nStress test in ___ with area of inducible ischemia in LCx \ndistribution. Trop peaked at 0.06 (iso CKD) and then \ndowntrended. No EKG changes seen. Continued home carvedilol, ASA \nand high dose atorvastatin. \n# CKD: Cr at presentation close to baseline. Underlying etiology \nlikely combination of HTN, DM. \n# Hypothyroidism: Continued home levothyroxine 100 mcg daily\n \nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Furosemide 40 mg PO 3X/WEEK (___) \n2. sevelamer CARBONATE 800 mg PO TID W/MEALS \n3. Minoxidil 2.5 mg PO DAILY \n4. Levothyroxine Sodium 100 mcg PO DAILY \n5. CARVedilol 37.5 mg PO BID \n6. amLODIPine 10 mg PO DAILY \n7. Albuterol Inhaler 2 PUFF IH Q6H \n8. Jardiance (empagliflozin) 10 mg oral DAILY \n9. Victoza 3-Pak (liraglutide) 1.2 mg subcutaneous DAILY']","Based on the provided medical context, for patients with Hypothyroidism, alongside multiple comorbidities such as Hypertension, IDDM (Insulin-Dependent Diabetes Mellitus), and CKD (Chronic Kidney Disease), the continued home dosage of Levothyroxine is consistently noted as 100mcg daily. This dosage is mentioned across different patient scenarios, suggesting a standard approach for Hypothyroidism management in these complex cases, under the care coordination observed.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

Based on the provided documents, we can analyze the treatment approach for the patient's Hypothyroidism within the context of multiple comorbidities. However, determining the ""standard"" dosage of Levothyroxine (LT4) for Hypothyroidism with multiple comorbidities like Hypertension, IDDM (Insulin-Dependent Diabetes Mellitus), and CKD (Chronic Kidney Disease) requires understanding that standard dosages can vary widely among patients due to individual factors such as age, weight, severity of hypothyroidism, and the presence of comorbid conditions.

**Patient-Specific Information from Documents:**

- **Patient/Subject ID:** Consistently listed as **13180007** across all documents (Document 1 through Document 5), indicating all information pertains to the same patient.
- **Levothyroxine Dosage for Hypothyroidism:**
  - **Document 1 (Medications on Admission):** Levothyroxine Sodium 100 mcg PO DAILY.
  - **Document 2 (CHRONIC PROBLEMS):** He was continued on home levothyroxine 100mcg daily.
  - **Document 3 (Discharge Medications):** Levothyroxine Sodium 100 mcg PO DAILY.

**Observation and Answer:**
The patient with Hypothyroidism, alongside comorbidities (Hypertension, IDDM, CKD, among others), is consistently noted to be on **Levothyroxine Sodium 100 mcg PO DAILY** across the admission and discharge documents. This suggests that, for this patient, 100 mcg daily was deemed appropriate by the healthcare providers, considering the patient's specific clinical context.

**Important Note:**
- The question asks for the ""standard dosage"" in a context that implies a need for a generalized answer based on the provided patient's situation. However, **there is no one-size-fits-all ""standard"" dosage for Levothyroxine in patients with multiple comorbidities**. The appropriate dosage is highly individualized, based on thyroid function tests (TFTs), clinical response, and adjustments for comorbid conditions and medications that may interact with LT4.
- For this patient (ID: **13180007**), the maintained dosage is 100 mcg daily, but this should not be taken as a standard for all similar cases without considering the specific clinical details and laboratory results of another patient.

**IDs and Dates as per Instructions:**
- **Patient/Subject ID:** **13180007** (consistent across all documents)
- **Note ID:** **13180007-DS-19** (consistent across all documents)
- **Admission ID:** **20774429** (consistent across all documents)
- **Chart Time and Store Time** are consistently **20/06/62 0:00** and **21/06/62 9:56**, respectively, across all documents.","['CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver', 'ACUTE PROBLEMS\n==============\n# Acute on chronic HFpEF: \nPatient presented with dyspnea and lower extremity edema and\nfound to be volume overloaded on exam. Warm and wet on exam.\nTrigger for HF exacer']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
"What are the relevent medicashuns and ther underlaying efectivness for a pashent with a Hx of CAD, ischemic CVA, CKD (likely due to HTN, DM), and Hypothyroidism, consiederin the pashent is alredy on carvedilol, ASA, and high dose atorvastatin?","['8c0badb1-fe3b-4585-8010-1ef4ba8fdd98\n\n================\n# Hx of CAD \n# Hx of ischemic CVA\nStress test in ___ with area of inducible ischemia in LCx \ndistribution. Trop peaked at 0.06 (iso CKD) and then \ndowntrended. No EKG changes seen. Continued home carvedilol, ASA \nand high dose atorvastatin. \n# CKD: Cr at presentation close to baseline. Underlying etiology \nlikely combination of HTN, DM. \n# Hypothyroidism: Continued home levothyroxine 100 mcg daily\n \nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Furosemide 40 mg PO 3X/WEEK (___) \n2. sevelamer CARBONATE 800 mg PO TID W/MEALS \n3. Minoxidil 2.5 mg PO DAILY \n4. Levothyroxine Sodium 100 mcg PO DAILY \n5. CARVedilol 37.5 mg PO BID \n6. amLODIPine 10 mg PO DAILY \n7. Albuterol Inhaler 2 PUFF IH Q6H \n8. Jardiance (empagliflozin) 10 mg oral DAILY \n9. Victoza 3-Pak (liraglutide) 1.2 mg subcutaneous DAILY']","Based on the provided context, the patient's relevant medications and their underlying effectiveness for the mentioned conditions are as follows:  - **For CAD and Ischemic CVA Prevention:**   - **Carvedilol (CARVedilol 37.5 mg PO BID):** Continued for heart-related conditions, indicating its ongoing effectiveness.   - **ASA (Aspirin, dosage not specified in the context but mentioned as continued):** For antiplatelet effects to prevent further ischemic events.   - **Atorvastatin (dosage not specified, but mentioned as high dose):** For managing cholesterol, crucial in CAD management.  - **For CKD (with likely underlying etiology of HTN, DM):**   - **Furosemide 40 mg PO 3X/WEEK:** For fluid management in CKD.   - **Sevelamer CARBONATE 800 mg PO TID W/MEALS:** To control phosphorus levels in CKD patients.   - **Minoxidil 2.5 mg PO DAILY:** For blood pressure management (HTN).   - **AmLODIPine 10 mg PO DAILY:** Also for HTN management.   - **Jardiance (Empagliflozin) 10 mg oral DAILY:** Specifically for DM management, with the added benefit of renal protection in CKD.  - **For Hypothyroidism:**   - **Levothyroxine Sodium 100 mcg PO DAILY:** Continued for thyroid hormone replacement.  - **Additional for DM (as part of the themes):**   - **Victoza 3-Pak (Liraglutide) 1.2 mg subcutaneous DAILY:** For DM management, helping with glucose control and possibly aiding in weight management, which can be beneficial for overall cardiovascular health.",custom_multi_hop_query_synthesizer,"Based on the provided documents and the question, here's a structured answer focusing on the relevant medications and their underlying effectiveness for the patient's conditions, considering the patient's existing medication regimen (carvedilol, ASA, and high-dose atorvastatin).

**Patient's Conditions and Existing Medications:**

1. **History (Hx) of:**
	* Coronary Artery Disease (CAD)
	* Ischemic Cerebrovascular Accident (CVA)
	* Chronic Kidney Disease (CKD), likely due to:
		+ Hypertension (HTN)
		+ Diabetes Mellitus (DM)
2. **Hypothyroidism**
3. **Existing Medications:**
	* **Carvedilol (Coreg)**: A beta-blocker for HTN, heart failure, and to reduce the risk of hospitalization in patients with heart failure.
	* **Aspirin (ASA)**: Antiplatelet for prevention of ischemic events in CAD and CVA.
	* **High-dose Atorvastatin**: A statin for managing high cholesterol and reducing the risk of cardiovascular events in patients with CAD.

**Relevant Medications and Their Underlying Effectiveness for the Patient's Conditions:**

### For CAD and Ischemic CVA:

* **Continuation of:**
	+ **ASA**: Effective for antiplatelet therapy to prevent further ischemic events.
	+ **High-dose Atorvastatin**: Effective in reducing major vascular events in patients with CAD.
	+ **Carvedilol**: Beneficial for patients with heart failure or left ventricular dysfunction post-MI, but its direct effectiveness in primary prevention of CAD events is more nuanced; it helps with overall cardiovascular risk reduction through blood pressure management.

### For CKD (likely due to HTN, DM):

* **Medications with Renal Protective Effects:**
	+ **Carvedilol**: While primarily for HTN and heart failure, its use can indirectly benefit CKD by controlling blood pressure, a key factor in CKD progression.
	+ **No direct CKD treatment mentioned** in the provided medications. Typically, medications like ACE inhibitors or ARBs are considered first-line for renal protection in patients with CKD and HTN or DM, but they are not listed here.

### For Hypothyroidism:

* **Levothyroxine Sodium 100 mcg PO DAILY**: Effective for replacing thyroid hormone in hypothyroidism, aiming to maintain normal thyroid function and prevent complications.

### For HTN (contributing to CKD):

* **Existing:**
	+ **Carvedilol (Coreg) 50 mg PO BID**: Effective for blood pressure control.
	+ **Amlodipine 10 mg PO DAILY**: A calcium channel blocker, effective in managing hypertension.
	+ **Minoxidil 10 mg PO DAILY**: A potent antihypertensive, often used in resistant cases; its effectiveness is noted, but typically, it's used when other options have failed due to its side effect profile.

### For DM (contributing to CKD):

* **Existing:**
	+ **Insulin regimen (70/30, doses specified)**: Effective for glucose control, crucial in managing diabetic complications, including CKD.
	+ **Victoza (Liraglutide)**: A GLP-1 receptor agonist, beneficial for glycemic control and has shown renal protective effects in clinical trials.

**Metadata IDs for Reference:**

* **Patient/Subject ID:** 13180007 (consistent across all documents)
* **Note ID:** 13180007-DS-19 (consistent across all documents)
* **Admission ID:** 20774429 (consistent across all documents)
* **Chart Time & Store Time:** Consistent across all documents, indicating simultaneous or very closely timed charting and storage.","['CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', '# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', 'Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
"What changes, if any, occurred in the patient's Furosemide dosage from admission to discharge, and what could be the clinical rationale behind such adjustments for a patient initially presenting with worsening shortness of breath, increased leg swelling, and weight gain?","['8c579626-76a5-4cd0-9f53-1feadb6904be\n\nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath \n2. amLODIPine 10 mg PO DAILY \n3. Atorvastatin 80 mg PO QPM \n4. CARVedilol 50 mg PO BID \n5. Furosemide 80 mg PO DAILY \n6. 70/30 30 Units Breakfast\n70/30 10 Units Lunch\n7. Levothyroxine Sodium 100 mcg PO DAILY \n8. Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY \n9. Minoxidil 10 mg PO DAILY \n10. Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine \n11. sevelamer CARBONATE 800 mg PO TID W/MEALS \n12. Aspirin 81 mg PO DAILY \n13. Vitamin D 1000 UNIT PO DAILY \n \nDischarge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast', 'cd30826d-ad9e-4a08-8b63-15e1e3bbfe0c\n\nYou were admitted to the hospital because:\n================================\n-You had worsening shortness of breath, with increased leg \nswelling and weight gain.\nDuring your stay:\n============\n-You had too much volume onboard so you were given IV diuretic \nmedications,. You improved significantly.\nAfter your discharge:\n================\n-Please continue taking all medications as prescribed (see \nbelow).\n-Please stop taking Lisinopril and metoprolol.\n-Please continue taking insulin according to the regimen you \nwere following before this admission.\n-New medications:\n  - Aspirin 81mg once daily\n  - Carvedilol 25mg twice daily\n  - Furosemide 40mg twice daily\n  - Hydralazine 100mg three times daily\n-Please attend any upcoming outpatient appointments you have \n(see below).\nWe wish you the very best!']","Upon admission, the patient was taking Furosemide 80 mg PO DAILY. At discharge, the medication regimen was adjusted to Furosemide 40mg twice daily. The initial presentation of worsening shortness of breath, increased leg swelling, and weight gain suggests fluid overload, for which IV diuretic medications were effectively administered during the hospital stay. The adjustment to a twice-daily regimen at a lower cumulative daily dose (40mg twice daily equals 80mg total daily) might reflect a clinical decision to maintain diuretic efficacy while minimizing potential side effects, considering the patient's improved condition following in-hospital diuretic treatment. This adjustment could also be tailored to manage outpatient fluid balance, given the patient's response to diuretics during the hospitalization.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Patient ID for Context:** 13180007 (consistent across all documents: Document 1, Document 2, Document 3, Document 4, and Document 5)

**Admission and Discharge Medication Details Relevant to Furosemide:**

* **Admission (Implicit from Document Content, as direct admission meds are not listed in provided metadata or content snippets):**
	+ Document 2 (DISCHARGE LABS) mentions ""IV Lasix 80"" as part of the hospital treatment, implying the patient received Furosemide (Lasix) during admission. The exact timing and dosage adjustments during the stay are not specified in the provided documents.
* **Discharge:**
	+ Document 3 (Discharge Medications) lists ""1. Torsemide 100 mg PO DAILY"" as a discharge medication.

**Changes in Diuretic Dosage from Admission to Discharge:**

* **Change from Furosemide (Lasix) to Torsemide:** The patient was treated with IV Furosemide (Lasix) during the hospital stay but was discharged on oral Torsemide.
* **Dosage Adjustment:** The dosage of the diuretic changed from an implied IV Furosemide 80mg (based on treatment mentions) to oral Torsemide 100mg daily at discharge.

**Clinical Rationale:**

1. **Conversion from IV to Oral Administration:** Switching from IV (intravenous) Furosemide to oral Torsemide at discharge is common, as IV administration is typically reserved for acute, in-hospital management to rapidly achieve diuresis. Oral administration is more suitable for ongoing, outpatient management.
   
2. **Change from Furosemide to Torsemide:** This change might be due to several reasons:
	* **Efficacy and Potency:** Torsemide is often considered more potent than Furosemide, with a longer duration of action, which can lead to more convenient once-daily dosing and potentially better blood pressure control.
	* **Tolerability and Side Effects:** Some patients may experience fewer side effects with Torsemide compared to Furosemide, such as less frequent urination (due to its longer action) or reduced risk of ototoxicity (though this is more relevant at very high IV doses).
	* **Patient Compliance:** A once-daily oral medication regimen can enhance patient compliance.

3. **Management of Heart Failure and Fluid Overload:** The patient's presentation with dyspnea, chest pain, and worsening lower extremity edema suggests fluid overload, a common complication in heart failure. The adjustment to Torsemide at discharge aims to maintain diuresis, manage fluid status, and prevent further exacerbations of heart failure, aligning with the management goals for a patient with acute on chronic diastolic heart failure exacerbation.

**Metadata Consistency for IDs:**
- **Patient/Subject ID:** Consistently listed as 13180007 across all documents.
- **Note ID, Admission ID, Chart Time, and Store Time** are also consistent across all provided documents, indicating these documents pertain to the same hospital admission and discharge process for the patient.","['TRANSITIONAL ISSUES\n===================\n[ ] At discharge his symptoms associated with volume overload \nhad subsided, but he was still slightly volume up on exam with \n1+ edema to ankles bilaterally an', 'DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'WHAT HAPPENED WHILE I WAS IN THE HOSPITAL?  \n You were given medications to help get the fluid out. Your \nsymptoms got better and were ready to leave the hospital.  \n\n WHAT DO YOU NEED TO DO WHEN YOU ', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
"What is the role of Hydralazine in the treatment regimen for a patient discharged with a primary diagnosis of Acute on chronic heart failure with preserved ejection fraction, and how is its dosage administered?","['5d1619ab-197a-416d-b0af-616eff82199c\n\n#*60 Tablet Refills:*0 \n12.  HydrALAZINE 100 mg PO TID \nRX *hydralazine 100 mg 1 tablet(s) by mouth three times a day \nDisp #*90 Tablet Refills:*0 \n13.  Levothyroxine Sodium 100 mcg PO DAILY \nRX *levothyroxine 100 mcg 1 tablet(s) by mouth once a day Disp \n#*30 Tablet Refills:*0 \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPRIMARY DIAGNOSIS\n==================\nAcute on chronic heart failure with preserved ejection fraction\nSECONDARY DIAGNOSES\n====================\nAcute kidney injury\nCoronary artery disease\nType 2 Diabetes Mellitus\nHyperkalemia', 'ab26554b-50b4-4fe8-adc0-d18910279c6b\n\n=============== \n#Acute exacerbation of HFpEF (EF 57%)\nLikely ___s possible ischemia given his \npositive stress in ___. Also possibly triggered by \npneumonia. Did endorse occasional angina symptoms, but trop was \nflat with no EKG changes. TTE showed no regional wall motion \nabnormalities and no mitral regurgitation. He was actively \ndiuresed. His lisinopril was held due to ___. His heart failure \nregimen upon discharge:\nDIURESIS: Torsemide 40 mg QD\nAFTERLOAD: Hydralazine 100 mg TID\nClonidine 0.2 mg BID\nHeld lisinopril given ___\nAmlodipine 10 mg QD\nNHBK: Carvedilol 37.5 mg BID; \n- Discharge weight: 72.7 kg (160.27 lb) \n- Discharge Cr: 3.7\n___ on CKD:\n#Hyperkalemia:\nInitially due to venous congestion, then likely due to \noverdiuresis. He had underlying CKD and his creatinine did not \nreturn to his baseline upon discharge. We suspect that he will \nneed to initiate HD in the near future. His K rose to about 5.8 \nthe week prior to discharge, but this improved with Lasix IV, \nkayexelate, and low potassium diet.']","According to the patient's discharge information, Hydralazine plays a role in the 'AFTERLOAD' component of the heart failure treatment regimen. The dosage of Hydralazine is specifically 100 mg, administered three times a day (TID). This is part of a broader regimen that includes DIURESIS with Torsemide, additional blood pressure management with Clonidine and Amlodipine, and NHBK (likely referring to Neurohormonal Blockade) with Carvedilol. The use of Hydralazine in this context suggests its application in managing afterload reduction, crucial for heart failure management, especially in a patient with preserved ejection fraction and other complicating factors like coronary artery disease and hyperkalemia.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Role of Hydralazine in the Treatment Regimen:**
* **Presence in Treatment Regimen:** Hydralazine is **NOT MENTIONED** in the provided documents (1 through 5) as part of the patient's discharge medications or treatment regimen.

**Dosage Administration (if applicable):**
* **N/A (Not Applicable)** since Hydralazine is not mentioned in the treatment regimen across all provided documents.

**Additional Observations Relevant to the Question Context:**

* **Patient's Primary Diagnosis:** Acute on chronic diastolic heart failure exacerbation (as per Document 1, Discharge Diagnosis).
* **Heart Failure Treatment Regimen:** The patient is discharged with medications including Torsemide (a diuretic), Carvedilol (a beta-blocker), and other medications for comorbid conditions (as detailed in Document 1, Discharge Medications).
* **Common Alternatives or Comparisons for Heart Failure Treatment:** While Hydralazine (often in combination with nitrates) is used in certain cases of heart failure, particularly in patients who cannot tolerate ACE inhibitors or ARBs due to renal concerns or hyperkalemia, the provided documents do not indicate its use for this patient. Instead, the focus is on diuresis (Torsemide), beta-blockade (Carvedilol), and management of comorbidities.

**Metadata Consistency Across Documents (as per instruction 3):**
* **Patient/Subject ID:** Consistently listed as **13180007** across all documents (1 through 5).
* **Note ID:** Consistently listed as **13180007-DS-19** across all documents (1 through 5).
* **Admission ID:** Consistently listed as **20774429** across all documents (1 through 5).
* **Chart Time and Store Time:** Consistently listed as **20/06/62 0:00** and **21/06/62 9:56**, respectively, across all documents (1 through 5).","['Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'ACUTE PROBLEMS\n==============\n# Acute on chronic HFpEF: \nPatient presented with dyspnea and lower extremity edema and\nfound to be volume overloaded on exam. Warm and wet on exam.\nTrigger for HF exacer', 'DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
Whats the ushual dose of Vitimin D prescribd to pashents in thes hospitl recrds?,"['080dba33-29e9-4409-89cb-54a03af0e470\n\n8.  Levothyroxine Sodium 100 mcg PO DAILY  \n9.  Minoxidil 10 mg PO DAILY  \n10.  Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine  \n11.  sevelamer CARBONATE 800 mg PO TID W/MEALS  \n12.  Torsemide 100 mg PO DAILY  \n13.  Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY  \n14.  Vitamin D 1000 UNIT PO DAILY  \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPRIMARY DIAGNSOIS:\n==================\nAcute Hypoxemic Respiratory Failure\nAcute on Chronic Diastolic Heart Failure\nHyperglycemia, Type 2 Diabetes \n___ on CKD \nSECONDARY DIAGNOSIS:', '9c9ab9ab-4a9f-4e03-8ad8-d377af91b9d0\n\n11.  Tresiba U-100 Insulin (insulin degludec) 50 units \nsubcutaneous DAILY  \n12.  Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY  \n13.  Vitamin D ___ UNIT PO 1X/WEEK (WE)  \n14. HELD- CloNIDine 0.4 mg PO BID  This medication was held. Do \nnot restart CloNIDine until see what BP is at PCP visit, to see \nif need more meds\n15. HELD- Gabapentin 400 mg PO TID  This medication was held. Do \nnot restart Gabapentin until you discuss with PCP the need for \nit, was not needed during this hospital stay\n16. HELD- HydrALAZINE 100 mg PO TID  This medication was held. \nDo not restart HydrALAZINE until discuss with primary care \ndoctor\n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nType II diabetes']","Based on the provided hospital records, two different dosages of Vitamin D are mentioned for patients:               1. **1000 UNIT PO DAILY** (Record: 080dba33-29e9-4409-89cb-54a03af0e470)              2. **___ UNIT PO 1X/WEEK (WE)** (Record: 9c9ab9ab-4a9f-4e03-8ad8-d377af91b9d0) - *Note: The exact unit dosage is not specified in this record.*",custom_multi_hop_query_synthesizer,"Based on the provided instructions, I'll answer your question to the best of my abilities.

**Question:** What's the usual dose of Vitamin D prescribed to patients in these hospital records?

**Answer:**

* **Usual Dose of Vitamin D (as per provided records):** 
	+ Based on the documents, there is only one mention of a specific Vitamin D dose for the patient with ID **13180007** (common across all documents).
	+ The dose is: **Vitamin D 1000 UNIT PO DAILY**
		- Document 2: Discharge Medications (List #13)
		- Document 3: Medications on Admission (List #13)

**Important Notes:**

1. **No comparative analysis across patients is possible** since all documents pertain to the same patient (**Patient/Subject ID: 13180007**).
2. **No range or alternative doses are mentioned** in the provided documents for Vitamin D prescriptions for this patient or any other patient (since only one patient's records are shared).
3. **Metadata Priority (Instruction 1)**: While the question doesn't directly ask for IDs or dates, it's confirmed that the patient's ID (**13180007**) is consistent across all documents, reinforcing the context for the Vitamin D dosage query.

**Response Format Compliance:**
- **Exact ID Value**: Patient/Subject ID: **13180007** (mentioned for context, as per Instruction 2)
- **ID Consistency Across Documents**: Yes, the same ID appears in all documents (Document 1 through Document 5), as noted in Instruction 3.
- **Metadata Priority for ID Values**: Confirmed, though not directly applicable to the dosage question.","['___ 09:01AM BLOOD WBC-4.8 RBC-2.88* Hgb-7.4* Hct-24.0* \nMCV-83 MCH-25.7* MCHC-30.8* RDW-16.1* RDWSD-48.5* Plt ___\n___ 09:01AM BLOOD Neuts-78.5* Lymphs-12.1* Monos-7.5 \nEos-1.3 Baso-0.4 Im ___ AbsNeut-', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'In the ED:  \nInitial VS: T 98.5, HR 102, BP 178/76, RR 22, SpO2 98% RA \n \nExam:\nGeneral- NAD\nHEENT- PERRL, EOMI, normal oropharynx\nLungs- Non-labored breathing, CTAB\nCV- RRR, systolic murmur, normal S', 'Social History:\n___\nFamily History:\nHis parents have heart disease.  Mother is ___ with heart \nproblems\nand diabetes.  Father, ___, with diabetes.  He has 16 brothers \nand\nsisters.  There is no known ']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
Whats the perscribd dose of Asprin for the pashent in the givn clinikal kontext?,"['5a643f48-aebd-476f-bd5e-af9cd241686d\n\nCORE MEASURES\n==============\n#CODE: Full\n#CONTACT: ___ daughter HCP\n \n___ on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Lisinopril 2.5 mg PO DAILY \n2. CloNIDine 0.2 mg PO BID \n3. amLODIPine 10 mg PO EVERY OTHER DAY \n4. HydrALAZINE 100 mg PO TID \n5. Aspirin 81 mg PO DAILY \n6. CARVedilol 25 mg PO BID \n7. Atorvastatin 80 mg PO QPM \n8. liraglutide 1.2 mg subcutaneous DAILY \n9. Levothyroxine Sodium 100 mcg PO DAILY \n10. Glargine 55 Units Breakfast\n11. Furosemide 40 mg PO BID \n12. Albuterol Inhaler ___ PUFF IH Q6H:PRN wheezing, SOB \n \nDischarge Medications:\n1.  BD Ultra-Fine Short Pen Needle (pen needle, diabetic) 31 \ngauge x ___ miscellaneous ASDIR  \n2.  Fluticasone-Salmeterol Diskus (250/50)  1 INH IH BID \nRX *fluticasone-salmeterol [Advair Diskus] 250 mcg-50 mcg/dose 1', 'c91e9f73-a3db-4de7-b32b-2595064882de\n\ndose inhaled twice a day Disp #*1 Disk Refills:*0 \n3.  sevelamer CARBONATE 800 mg PO TID W/MEALS \nRX *sevelamer carbonate 800 mg 1 tablet(s) by mouth three times \na day with meals Disp #*90 Tablet Refills:*0 \n4.  Torsemide 40 mg PO DAILY \nRX *torsemide 20 mg 2 tablet(s) by mouth once a day Disp #*60 \nTablet Refills:*0 \n5.  amLODIPine 10 mg PO DAILY  \n6.  CARVedilol 37.5 mg PO BID \nRX *carvedilol 25 mg 1.5 tablet(s) by mouth twice a day Disp \n#*90 Tablet Refills:*0 \n7.  Glargine 30 Units Breakfast\nGlargine 10 Units Bedtime\nHumalog 5 Units Breakfast\nHumalog 5 Units Lunch\nHumalog 5 Units Dinner\nInsulin SC Sliding Scale using HUM Insulin \n8.  Albuterol Inhaler ___ PUFF IH Q6H:PRN wheezing, SOB  \n9.  Aspirin 81 mg PO DAILY \nRX *aspirin 81 mg 1 tablet(s) by mouth once a day Disp #*30 \nTablet Refills:*0 \n10.  Atorvastatin 80 mg PO QPM \nRX *atorvastatin 80 mg 1 tablet(s) by mouth once a day Disp #*30 \nTablet Refills:*0 \n11.  CloNIDine 0.2 mg PO BID \nRX *clonidine HCl 0.2 mg 1 tablet(s) by mouth twice a day Disp']","According to the provided clinical context, the prescribed dose of Aspirin is 81 mg PO (orally) DAILY. This is consistent across both the preadmission medication list (context node: 5a643f48-aebd-476f-bd5e-af9cd241686d, item 5) and the discharge medications (context node: c91e9f73-a3db-4de7-b32b-2595064882de, item 9), with the latter specifying a dispensing quantity of *30 tablets with 0 refills.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, here is the answer to the question:

**Question:** What's the prescribed dose of Aspirin for the patient in the given clinical context?

**Answer:**
* **Prescribed Dose of Aspirin:** 81 mg PO DAILY

**Source:**
* **Document:** Document 5
* **Section:** Discharge Medications
* **Entry:** 5. Aspirin 81 mg PO DAILY

**Metadata Relevance for this Question:** None, as the question pertains to the prescribed medication dose, which is found in the document content, not in the metadata. However, for completeness regarding IDs, which are not directly relevant to this question but confirm the patient context:

* **Patient/Subject ID:** 13180007 (consistent across all documents)
* **Note ID:** 13180007-DS-19 (consistent across all documents)
* **Admission ID:** 20774429 (consistent across all documents)","['In the ED:  \nInitial VS: T 98.5, HR 102, BP 178/76, RR 22, SpO2 98% RA \n \nExam:\nGeneral- NAD\nHEENT- PERRL, EOMI, normal oropharynx\nLungs- Non-labored breathing, CTAB\nCV- RRR, systolic murmur, normal S', 'DISCHARGE PHYSICAL EXAM\n=======================\nGENERAL: NAD. Mood, affect appropriate.  \nHEENT: Normocephalic atraumatic. Sclera anicteric. EOMI.\nConjunctiva were pink. No pallor or cyanosis of the o', 'DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1', '___ 09:01AM BLOOD WBC-4.8 RBC-2.88* Hgb-7.4* Hct-24.0* \nMCV-83 MCH-25.7* MCHC-30.8* RDW-16.1* RDWSD-48.5* Plt ___\n___ 09:01AM BLOOD Neuts-78.5* Lymphs-12.1* Monos-7.5 \nEos-1.3 Baso-0.4 Im ___ AbsNeut-', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
What is the prescribed dosage and administration schedule for CloNIDine upon admission and at discharge?,"['44d8d766-27ad-43f8-9511-d17ad9f10f4d\n\nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. amLODIPine 10 mg PO DAILY \n2. Atorvastatin 80 mg PO QPM \n3. CloNIDine 0.2 mg PO BID \n4. Gabapentin 400 mg PO TID \n5. Lisinopril 40 mg PO DAILY \n6. MetFORMIN (Glucophage) 850 mg PO TID \n7. Metoprolol Tartrate 25 mg PO BID \n8. Basaglar (Glargine) 30 Units Breakfast\n9. Albuterol Inhaler 2 PUFF IH Q4H \n10. Levothyroxine Sodium 100 mcg PO DAILY \n11. Vitamin D ___ UNIT PO WEEKLY \n \nDischarge Medications:\n1.  Aspirin 81 mg PO DAILY \nRX *aspirin 81 mg 1 tablet(s) by mouth once daily Disp #*30 \nTablet Refills:*0 \n2.  Carvedilol 25 mg PO BID \nRX *carvedilol 25 mg 1 tablet(s) by mouth twice daily Disp #*60 \nTablet Refills:*0 \n3.  Furosemide 40 mg PO BID \nRX *furosemide 40 mg 1 tablet(s) by mouth twice daily Disp #*60 \nTablet Refills:*0', 'c91e9f73-a3db-4de7-b32b-2595064882de\n\ndose inhaled twice a day Disp #*1 Disk Refills:*0 \n3.  sevelamer CARBONATE 800 mg PO TID W/MEALS \nRX *sevelamer carbonate 800 mg 1 tablet(s) by mouth three times \na day with meals Disp #*90 Tablet Refills:*0 \n4.  Torsemide 40 mg PO DAILY \nRX *torsemide 20 mg 2 tablet(s) by mouth once a day Disp #*60 \nTablet Refills:*0 \n5.  amLODIPine 10 mg PO DAILY  \n6.  CARVedilol 37.5 mg PO BID \nRX *carvedilol 25 mg 1.5 tablet(s) by mouth twice a day Disp \n#*90 Tablet Refills:*0 \n7.  Glargine 30 Units Breakfast\nGlargine 10 Units Bedtime\nHumalog 5 Units Breakfast\nHumalog 5 Units Lunch\nHumalog 5 Units Dinner\nInsulin SC Sliding Scale using HUM Insulin \n8.  Albuterol Inhaler ___ PUFF IH Q6H:PRN wheezing, SOB  \n9.  Aspirin 81 mg PO DAILY \nRX *aspirin 81 mg 1 tablet(s) by mouth once a day Disp #*30 \nTablet Refills:*0 \n10.  Atorvastatin 80 mg PO QPM \nRX *atorvastatin 80 mg 1 tablet(s) by mouth once a day Disp #*30 \nTablet Refills:*0 \n11.  CloNIDine 0.2 mg PO BID \nRX *clonidine HCl 0.2 mg 1 tablet(s) by mouth twice a day Disp']","According to the provided medication lists, the prescribed dosage and administration schedule for CloNIDine are consistent across both admission and discharge: **CloNIDine 0.2 mg PO (orally) BID (twice a day)**. No changes in dosage or administration schedule are noted between admission and discharge medications.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, here is the response to the current question:

**Question:** What is the prescribed dosage and administration schedule for CloNIDine upon admission and at discharge?

**Answer:**

* **Prescribed Dosage and Administration Schedule for CloNIDine:**
	+ **Upon Admission:** NOT MENTIONED in any of the provided documents (1 through 5).
	+ **At Discharge:** NOT MENTIONED in any of the provided documents (1 through 5), specifically not listed among the **Discharge Medications** in **Document 1**.

**Additional Observations (as per instructions):**

* **Patient/Subject ID:** Consistently reported across all documents as **13180007**.
* **Note ID, Admission ID, Chart Time, and Store Time:** Also consistent across all documents, but not directly relevant to the question about CloNIDine.
* **Medications Mentioned at Discharge (Document 1):** A list of 13 medications is provided, but CloNIDine is not among them. The medications listed include Torsemide, 70/30 Insulin, Albuterol Inhaler, among others.","['Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'DISCHARGE PHYSICAL EXAM\n=======================\nGENERAL: NAD. Mood, affect appropriate.  \nHEENT: Normocephalic atraumatic. Sclera anicteric. EOMI.\nConjunctiva were pink. No pallor or cyanosis of the o', 'Discharge Condition:\nMental Status: Clear and coherent.\nLevel of Consciousness: Alert and interactive.\nActivity Status: Ambulatory - Independent.\n\n \nDischarge Instructions:\n Dear ___,  \n\n It was a ple', 'WHAT HAPPENED WHILE I WAS IN THE HOSPITAL?  \n You were given medications to help get the fluid out. Your \nsymptoms got better and were ready to leave the hospital.  \n\n WHAT DO YOU NEED TO DO WHEN YOU ', 'DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
"What is the role of Aspirin in the treatment of a patient with multiple conditions including hypertension, CAD with inducible ischemia, and NSTEMI, based on the provided medical context?","['5a643f48-aebd-476f-bd5e-af9cd241686d\n\nCORE MEASURES\n==============\n#CODE: Full\n#CONTACT: ___ daughter HCP\n \n___ on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Lisinopril 2.5 mg PO DAILY \n2. CloNIDine 0.2 mg PO BID \n3. amLODIPine 10 mg PO EVERY OTHER DAY \n4. HydrALAZINE 100 mg PO TID \n5. Aspirin 81 mg PO DAILY \n6. CARVedilol 25 mg PO BID \n7. Atorvastatin 80 mg PO QPM \n8. liraglutide 1.2 mg subcutaneous DAILY \n9. Levothyroxine Sodium 100 mcg PO DAILY \n10. Glargine 55 Units Breakfast\n11. Furosemide 40 mg PO BID \n12. Albuterol Inhaler ___ PUFF IH Q6H:PRN wheezing, SOB \n \nDischarge Medications:\n1.  BD Ultra-Fine Short Pen Needle (pen needle, diabetic) 31 \ngauge x ___ miscellaneous ASDIR  \n2.  Fluticasone-Salmeterol Diskus (250/50)  1 INH IH BID \nRX *fluticasone-salmeterol [Advair Diskus] 250 mcg-50 mcg/dose 1', '5afc91e0-6481-46b3-aa3c-473b2c2e6895\n\n#Community acquired pneumonia\nCough, worsened SOB, hypoxemia (although alternate explanation) \nbut no leukocytosis or fevers; influenza negative. Legionella \nand strep were negative. Patient was given a 5-day course of \nceftriaxone and azithromycin. \n#Hypertension\nGoal <130/80. As patient is on several anti-hypertensives with \nstill an elevated blood pressure, he underwent a secondary \nhypertension workup. His last renal ultrasound in ___ was \nwithin normal limits. He was placed on continuous O2 monitoring \novernight, and patient did not desaturate. His aldosterone to \nrenin ratio was 0.13, indicating no primary hyperaldosteronism. \n24 hour urine metanephrines and catecholamines were within \nnormal limits.\n#CAD w/ inducible ischemia\n#NSTEMI\nTroponin peaked at 0.02, thought to be type 2 due to volume \noverload. Continued aspirin, atorvastatin, carvedilol. The \ndecision was made to hold off on coronary angiogram due to \nkidney function and the suspicion that this was type 2.\n#H/o CVA\nPatient had an episode while in hospital with dysarthria,']","Based on the provided context, Aspirin (81 mg PO DAILY) is continued as part of the patient's treatment regimen for CAD with inducible ischemia and NSTEMI. Specifically, for NSTEMI, which was considered type 2 due to volume overload (with a troponin peak at 0.02), Aspirin is maintained alongside atorvastatin and carvedilol. This indicates its importance in managing cardiac conditions, likely for antiplatelet effects to prevent further cardiac events, although the context does not explicitly state its rationale beyond continuation in treatment.",custom_multi_hop_query_synthesizer,"Based on the provided medical context and instructions, here's the answer to the question:

**Question:** What is the role of Aspirin in the treatment of a patient with multiple conditions including hypertension, CAD with inducible ischemia, and NSTEMI, based on the provided medical context?

**Answer Analysis:**

1. **Patient Context**: The patient in question is identified by:
	* **Patient/Subject ID**: 13180007 (consistent across all 5 documents)
	* **Admission ID**: 20774429 (consistent across all 5 documents)
	* **Note ID**: 13180007-DS-19 (consistent across all 5 documents)
2. **Medical Conditions**:
	* **Hypertension**: Confirmed (Document 3)
	* **CAD with Inducible Ischemia**: Not explicitly confirmed; Document 4 mentions ""No known history of CAD"" and ""risk factors for ischemia"" but does not confirm inducible ischemia.
	* **NSTEMI**: Not explicitly mentioned; Document 4 refers to ""chest pain and mild troponin elevation with flat CK-MB"" but does not confirm NSTEMI.
3. **Role of Aspirin**:
	* Based on the provided documents, Aspirin (81 mg PO DAILY) is mentioned in:
		+ **Document 2**: Listed under ""Medications on Admission"" without specific rationale.
		+ **Document 3**: Continued on home aspirin for a history of CVA (Cerebrovascular Accident).
		+ **Document 4**: Continued on ASA (Aspirin) and atorvastatin for chest pain presentation, though CAD/NSTEMI is not confirmed.

**Conclusion**:
Given the patient's confirmed history of CVA (Document 3) and the presence of risk factors for ischemia without confirmed CAD or NSTEMI, the role of Aspirin in this patient's treatment, as per the provided context, appears to be primarily for:

* **Secondary prevention of CVA** (based on Document 3).
* **Potential primary prevention of cardiovascular events** given the patient's risk factors, though this is less clear without explicit diagnosis of CAD or NSTEMI.

**IDs for Reference**:
- **Patient/Subject ID**: 13180007
- **Admission ID**: 20774429
- **Note ID**: 13180007-DS-19 (all documents)","['Social History:\n___\nFamily History:\nHis parents have heart disease.  Mother is ___ with heart \nproblems\nand diabetes.  Father, ___, with diabetes.  He has 16 brothers \nand\nsisters.  There is no known ', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', '# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
"What are the primary reasons for hospital admission and the corresponding in-hospital treatments for patients with conditions related to uncontrolled diabetes and heart failure, based on recent discharge summaries?","['462328c3-90c8-4169-90f0-27fed5e6b04f\n\nDischarge Instructions:\nDear ___, \nIt was a pleasure caring for you here at ___ \n___!\nWHY WAS I IN THE HOSPITAL?\n================================\n- You were admitted to the hospital due to uncontrolled diabetes \nwith blood glucose in a dangerous range. \nWHAT HAPPENED IN THE HOSPITAL?\n================================\n- You were given an insulin drip acutely to lower your glucose, \nfollowed by observation/stabilization on the medicine floor.\n- The ___ diabetes doctors came to help you with your insulin \nregimen; we gave you long acting insulin and insulin with your \ndaily meals. The ___ diabetes doctors talked with your \ndaughters and you to continue 2 medications at home with 2 \ninjections. We monitored your blood sugars here and made sure \nyou ate a healthy diet.\n- You were also given medication to lower your total volume in \nthe body.   \nWHAT SHOULD I DO WHEN I LEAVE THE HOSPITAL?', 'bc70aec9-8d49-462b-9afd-e5bb15b22e94\n\nDischarge Condition:\nMental Status: Clear and coherent.\nLevel of Consciousness: Alert and interactive.\nActivity Status: Ambulatory - Independent.\n \nDischarge Instructions:\nDear ___,  \nIt was a pleasure participating in your care. Please read \nthrough the following information.\nWHY WAS I ADMITTED TO THE HOSPITAL? \n- You were admitted to the hospital because you had been feeling \nshort of breath and you were found to have fluid on your lungs. \nThis was felt to be due to a condition called heart failure, \nwhere your heart does not pump hard enough and fluid backs up \ninto your lungs. \nWHAT HAPPENED WHILE I WAS IN THE HOSPITAL? \n- You were given a diuretic medication through the IV to help \nget the fluid out. You improved considerably and were ready to \nleave the hospital.  \n- You underwent an echocardiogram, which is an ultrasound of']","Based on recent discharge summaries, two primary reasons for hospital admission and their corresponding in-hospital treatments are as follows: nn1. **Uncontrolled Diabetes:**n   - **Reason for Admission:** Uncontrolled diabetes with blood glucose in a dangerous range.n   - **In-Hospital Treatment:** Patients were given an insulin drip to lower glucose levels, followed by observation and stabilization. Specialist diabetes doctors adjusted the patient's insulin regimen, including long-acting insulin and mealtime insulin, with educational support for patients and their families.nn2. **Heart Failure (leading to fluid on the lungs):**n   - **Reason for Admission:** Shortness of breath due to fluid buildup in the lungs, attributed to heart failure where the heart doesn't pump sufficiently.n   - **In-Hospital Treatment:** Administration of diuretic medication intravenously to reduce fluid, significantly improving the patient's condition. Additionally, an echocardiogram (ultrasound of the heart) was performed for further assessment.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Primary Reasons for Hospital Admission:**

Based on the provided discharge summaries (Documents 1-5), the primary reasons for hospital admission for the patient with **ID: 13180007** (common across all documents, indicating they refer to the same patient) are:

1. **Acute on Chronic Diastolic Heart Failure Exacerbation** (Document 1: Discharge Diagnosis - Primary Diagnosis)
2. Associated conditions contributing to the admission include:
	* **Acute Kidney Injury** (Document 1: Discharge Diagnosis - Secondary Diagnosis)
	* **Acute on Chronic Anemia** (Document 1: Discharge Diagnosis - Secondary Diagnosis, and detailed in Document 2)
	* **Type 2 Diabetes Mellitus (uncontrolled)** (Document 1: Discharge Diagnosis - Secondary Diagnosis, and detailed in Document 2 as ""Poorly controlled"" with an A1c of 14.4%)

**Corresponding In-Hospital Treatments:**

1. **For Heart Failure Exacerbation:**
	* **Diuresis with IV Lasix 80** (Document 4: Brief Hospital Course)
	* **Adjustment of Medications** (implied, with specific discharge medications listed in Document 1, including Torsemide, which is often used for heart failure)
2. **For Uncontrolled Diabetes (Type 2 Diabetes Mellitus):**
	* **Insulin Adjustment**:
		+ Initially given **Lantus 30u** at night of admission (Document 2)
		+ Transitioned to **70/30 Insulin** with **30u at breakfast and 10u at lunch** (Documents 1 and 2)
	* **Monitoring and Adjustment of A1c** (implied, with a noted decrease from 14.4% to 11.4% in Document 2, though the timeframe is not specified)
3. **For Acute on Chronic Anemia:**
	* **Ferric Gluconate 250 mg IV** (Document 2, received 3 doses, though the exact dates are not specified)

**Metadata Consistency:**
- **Patient/Subject ID:** Consistently **13180007** across all documents.
- **Note ID, Admission ID, Chart Time, and Store Time:** Also consistent across all documents, indicating these documents pertain to the same hospital admission and discharge process for the patient.","['Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', 'Discharge Condition:\nMental Status: Clear and coherent.\nLevel of Consciousness: Alert and interactive.\nActivity Status: Ambulatory - Independent.\n\n \nDischarge Instructions:\n Dear ___,  \n\n It was a ple', 'DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
What are the notable trends and abnormalities in the patient's calcium levels based on the provided lab results?,"[""88b52764-61ad-4740-9004-35da4cf9a996\n\nAbsMono-0.42 AbsEos-0.09 AbsBaso-0.03\n___ 11:00AM BLOOD Glucose-98 UreaN-32* Creat-2.3* Na-139 \nK-4.1 Cl-100 HCO3-25 AnGap-14\n___ 11:00AM BLOOD ALT-8 AST-9 CK(CPK)-110 AlkPhos-144* \nTotBili-<0.2\n___ 11:00AM BLOOD Albumin-3.5 Calcium-9.2 Mg-2.3\nDISCHARGE LABS:\n___ 06:22AM BLOOD WBC-5.6 RBC-3.86* Hgb-10.1* Hct-32.1* \nMCV-83 MCH-26.2 MCHC-31.5* RDW-14.3 RDWSD-43.4 Plt ___\n___ 06:08AM BLOOD Glucose-157* UreaN-33* Creat-1.9* Na-138 \nK-4.5 Cl-100 HCO3-22 AnGap-16\nIMPORTANT RESULTS:\n___ 11:00AM BLOOD %HbA1c-14.4* eAG-367*\n___ 09:00PM BLOOD TSH-1.3\n___ 11:11AM BLOOD Lactate-1.6\n___ 11:00AM BLOOD CK-MB-4 proBNP-754*\nIMAGING:\nChest X-ray: \nComparison to ___.  On today's radiograph, a small\npleural left-sided calcification is seen.  There also is a small"", '9a673ed7-18d2-4d47-9b22-110fb9514b9b\n\nK-4.2 Cl-103 HCO3-22 AnGap-18\n___ 03:10PM BLOOD Glucose-236* UreaN-29* Creat-2.2* Na-135 \nK-4.1 Cl-96 HCO3-25 AnGap-14\n___ 07:27AM BLOOD Glucose-185* UreaN-27* Creat-2.1* Na-137 \nK-4.3 Cl-97 HCO3-27 AnGap-13\n___ 02:50PM BLOOD Glucose-248* UreaN-31* Creat-2.1* Na-137 \nK-4.6 Cl-97 HCO3-27 AnGap-13\n___ 06:45AM BLOOD Glucose-165* UreaN-27* Creat-2.0* Na-138 \nK-4.3 Cl-98 HCO3-26 AnGap-14\n___ 07:44AM BLOOD Calcium-9.0 Phos-4.4 Mg-1.7\n___ 05:00PM BLOOD Calcium-9.2 Phos-4.8* Mg-3.2*\n___ 07:00AM BLOOD Calcium-8.9 Phos-5.0* Mg-2.3\n___ 02:48PM BLOOD Calcium-9.0 Phos-5.3* Mg-2.2\n___ 07:35AM BLOOD Calcium-8.4 Phos-5.1* Mg-2.0\n___ 03:10PM BLOOD Calcium-8.8 Phos-5.0* Mg-2.1\n___ 07:27AM BLOOD Calcium-8.9 Phos-4.4 Mg-2.0\n___ 02:50PM BLOOD Calcium-8.5 Phos-4.4 Mg-2.1\n___ 06:45AM BLOOD Calcium-8.6 Phos-4.0 Mg-2.0\nLFTs\n___ 09:10AM BLOOD ALT-31 AST-25 AlkPhos-111 TotBili-<0.2\n___ 07:44AM BLOOD CK(CPK)-531*\n___ 07:00AM BLOOD CK(CPK)-509*\nCARDIAC ENZYMES:\n___ 09:10AM BLOOD proBNP-1140*']","Based on the lab results, here are the notable trends and abnormalities in the patient's calcium levels:      - **Variation in Calcium Levels:** Calcium levels fluctuated between 8.4 mg/dL (07:35 AM) and 9.2 mg/dL (05:00 PM and 11:00 AM in the first context node), indicating some variability throughout the day.     - **Abnormalities:** None of the calcium levels provided fall outside the typical normal range (approximately 8.6 to 10.2 mg/dL, though reference ranges may slightly vary). However, it's crucial to consider these in the context of the patient's overall health and other lab results.     - **Associated Abnormalities:** Notably, Phosphate (Phos) levels were occasionally elevated (* denotes abnormality), which can be related to calcium metabolism and may warrant further investigation. For example, a Phos level of 5.3* mg/dL at 02:48 PM is above the normal range (typically about 2.5 to 4.5 mg/dL for adults), which might suggest an imbalance in calcium-phosphate homeostasis.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, here's the response to the question about notable trends and abnormalities in the patient's calcium levels:

**Answer:**

* **Notable Trend/Abnormality:** None explicitly indicated as abnormal in the context of the provided documents. However, we can report the available calcium level.
* **Calcium Level:** 
	+ **Value:** 8.4 (as indicated in Document 1, under ""06:35AM BLOOD"" results, alongside other electrolytes and minerals)
	+ **Unit:** Not explicitly stated in the document, but commonly, calcium levels are reported in mg/dL; assuming this unit for context, 8.4 mg/dL is within the typical normal range (approximately 8.6 to 10.2 mg/dL, though reference ranges can slightly vary by lab).
* **Trend:** No trend can be established with a single data point. Multiple measurements over time would be necessary to identify any trends.
* **Abnormality:** Based on the single reported value (8.4), there is no indication of an abnormality given the common reference range. However, without a specific laboratory reference range provided in the documents, this interpretation is based on general clinical knowledge.

**Metadata Relevance to the Question:**
- **Patient/Subject ID:** 13180007 (consistent across all documents, confirming the lab results pertain to the same patient)
- **Note ID, Admission ID, Chart Time, and Store Time:** While these IDs and timestamps are consistent across documents, indicating the lab result is part of a cohesive set of notes from the same admission period, they do not directly inform the analysis of the calcium level trend or abnormality.","['DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1', 'Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', 'ACUTE PROBLEMS\n==============\n# Acute on chronic HFpEF: \nPatient presented with dyspnea and lower extremity edema and\nfound to be volume overloaded on exam. Warm and wet on exam.\nTrigger for HF exacer', '# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
Whats the perscribed dose of HydrALAZINE for this patient??,"['058d90f2-3d7b-4d29-bca6-e70e3cb19e4d\n\n4.  HydrALAZINE 100 mg PO TID \nRX *hydralazine 100 mg 1 tablet(s) by mouth three times daily \nDisp #*90 Tablet Refills:*0 \n5.  Glargine 30 Units Breakfast \n6.  Albuterol Inhaler 2 PUFF IH Q4H  \n7.  amLODIPine 10 mg PO DAILY  \n8.  Atorvastatin 80 mg PO QPM  \n9.  CloNIDine 0.2 mg PO BID  \n10.  Gabapentin 400 mg PO TID  \n11.  Levothyroxine Sodium 100 mcg PO DAILY  \n12.  MetFORMIN (Glucophage) 850 mg PO TID  \n13.  Vitamin D ___ UNIT PO WEEKLY  \n14. HELD- Lisinopril 40 mg PO DAILY  This medication was held. \nDo not restart Lisinopril until told to do so by your doctor\n15.Outpatient Lab Work\nChem-7 to be draw ___\nICD 10: I50.3: Diastolic (congestive) heart failure\nFax results to: ___ ATTN: ___\n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___', '5a643f48-aebd-476f-bd5e-af9cd241686d\n\nCORE MEASURES\n==============\n#CODE: Full\n#CONTACT: ___ daughter HCP\n \n___ on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Lisinopril 2.5 mg PO DAILY \n2. CloNIDine 0.2 mg PO BID \n3. amLODIPine 10 mg PO EVERY OTHER DAY \n4. HydrALAZINE 100 mg PO TID \n5. Aspirin 81 mg PO DAILY \n6. CARVedilol 25 mg PO BID \n7. Atorvastatin 80 mg PO QPM \n8. liraglutide 1.2 mg subcutaneous DAILY \n9. Levothyroxine Sodium 100 mcg PO DAILY \n10. Glargine 55 Units Breakfast\n11. Furosemide 40 mg PO BID \n12. Albuterol Inhaler ___ PUFF IH Q6H:PRN wheezing, SOB \n \nDischarge Medications:\n1.  BD Ultra-Fine Short Pen Needle (pen needle, diabetic) 31 \ngauge x ___ miscellaneous ASDIR  \n2.  Fluticasone-Salmeterol Diskus (250/50)  1 INH IH BID \nRX *fluticasone-salmeterol [Advair Diskus] 250 mcg-50 mcg/dose 1']","According to the medical records, the prescribed dose of HydrALAZINE for this patient is 100 mg, taken orally (PO) three times daily (TID). This is consistent across both the initial medication list (context ID: 058d90f2-3d7b-4d29-bca6-e70e3cb19e4d, item 4) and the CORE MEASURES list (context ID: 5a643f48-aebd-476f-bd5e-af9cd241686d, item 4).",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, here is the answer to the current question:

**Question:** What's the prescribed dose of HydrALAZINE for this patient??

**Answer:** **NOT MENTIONED**

* **Rationale:**
	+ None of the provided documents (1 to 5) mention ""HydrALAZINE"" in their content.
	+ Since HydrALAZINE is not mentioned, there is no prescribed dose to report.
	+ The documents do mention various other medications with their prescribed doses (e.g., Torsemide, Albuterol, Amlodipine, etc.), but HydrALAZINE is not among them.

**Metadata Relevance:** Not applicable for this question since the query is about a specific medication (HydrALAZINE) that is not mentioned in any of the documents, rather than IDs or dates.","['CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', 'TRANSITIONAL ISSUES\n===================\n[ ] At discharge his symptoms associated with volume overload \nhad subsided, but he was still slightly volume up on exam with \n1+ edema to ankles bilaterally an', 'DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
"What are the key findings and management strategies for a patient with a history of Coronary Artery Disease (CAD) and other comorbidities, as evident from recent hospital admissions and medication lists?","['2574c42a-a6ef-418e-ac90-a21855611d18\n\npulmonary edema. No pneumonia, no pneumothorax.  The lateral \nradiograph shows mild flattening of the hemidiaphragms, \npotentially as a consequence of functional obstruction.\n___ CT HEAD -\n1. No evidence of acute intracranial abnormality.\n2. Unchanged appearance of chronic infarcts within the right \nfrontal lobe and left occipital lobe.\n3. Chronic lacunar infarcts within the right basal ganglia.\n4. Re-demonstration of few calcifications within the pons, \nfindings which are unchanged in appearance and likely sequela of \nprior ischemic or inflammatory process.\nMICRO:\n___ 3:38 pm URINE\n                            **FINAL REPORT ___\n   URINE CULTURE (Final ___:    < 10,000 CFU/mL. \n \nBrief Hospital Course:\nMr. ___ is a ___ ___ speaking male with a \nPMH of prior CVA ___, residual emotional lability, \ndysarthria), HFpEF, uncontrolled DM2, HTN, CAD, CKD, \n?hypothyroidism, asthma, mild cognitive impairment who presented', '8c0badb1-fe3b-4585-8010-1ef4ba8fdd98\n\n================\n# Hx of CAD \n# Hx of ischemic CVA\nStress test in ___ with area of inducible ischemia in LCx \ndistribution. Trop peaked at 0.06 (iso CKD) and then \ndowntrended. No EKG changes seen. Continued home carvedilol, ASA \nand high dose atorvastatin. \n# CKD: Cr at presentation close to baseline. Underlying etiology \nlikely combination of HTN, DM. \n# Hypothyroidism: Continued home levothyroxine 100 mcg daily\n \nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Furosemide 40 mg PO 3X/WEEK (___) \n2. sevelamer CARBONATE 800 mg PO TID W/MEALS \n3. Minoxidil 2.5 mg PO DAILY \n4. Levothyroxine Sodium 100 mcg PO DAILY \n5. CARVedilol 37.5 mg PO BID \n6. amLODIPine 10 mg PO DAILY \n7. Albuterol Inhaler 2 PUFF IH Q6H \n8. Jardiance (empagliflozin) 10 mg oral DAILY \n9. Victoza 3-Pak (liraglutide) 1.2 mg subcutaneous DAILY']","Based on the provided context, key findings for the patient with a history of CAD include:    - **History of CAD** with a past stress test showing inducible ischemia in the LCx distribution, managed with carvedilol, ASA, and high-dose atorvastatin.   - **Comorbidities**: History of ischemic CVA, HFpEF, uncontrolled DM2, HTN, CKD, possible hypothyroidism, asthma, and mild cognitive impairment.   - **Recent Hospital Findings**: No acute intracranial abnormalities on CT HEAD, chronic infarcts in the right frontal and left occipital lobes, and unchanged calcifications within the pons.   - **Medication Management**: The patient is on a comprehensive medication regimen including diuretics (furosemide), sevelamer carbonate for CKD, minoxidil, levothyroxine for hypothyroidism, carvedilol and amlodipine for CAD and HTN, inhalers for asthma, and empagliflozin and liraglutide for DM2 management.   - **Urine Culture**: Showed < 10,000 CFU/mL, indicating no significant urinary tract infection.   Management strategies appear to focus on multifaceted pharmacological intervention to control the patients various comorbid conditions, alongside monitoring for any progression of CAD or other diseases.",custom_multi_hop_query_synthesizer,"**Response to Current Question**

**Patient Identifier:**
* **Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, Document 2, Document 3, Document 4, Document 5)
* **Note ID:** 13180007-DS-19 (consistent across all documents)
* **Admission ID:** 20774429 (consistent across all documents)

**Key Findings for CAD and Comorbidities:**

1. **Coronary Artery Disease (CAD):**
	* **History of CAD:** No known history of CAD (Document 4, # Chest pain)
	* **Risk Factors for Ischemia:** Present, though specifics not detailed (Document 4, # Chest pain)
	* **Recent Assessment:** Troponin elevation but difficult to interpret due to Chronic Kidney Disease (CKD); no evidence of focal wall motion abnormalities on TTE (Document 4, # Chest pain)
2. **Comorbidities and Management Strategies:**
	* **Hypertension (HTN):**
		+ **Control Status:** Currently well controlled (Document 2, # Hypertension)
		+ **Management:** amlodipine 10mg daily, Coreg (carvedilol) 50mg BID, minoxidil 10mg daily (Document 2, # Hypertension, and Document 3, Discharge Medications)
	* **Chronic Kidney Disease (CKD):**
		+ **Status on Admission:** Cr elevated to 2.6 from baseline of 1.8-2.2 (Document 4, # ___ on CKD)
		+ **Management:** Sevelamer continued (Document 4, # ___ on CKD, and Document 3, Discharge Medications)
	* **Diabetes Mellitus (DM):**
		+ **Type:** Type 2 Diabetes Mellitus (Document 3, Discharge Diagnosis)
		+ **Control Status:** Poorly controlled (A1c 14.4, later 11.4%) (Document 2, #IDDM)
		+ **Management:** Transitioned to home insulin with 70/30 30u with breakfast and 20u with lunch; previously given Lantus 30u (Document 2, #IDDM, and Document 3, Discharge Medications)
	* **Heart Failure with preserved Ejection Fraction (HFpEF):**
		+ **Status:** Exacerbation (Document 5, History of Present Illness, and Document 3, Discharge Diagnosis - Acute on chronic diastolic heart failure exacerbation)
		+ **Management:** Not explicitly detailed in provided documents, but patient was on Lasix (furosemide) 80mg daily prior to admission and had recent cardiac telehealth (Document 5, History of Present Illness); discharged with Torsemide 100mg PO daily (Document 3, Discharge Medications)
	* **Hypothyroidism:**
		+ **Management:** Levothyroxine Sodium 100mcg PO daily continued (Document 1, CHRONIC PROBLEMS, Document 2, CHRONIC PROBLEMS, and Document 3, Discharge Medications)
	* **Acute on Chronic Anemia:**
		+ **Status on Admission:** Hb 7.4, improved to 7.6 on discharge after receiving ferric gluconate (Document 2, # Acute on chronic anemia)
	* **Cerebrovascular Accident (CVA):**
		+ **Management:** Aspirin 81mg PO daily and atorvastatin 80mg PO QPM continued (Document 1, #History of CVA, and Document 3, Discharge Medications)

**Discharge Information:**
* **Disposition:** Home With Service (Document 3, Discharge Disposition)
* **Diagnoses at Discharge:**
	1. Primary: Acute on chronic diastolic heart failure exacerbation
	2. Secondary: Acute kidney injury, Acute on chronic anemia, Type 2 Diabetes Mellitus (Document 3, Discharge Diagnosis)","['CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', '# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
"What lab values indicate poor management of Diabetes Mellitus (DM) in the hospitalized male patient with HFpEF, and how might these relate to his discharge medication for diuresis?","['8d31665e-700b-4b64-8af5-51456ad55ff5\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-140 \nK-4.6 Cl-99 HCO3-25 AnGap-16\n___ 06:35AM BLOOD Calcium-8.4 Phos-6.0* Mg-2.1\n \nBrief Hospital Course:\nSUMMARY\n=======\n___ male with history of HFpEF (EF 55-60% in ___,\nprior CVA, CKD, DM, hypertension, and carotid artery disease\nwho presented with 1 day of dyspnea and discomfort, and was\nadmitted for HF exacerbation. The trigger was unclear, possible \nmedication non-compliance. He was diuresed with several doses of \nIV Lasix 80 and by time of discharge symptoms had improved. He \nwas still slightly volume up on exam, with JVP ~12 and 1+ edema \nto ankles.\nTRANSITIONAL ISSUES\n===================\n[ ] At discharge his symptoms associated with volume overload \nhad subsided, but he was still slightly volume up on exam with \n1+ edema to ankles bilaterally and JVP of 12cm. He is being \ndischarged on torsemide 100 daily for active diuresis, with \nabout 3lb of fluid still left to lose.']","Based on the provided context, lab values indicating poor management of Diabetes Mellitus (DM) include: Glucose-164* (elevated, suggesting hyperglycemia), Hgb-7.6* and Hct-24.3* (indicating anemia, which can be a complication of poorly managed DM), and Phos-6.0* (elevated phosphate, which can be seen in diabetic patients due to kidney impairment, as hinted at by CKD in the patient's history). The discharge medication, torsemide 100 daily for active diuresis, aims to reduce volume overload (noted by 1+ edema to ankles and JVP of 12cm at discharge). While torsemide does not directly manage DM, effective diuresis can help in managing fluid overload associated with diabetic nephropathy, indirectly benefiting DM management by reducing the body's fluid volume and, consequently, the workload on the kidneys.",custom_multi_hop_query_synthesizer,"**Answer**

**Patient Identification:**
* **Patient/Subject ID:** 13180007 (consistent across all 5 documents)
* **Note ID:** 13180007-DS-19 (consistent across all 5 documents)
* **Admission ID:** 20774429 (consistent across all 5 documents)

**Lab Values Indicating Poor Management of Diabetes Mellitus (DM):**
* **A1c Levels:**
	+ 14.4% (previous, date not specified in provided documents)
	+ 11.4% (repeat, date not specified in provided documents)
	**Source:** Document 2, `#IDDM` section
* **Glucose Level at Admission (implied, as part of the hospital course):**
	+ 164 (unit assumed to be mg/dL, common for glucose measurements)
	**Source:** Document 1, `DISCHARGE LABS` section, under `BLOOD` results

**Relation to Discharge Medication for Diuresis:**
* **Discharge Medication for Diuresis:** Torsemide 100 mg PO DAILY
* **Potential Relation to DM Management:**
	1. **Impact on Blood Glucose:** Diuretics like torsemide can affect blood glucose levels, potentially worsening glycemic control in diabetic patients. Monitoring of blood glucose is crucial.
	2. **Electrolyte Balance:** Diuretics can lead to electrolyte imbalances (e.g., potassium, sodium). For a patient with DM, especially with elevated glucose and potentially compromised renal function (eGFR not provided but implied with elevated Creatinine), careful monitoring of electrolytes is necessary to prevent complications.
	3. **Renal Function:** The patient's elevated Creatinine (2.9) at discharge, alongside a history of CKD, suggests compromised renal function. Diuretics need to be managed carefully to avoid further renal impairment, which could, in turn, affect glycemic control and overall DM management.

**Recommendation Based on Analysis:**
- Close monitoring of blood glucose levels due to the potential impact of torsemide on glycemic control.
- Regular checks of electrolyte levels to prevent imbalances.
- Scheduled follow-up for renal function assessment, as indicated in Document 5, to adjust medications (including diuretics and potentially those for DM) as necessary to protect renal health and optimize DM management.","['DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', 'ACUTE PROBLEMS\n==============\n# Acute on chronic HFpEF: \nPatient presented with dyspnea and lower extremity edema and\nfound to be volume overloaded on exam. Warm and wet on exam.\nTrigger for HF exacer', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'TRANSITIONAL ISSUES\n===================\n[ ] At discharge his symptoms associated with volume overload \nhad subsided, but he was still slightly volume up on exam with \n1+ edema to ankles bilaterally an']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
"What is the current management and recommendation for the patient's hypertension, specifically regarding the use of hydralazine, given its prior discontinuation by the primary care physician before admission?","['71b11357-64d1-43f3-b5b3-9e2b962adaf4\n\n# Volume overload\n# HFpEF, LVEF 55-60% in ___\nVolume overload on exam. Diuresis began while in ICU, net \nnegative 1.8L prior to transfer. Dry weight appears to be \n154-157. s/p Lasix 80mg x 2 so far. 163.4 lb on ___ A-Strict \nI/Os, daily weights. Continued home carvedilol at increased dose \nas below. He was sent home with PO 60 mg Lasix daily and was net \neven in the hospital. \n# HTN\nBlood pressure medications initially held when he was started on \npropofol. Anti-HTN meds started on day of transfer. Persistently \nhypertensive. Increased carvedilol to 50 mg BID and increased \nminoxidil to 5 mg and continued amlodipine 10 mg QD. Of note, he \nhad been on clonidine and hydralazine but these were stopped by \nPCP just prior to admission. He remained mostly normotensive \nalthough goal SBP <130 and should continue to be goal as an \noutpatient. \n# Normocytic Anemia\nBaseline of ___, secondary to CKD and possible AoCD. Required \n1u pRBC on arrival. Hb stable. \nCHRONIC ISSUES:', '9c9ab9ab-4a9f-4e03-8ad8-d377af91b9d0\n\n11.  Tresiba U-100 Insulin (insulin degludec) 50 units \nsubcutaneous DAILY  \n12.  Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY  \n13.  Vitamin D ___ UNIT PO 1X/WEEK (WE)  \n14. HELD- CloNIDine 0.4 mg PO BID  This medication was held. Do \nnot restart CloNIDine until see what BP is at PCP visit, to see \nif need more meds\n15. HELD- Gabapentin 400 mg PO TID  This medication was held. Do \nnot restart Gabapentin until you discuss with PCP the need for \nit, was not needed during this hospital stay\n16. HELD- HydrALAZINE 100 mg PO TID  This medication was held. \nDo not restart HydrALAZINE until discuss with primary care \ndoctor\n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nType II diabetes']","According to the provided context, hydralazine (100 mg PO TID) was held during the hospital stay. The patient's hypertension management was adjusted by increasing carvedilol to 50 mg BID and minoxidil to 5 mg, continuing amlodipine 10 mg QD, which resulted in mostly normotensive readings, though aiming for SBP <130. The recommendation is not to restart hydralazine until discussed with the primary care doctor, implying that outpatient follow-up will determine the necessity of its reinitiation or alternative adjustments to achieve the desired blood pressure goal.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, I'll address the question to the best of my abilities. However, please note that the question specifically asks about the current management and recommendation for the patient's hypertension, particularly regarding the use of hydralazine, which is not mentioned in any of the provided documents.

**Answer to the Question:**

* **Current Management for Hypertension (as per available documents):**
	+ The patient is currently managed with:
		- Amlodipine 10 mg PO DAILY (Document 1 and Document 4)
		- Carvedilol (Coreg) 50 mg PO BID (Document 1 and Document 2, listed as CARVedilol)
		- Minoxidil 10 mg PO DAILY (Document 1, Document 2, and Document 4)
	+ **No mention of hydralazine** in any of the documents, including its discontinuation by a primary care physician.
	+ **Recommendation regarding hydralazine:** Since hydralazine is not mentioned in any document, there is no recommendation provided in the context of these documents.

**Additional Observations Relevant to the Question:**

* **Patient/Subject ID, Note ID, Admission ID Consistency:** All documents (1 through 5) share the same:
	+ **Patient/Subject ID:** 13180007
	+ **Note ID:** 13180007-DS-19
	+ **Admission ID:** 20774429
	+ **Chart Time and Store Time:** Identical across all documents, indicating simultaneous or very closely timed updates.

* **Hypertension Management Summary (from available data):** The patient's hypertension is described as ""currently well controlled"" in Document 1, with the mentioned medications (amlodipine, carvedilol, and minoxidil). However, without explicit blood pressure readings or further context, the effectiveness of this management can only be inferred from the document's statement.","['# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'TRANSITIONAL ISSUES\n===================\n[ ] At discharge his symptoms associated with volume overload \nhad subsided, but he was still slightly volume up on exam with \n1+ edema to ankles bilaterally an', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
"What are the key considerations and potential complications for a patient with asthma, presenting with no current respiratory distress, but having a complex past medical history including cardiac risk factors and cerebrovascular disease, in a long-term healthcare management context?","['281ec1ee-1c32-43a3-8667-6c9eaa2f4734\n\nEKG:  SR, NL axis, NIs, TWIs laterally (c/w prior) \nLabs/studies notable for:  proBNP: 1140, Cr 1.9\nPatient was given:  IV Furosemide 10mg\nOn the floor...  \n---------------\nStates that he feels better than he did when he came to the\nhospital. No SOB, CP, or palpitations. Only complaint is the\nburning/itching in his lower extremities. \n \nPast Medical History:\n1. CARDIAC RISK FACTORS  \n- Type 2 Diabetes Mellitus\n- Hypertension  \n- Dyslipidemia  \n- Coronary artery disease\n2. CARDIAC HISTORY  \n- Secondum ASD\n- Mild AR\n3. OTHER PAST MEDICAL HISTORY  \n- Extensive intracranial atherosclerosis, worse in the right\nMCA territory.\n- Cerebrovascular disease, status post CVA in ___\n- Asthma\n- OSteoarthritis', '3a943d1f-0e52-4cc8-939c-42f2386be179\n\n- Cerebrovascular disease, status post CVA in ___\n- Asthma\n- OSteoarthritis\n \nSocial History:\n___\nFamily History:\nBoth parents have heart disease. Mother-___ w/ heart problems and\ndiabetes & father is ___ w/ diabetes. 16 brothers and sisters. No\nknown hx of early coronary artery disease or sudden cardiac \ndeath.\n \nPhysical Exam:\nADMISSION EXAM:\nVS: ___ Temp: 97.3 PO BP: 168/78 HR: 85 RR: 18 O2 sat:\n97% O2 delivery: RA Dyspnea: 0 RASS: 0 Pain Score: ___ \nGEN: alert and interactive, comfortable, no acute distress\nHEENT: PERRL, anicteric, conjunctiva pink, oropharynx without\nlesion or exudate, moist mucus membranes, ears without lesions \nor\napparent trauma\nLYMPH: no anterior/posterior cervical, supraclavicular \nadenopathy']","Based on the provided context, key considerations for managing a patient with asthma, like the one described, include monitoring for potential exacerbations, especially given the patient's complex past medical history. Notably, the patient's current presentation without SOB (shortness of breath), CP (chest pain), or palpitations, but with a complaint of burning/itching in lower extremities, suggests that asthma is not currently the primary acute concern. However, the patient's history of cardiac risk factors (Type 2 Diabetes Mellitus, Hypertension, Dyslipidemia, Coronary artery disease), cardiac history (Secondum ASD, Mild AR), and cerebrovascular disease (status post CVA), alongside extensive intracranial atherosclerosis, necessitates a holistic approach. This includes careful management of medications (e.g., the IV Furosemide given for an unspecified but likely cardiac-related issue, given the proBNP and Cr levels), regular monitoring for signs of cardiac decompensation or stroke, and adjusting asthma management to prevent triggering other conditions. The patient's family history of heart disease and diabetes also warrants close long-term monitoring for early signs of these conditions. Physical exams, like the one documented, are crucial for ongoing assessment, particularly focusing on the patient's comfort, distress levels, and specific systemic evaluations (e.g., HEENT, Lymphatic).",custom_multi_hop_query_synthesizer,"**Key Considerations and Potential Complications for Long-term Healthcare Management**

**Patient Identification:**
* **Patient/Subject ID:** 13180007 (consistent across all 5 documents)
* **Note ID:** 13180007-DS-19 (consistent across all 5 documents)
* **Admission ID:** 20774429 (consistent across all 5 documents)

**Clinical Summary:**

1. **Asthma:** Currently, no respiratory distress is noted (Document 3: Physical Exam, and implied in Document 2: Vitals and Symptoms). However, management of asthma is crucial to prevent exacerbations, especially with a history of dyspnea on exertion (Document 4: History of Present Illness).
   
2. **Cardiac Risk Factors and Disease:**
   - **Hypertension** (Document 2: Past Medical History)
   - **Dyslipidemia** (Document 2: Past Medical History)
   - **Carotid Artery Disease** (Document 2: Past Medical History)
   - **Secundum ASD** (Document 2: Past Medical History)
   - **Mild AR** (Document 2: Past Medical History)
   - **History of CVA** (Document 1: Chronic Problems, Document 2: Past Medical History)
   - **Extensive Intracranial Atherosclerosis** (Document 2: Past Medical History)
   - **HFpEF (EF 55-60%)** (Document 4: History of Present Illness)

3. **Other Relevant Conditions:**
   - **Diabetes Mellitus Type 2** (Document 2: Past Medical History)
   - **Chronic Kidney Disease (CKD)** with elevated Cr (2.6 on admission, 2.9 at discharge) (Document 5: # ___ on CKD)
   - **Hypothyroidism** (Document 1: Chronic Problems)
   - **Osteoarthritis** (Document 2: Past Medical History)

**Key Considerations for Long-term Management:**

1. **Multidisciplinary Care Approach:** Given the complexity of the patient's medical history, a team of specialists (cardiologist, neurologist, endocrinologist, nephrologist, pulmonologist) should collaborate for comprehensive management.

2. **Medication Management:**
   - **Adherence Monitoring:** Ensure compliance with the extensive medication list (Document 1: Medications on Admission), emphasizing the importance of each drug in managing their conditions.
   - **Regular Review and Adjustment:** Periodically review medications to minimize polypharmacy risks, adjust doses as necessary (e.g., for CKD, renal function impacts drug clearance), and manage potential interactions.

3. **Monitoring and Surveillance:**
   - **Regular Cardiac and Neurological Evaluations:** To assess for progression of cardiac disease or new cerebrovascular events.
   - **Renal Function Monitoring:** Regular serum creatinine checks to manage CKD progression.
   - **Diabetic Care:** Tight blood glucose control through diet, exercise, and medication adjustments as needed.
   - **Asthma Management:** Regular peak flow monitoring, symptom assessment, and adjustment of asthma medications to prevent exacerbations.

4. **Lifestyle Modifications:**
   - **Dietary Counseling:** For management of diabetes, dyslipidemia, hypertension, and CKD.
   - **Exercise Program:** Tailored to the patient's capabilities, focusing on cardiovascular health, strength, and flexibility, while considering osteoarthritis.
   - **Smoking Cessation (if applicable):** Given the cardiac and cerebrovascular risks.

5. **Family History and Genetic Counseling:**
   - **Heart Disease and Diabetes in Family History:** Discuss implications with the patient and consider screening for family members if warranted.

**Potential Complications to Anticipate and Prevent:**

1. **Cardiovascular Events:** Myocardial infarction, stroke, or transient ischemic attack due to untreated or undertreated risk factors.
2. **Renal Function Decline:** Progression of CKD to end-stage renal disease requiring dialysis or transplantation.
3. **Diabetic Complications:** Neuropathy, retinopathy, or nephropathy from poorly controlled diabetes.
4. **Asthma Exacerbations:** Severe respiratory distress requiring emergency intervention.
5. **Medication Adverse Effects:** Especially in the context of polypharmacy and renal impairment.","['CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n', 'Social History:\n___\nFamily History:\nHis parents have heart disease.  Mother is ___ with heart \nproblems\nand diabetes.  Father, ___, with diabetes.  He has 16 brothers \nand\nsisters.  There is no known ', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver', '# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
What is the prescribed dosage of Hydralazine for a patient post-hospital discharge for managing hypertension alongside other conditions?,"['71b11357-64d1-43f3-b5b3-9e2b962adaf4\n\n# Volume overload\n# HFpEF, LVEF 55-60% in ___\nVolume overload on exam. Diuresis began while in ICU, net \nnegative 1.8L prior to transfer. Dry weight appears to be \n154-157. s/p Lasix 80mg x 2 so far. 163.4 lb on ___ A-Strict \nI/Os, daily weights. Continued home carvedilol at increased dose \nas below. He was sent home with PO 60 mg Lasix daily and was net \neven in the hospital. \n# HTN\nBlood pressure medications initially held when he was started on \npropofol. Anti-HTN meds started on day of transfer. Persistently \nhypertensive. Increased carvedilol to 50 mg BID and increased \nminoxidil to 5 mg and continued amlodipine 10 mg QD. Of note, he \nhad been on clonidine and hydralazine but these were stopped by \nPCP just prior to admission. He remained mostly normotensive \nalthough goal SBP <130 and should continue to be goal as an \noutpatient. \n# Normocytic Anemia\nBaseline of ___, secondary to CKD and possible AoCD. Required \n1u pRBC on arrival. Hb stable. \nCHRONIC ISSUES:', 'cd30826d-ad9e-4a08-8b63-15e1e3bbfe0c\n\nYou were admitted to the hospital because:\n================================\n-You had worsening shortness of breath, with increased leg \nswelling and weight gain.\nDuring your stay:\n============\n-You had too much volume onboard so you were given IV diuretic \nmedications,. You improved significantly.\nAfter your discharge:\n================\n-Please continue taking all medications as prescribed (see \nbelow).\n-Please stop taking Lisinopril and metoprolol.\n-Please continue taking insulin according to the regimen you \nwere following before this admission.\n-New medications:\n  - Aspirin 81mg once daily\n  - Carvedilol 25mg twice daily\n  - Furosemide 40mg twice daily\n  - Hydralazine 100mg three times daily\n-Please attend any upcoming outpatient appointments you have \n(see below).\nWe wish you the very best!']","According to the discharge instructions, the patient is prescribed Hydralazine 100mg three times daily, in addition to other medications such as Carvedilol and Furosemide, for managing conditions that include hypertension, indicating a return to this medication after it was stopped by the PCP just prior to the hospital admission.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Prescribed Dosage of Hydralazine:**
* **Dosage:** Not Specified
* **Reason:** Hydralazine is not mentioned in any of the provided documents (Document 1 through Document 5) as part of the patient's discharge medications or hospital treatment plan.

**Relevant Hypertension Management Medications (as per the documents):**
* **amLODIPine 10 mg PO DAILY** (mentioned in Document 1 and Document 2 as part of the patient's discharge and admission medications, respectively)
* **CARVedilol 50 mg PO BID** (mentioned in Document 1 and Document 2 as part of the patient's discharge and admission medications, respectively)
* **Torsemide 100 mg PO DAILY** (mentioned in Document 1 as a discharge medication for active diuresis, which can also be relevant in managing volume overload associated with heart failure, a condition that often co-exists with hypertension)

**Metadata Consistency for Patient/Subject ID, Note ID, and Admission ID across Documents:**
* **Patient/Subject ID:** Consistently listed as **13180007** across all documents.
* **Note ID:** Consistently listed as **13180007-DS-19** across all documents.
* **Admission ID:** Consistently listed as **20774429** across all documents.
* **Chart Time and Store Time:** Consistent across all documents, indicating simultaneous or closely timed charting and storage of these notes.","['Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1', 'Discharge Condition:\nMental Status: Clear and coherent.\nLevel of Consciousness: Alert and interactive.\nActivity Status: Ambulatory - Independent.\n\n \nDischarge Instructions:\n Dear ___,  \n\n It was a ple', 'TRANSITIONAL ISSUES\n===================\n[ ] At discharge his symptoms associated with volume overload \nhad subsided, but he was still slightly volume up on exam with \n1+ edema to ankles bilaterally an']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
"What treatment approach was taken for patient with CAD w/ inducible ischemia & NSTEMI, considering kidney function?","['5afc91e0-6481-46b3-aa3c-473b2c2e6895\n\n#Community acquired pneumonia\nCough, worsened SOB, hypoxemia (although alternate explanation) \nbut no leukocytosis or fevers; influenza negative. Legionella \nand strep were negative. Patient was given a 5-day course of \nceftriaxone and azithromycin. \n#Hypertension\nGoal <130/80. As patient is on several anti-hypertensives with \nstill an elevated blood pressure, he underwent a secondary \nhypertension workup. His last renal ultrasound in ___ was \nwithin normal limits. He was placed on continuous O2 monitoring \novernight, and patient did not desaturate. His aldosterone to \nrenin ratio was 0.13, indicating no primary hyperaldosteronism. \n24 hour urine metanephrines and catecholamines were within \nnormal limits.\n#CAD w/ inducible ischemia\n#NSTEMI\nTroponin peaked at 0.02, thought to be type 2 due to volume \noverload. Continued aspirin, atorvastatin, carvedilol. The \ndecision was made to hold off on coronary angiogram due to \nkidney function and the suspicion that this was type 2.\n#H/o CVA\nPatient had an episode while in hospital with dysarthria,', 'd2113a66-fe4f-4869-b3c0-73646862b32b\n\ngluconate (received 3 doses ___. Upon review of recent \noutpatient visit notes, it appears his volume exam is similar to \nbaseline, and patient was asymptomatic during hospital course. \nHe was diuresed effectively with IV Lasix 80. He was \ntransitioned to PO torsemide 100. His BP was well controlled \nwith regimen as described below.\n# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\nat or lower than levels earlier this year. He has denied chest\npain during admission. He does have risk factors for ischemia \nand\nhas not had stress since ___. However, findings and history \nto\ndate are not suggestive of ischemia and he has an ___. TTE did \nnot show evidence of focal wall motion abnormalities or other \nfindings suggestive of ischemia, so further workup was not \npursued. He was continued on ASA and atorvastatin.\n# ___ on CKD:\nCr elevated to 2.6 on admission from baseline of 1.8-2.2. Given\nevidence of congestion elsewhere, concerns for renal congestion\ncausing renal dysfunction. Cr remained stable and was 2.9 on day \nof discharge. He was continued on home sevelamer.']","For the patient with CAD w/ inducible ischemia & NSTEMI, the decision was made to hold off on coronary angiogram due to kidney function concerns and the suspicion that the NSTEMI was type 2 (likely due to volume overload, as troponin peaked at 0.02). The patient was continued on aspirin, atorvastatin, and carvedilol.",custom_multi_hop_query_synthesizer,"Based on the provided documents and the instructions for answering, here's the response to the current question:

**Question:** What treatment approach was taken for patient with CAD w/ inducible ischemia & NSTEMI, considering kidney function?

**Answer Analysis:**

1. **Patient ID Confirmation**: The patient's ID, as per the metadata across all documents (1 through 5), is consistently **13180007**. This ID is mentioned in every document's metadata, confirming it as the subject's identifier.

2. **CAD w/ Inducible Ischemia & NSTEMI Treatment Approach**:
   - **CAD and Ischemia**: Document 1 discusses chest pain with mild troponin elevation but suggests that findings and history to date are ""not suggestive of ischemia."" It mentions the patient has risk factors for ischemia but does not confirm inducible ischemia or NSTEMI. The treatment approach for CAD risk factors includes continuation of ASA (Aspirin) and atorvastatin.
   - **NSTEMI**: There is no explicit mention of NSTEMI (Non-ST Elevation Myocardial Infarction) in the provided documents. The closest reference is to ""chest pain with mild troponin elevation,"" but this is interpreted in the context of CKD (Chronic Kidney Disease), not definitively as NSTEMI.
   - **Considering Kidney Function (CKD)**: 
     - For **CKD**, the approach includes monitoring and managing elevated Creatinine (Cr) levels. The patient's Cr was elevated at admission (2.6) and remained so at discharge (2.9), with concerns for renal congestion causing renal dysfunction. The patient was continued on home sevelamer (Document 1).
     - **Iron Deficiency Anemia in CKD**: The patient received ferric gluconate (250 mg IV, with 3 doses mentioned across documents) for acute on chronic anemia, possibly related to worsening renal function (Document 2 and Document 4).

**Treatment Approach Summary (Based on Provided Documents)**:
- **For CAD Risk Factors**: Continuation of ASA and atorvastatin.
- **For CKD and Related Anemia**: Monitoring of Cr levels, continuation of home sevelamer, and treatment with ferric gluconate for anemia.
- **Note**: The specific scenario of ""CAD w/ inducible ischemia & NSTEMI"" is not directly addressed in the documents as the primary conditions discussed. The response provides the closest relevant treatment approaches based on the information given.

**Metadata ID Confirmation**:
- **Patient/Subject ID**: 13180007 (Consistent across Documents 1 through 5)
- **Note ID**: 13180007-DS-19 (Consistent across Documents 1 through 5)
- **Admission ID**: 20774429 (Consistent across Documents 1 through 5)","['# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'ACUTE PROBLEMS\n==============\n# Acute on chronic HFpEF: \nPatient presented with dyspnea and lower extremity edema and\nfound to be volume overloaded on exam. Warm and wet on exam.\nTrigger for HF exacer', 'TRANSITIONAL ISSUES\n===================\n[ ] At discharge his symptoms associated with volume overload \nhad subsided, but he was still slightly volume up on exam with \n1+ edema to ankles bilaterally an']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
"What are the key findigns from the CT scans (head, abd/pelvis, C spine) for a patient with edema, and how do these relait to possibl aspiration or pneumonia, based on the providd medikal imagig reports?","['a0523bf3-a15e-4abc-bd78-1c98b6c5dc7e\n\nedema.  No\nevidence of displaced fracture.\nCT head ___:\nThere is no evidence of infarction, hemorrhage, edema,or midline \nshift.  There\nis prominence of the ventricles and sulci suggestive of \ninvolutional changes.\n \nThere is no evidence of fracture.  Opacification of the mastoid \nair cells. \nThe visualized portion of the paranasal sinuses, mastoid air \ncells, and middle\near cavities are clear.  The visualized portion of the orbits \nare\nunremarkable.\nCT abd/pelvis ___:\n1. Bilateral lower lobe opacities, concerning for aspiration or \npneumonia.\n2. No acute finding in the abdomen or pelvis.\nCT C spine ___:\nNG tube and endotracheal tube are noted.  Alignment is normal. \nNo fractures\nare identified. There is no evidence of high-grade spinal canal', 'dd2587c0-7ebc-4cd2-878e-f8cd5d8d0c1b\n\nBMP - Na 135, K 5, Cr 2.0 (baseline ___, HCO3 20, BG 625, AG 16\nCa 8, phos 6.6\nUA - neg leuk, neg nitr, 7 WBC, neg ketone, 1000 glucose\nUrine tox negative\nTSH pending\nBCx, UCx\nTrop 0.03 -> 0.06\nEKG with T-wave inversion in lateral leads, unchanged from prior\nImaging:  \n- CT head w/o contrast:\n1. No evidence of intracranial bleed. No evidence of acute\nintracranial abnormality.\n2. Opacification of the mastoid air cells.\n- CT C-spine w/o contrast\nNo evidence of acute fracture or malalignment\n- CT A/P w/o contrast\n1. No evidence of acute abdominal or pelvic abnormality. \n2. Extensive bibasilar atelectasis. \n3. Small left pleural effusion. \n- CXR\nSmall left pleural effusion. Opacities likely represent\natelectasis however pneumonia cannot be excluded in the correct\nclinical setting. \nConsults: none']","Based on the provided medical imaging reports, here are the key findings from the CT scans and their relation to possible aspiration or pneumonia:       1. **CT Head**: No evidence of infarction, hemorrhage, edema, or midline shift. Prominence of ventricles and sulci suggests involutional changes. No fracture, but opacification of mastoid air cells is noted.       2. **CT Abd/Pelvis**: **Key Finding Relevant to Aspiration/Pneumonia**: Bilateral lower lobe opacities, concerning for **aspiration or pneumonia**. No acute findings in the abdomen or pelvis.       3. **CT C Spine**: Normal alignment, no fractures, and no evidence of high-grade spinal canal stenosis. NG and endotracheal tubes are noted, which might relate to the patient's condition leading to or resulting from aspiration or pneumonia, but the CT C Spine itself does not directly indicate aspiration or pneumonia.       **Relation to Aspiration/Pneumonia**: The primary indicator from the CT scans for aspiration or pneumonia comes from the **CT Abd/Pelvis**, highlighting bilateral lower lobe opacities. This finding, coupled with the clinical context (e.g., edema, the presence of endotracheal tubes suggesting respiratory support), supports the concern for aspiration or pneumonia. The **CXR** from the second report further supports this with small left pleural effusion and opacities likely representing atelectasis, though it also cannot exclude pneumonia without the correct clinical setting.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, I must point out that:

1. **There are no CT scan reports (head, abd/pelvis, C spine) mentioned in the provided documents**. The documents primarily discuss the patient's admission, treatment, labs, and discharge instructions, with some mentions of imaging, but specifically:
	* Document 1 mentions a **CXR (Chest X-Ray)**, not a CT scan, showing ""Mild pulmonary vascular congestion with small bilateral pleural effusions, left greater than right.""
	* No other imaging reports (CT scans for head, abd/pelvis, C spine) are referenced in the provided documents.
2. **No direct information is provided regarding aspiration or pneumonia** in the context of CT scans, as no such scans are reported.

Given these observations, I must provide a response that aligns with the instructions while highlighting the absence of relevant information:

**Answer to the Current Question:**

* **Key findings from CT scans (head, abd/pelvis, C spine):** **NOT AVAILABLE** (No CT scan reports for these areas are provided in the documents.)
* **Relation to possible aspiration or pneumonia based on provided medical imaging reports:** **NOT APPLICABLE** (Due to the absence of relevant CT scan reports and direct mentions of aspiration or pneumonia in the context of such scans.)

**Metadata Observations (as per instruction 3):**

* **Patient/Subject ID: 13180007** is consistently mentioned across all documents (1 through 5).
* **Note ID: 13180007-DS-19**, **Admission ID: 20774429**, **Chart Time: 20/06/62 0:00**, and **Store Time: 21/06/62 9:56** are also identical across all five documents.","['In the ED:  \nInitial VS: T 98.5, HR 102, BP 178/76, RR 22, SpO2 98% RA \n \nExam:\nGeneral- NAD\nHEENT- PERRL, EOMI, normal oropharynx\nLungs- Non-labored breathing, CTAB\nCV- RRR, systolic murmur, normal S', 'Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n', 'TRANSITIONAL ISSUES\n===================\n[ ] At discharge his symptoms associated with volume overload \nhad subsided, but he was still slightly volume up on exam with \n1+ edema to ankles bilaterally an', 'DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1', 'WHAT HAPPENED WHILE I WAS IN THE HOSPITAL?  \n You were given medications to help get the fluid out. Your \nsymptoms got better and were ready to leave the hospital.  \n\n WHAT DO YOU NEED TO DO WHEN YOU ']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
"What is the current treatment plan for a patient with Hypothyroidism, and how does it relate to their other chronic conditions like Hypertension and IDDM, considering their recent discharge diagnosis and condition?","['08e7114b-32bf-470b-a3c6-d919c6de4e69\n\n# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n# Acute on chronic anemia:\nHb on admission was 7.4. No evidence of bleeding per history or \nexam. Possibly related to worsening of his renal function vs \ndilutional iso heart failure. His Hb was 7.6 on discharge. He \nreceived 3 doses of ferric gluconate 250 mg IV on ___.\n#IDDM\nPoorly controlled. A1c 14.4 in ___ in ___ at ___. \nRepeat A1C ___ was 11.4%. He was given Lantus 30u night of \nadmission, then transitioned to home insulin ___ with 70/30 \n30u with breakfast and 20u with lunch. He was also on ISS while \ninpatient.\nCHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.', '8ffe5463-ba8e-4c92-be15-e075478499d9\n\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPRIMARY:\n=======================================\nHyperglycemic hyperosmolar syndrome \nType 2 diabetes mellitus\nSECONDARY: \n=======================================\nCoronary artery disease\nChronic kidney disease\nHypertension\nHeart failure preserved ejection fraction\nNormocytic Anemia\nHypothyroidism\n \nDischarge Condition:\nMental Status: Clear and coherent.\nLevel of Consciousness: Alert and interactive.\nActivity Status: Ambulatory - Independent.']","According to the patient's records, for Hypothyroidism, the patient is continued on home levothyroxine 100mcg daily. This treatment plan is managed alongside other chronic conditions. For Hypertension, the patient is on home amlodipine 10, Coreg 50 BID, and minoxidil 10 daily, with the condition currently well controlled. For IDDM (Poorly controlled with an A1c of 14.4, later improved to 11.4%), the patient was transitioned from Lantus 30u at night of admission to home insulin with 70/30 30u with breakfast and 20u with lunch, also utilizing ISS while inpatient. At discharge, the patient's mental status was clear and coherent, alert, interactive, and ambulatory-independent, with Hypothyroidism listed among the secondary discharge diagnoses, indicating its ongoing management as part of the patient's overall care plan.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Patient Identification:**
Based on the provided metadata, the patient's details are consistent across all documents:
* **Patient/Subject ID:** 13180007
* **Note ID:** 13180007-DS-19 (consistent across all documents, indicating these notes are part of the same medical record)
* **Admission ID:** 20774429 (also consistent, confirming a single admission period for these notes)

**Current Treatment Plan for Hypothyroidism and Relation to Other Conditions:**

1. **Hypothyroidism Treatment:**
   - **Current Treatment:** Levothyroxine Sodium 100 mcg PO DAILY (as per Document 1 and Document 2)
   - **Relation to Other Conditions:** The treatment for hypothyroidism is maintained consistently across the documents, indicating no adjustments were made in response to the patient's recent discharge diagnoses (Acute on chronic diastolic heart failure exacerbation, acute kidney injury, acute on chronic anemia, type 2 diabetes mellitus). This suggests that the hypothyroidism is being managed independently of the acute conditions, with the current dosage deemed appropriate.

2. **Hypertension:**
   - **Current Treatment (as per Document 2):** 
     - Amlodipine 10 mg PO DAILY
     - Coreg (Carvedilol) 50 BID
     - Minoxidil 10 mg PO DAILY
   - **Relation to Hypothyroidism and Recent Diagnoses:** The hypertension treatment plan is not directly adjusted in response to the hypothyroidism treatment. However, the overall management of the patient's conditions, including the recent heart failure exacerbation, likely influences the choice to maintain or adjust the hypertension medications. The consistent use of these medications across the documents (e.g., Document 1 lists the preadmission medications which include these, and Document 3 lists them as discharge medications) suggests a balanced approach to managing both hypertension and the other conditions without needing to adjust the hypothyroidism treatment.

3. **IDDM (Insulin-Dependent Diabetes Mellitus) / Type 2 Diabetes Mellitus:**
   - **Current Treatment (as per Document 2 and Document 3):**
     - Insulin regimen: 70/30 30 Units with Breakfast and 10 Units with Lunch
     - Additional medications like Victoza (Liraglutide) for diabetes management are continued (Document 1 and Document 3)
   - **Relation to Hypothyroidism and Recent Diagnoses:** The management of IDDM/Type 2 Diabetes Mellitus is closely monitored, with adjustments made during the admission (e.g., the transition to a specific insulin regimen). The treatment for hypothyroidism is not directly linked to the adjustments in diabetes management, but both are part of the patient's overall chronic condition management plan. The recent discharge diagnoses, particularly the acute on chronic conditions, necessitate careful monitoring of the diabetes management plan, but the hypothyroidism treatment remains consistent.

**Summary:**
- The patient's hypothyroidism is managed with a consistent dose of Levothyroxine Sodium.
- The treatments for hypertension and IDDM/Type 2 Diabetes Mellitus are managed concurrently, with adjustments based on the patient's recent acute conditions, but without direct impact on the hypothyroidism treatment plan.
- All treatments are part of a comprehensive approach to managing the patient's multiple chronic and acute conditions.","['CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'TRANSITIONAL ISSUES\n===================\n[ ] At discharge his symptoms associated with volume overload \nhad subsided, but he was still slightly volume up on exam with \n1+ edema to ankles bilaterally an', 'DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
"What specific adjustments were made to the patient's medication regimen during the recent hospitalization to manage poorly-controlled Type 2 Diabetes Mellitus (T2DM) with Hyperosmolar Hyperglycemic State (HHS), and what follow-up actions are recommended for the Clinical Care Coordinator to ensure the patient's continued care?","['386e4975-89d1-411a-99a3-9d225138df6c\n\n[] Ensure that patient was able to adhere to a diabetic diet\nPCP:\n[] Had elevated SBP in 130s-150s. Increased minoxidil to 5mg and \ncarvedilol to 50 mg BID. Please follow-up on blood pressures. \n[] Follow up on diuretics and volume status. Please get \nfollow-up labs BUN/Cr at follow-up appointment.\nNew meds: 70-30 novolog (30 units in AM, 20 units at dinner)\nStopped meds: none\nChanged meds: Carvedilol 50 mg twice a day, increased minoxidil \n5 mg daily \nACUTE ISSUES: \n=============== \n# HHS\n# T2DM\nPatient has history of poorly-controlled DM w/ A1c ~14. Based on \nlabs, determined to be in HHS likely precipitated by med \nnon-adherence or difficulty understanding multi-step process. No \nclear infection was identified. Of note, he tends to have high \ninsulin requirements. Pt was continued on insulin basal/bolus \nwhile inpatient. There was significant efforts to have him bring \nin home Victoza but he only had a half dose so he was continued \non basal/bolus course and made a plan for close outpatient \nfollow up and home 2 injections (Victoza and pre-mixed insulin).']","During the hospitalization, adjustments to the patient's medication regimen included increasing carvedilol to 50 mg twice a day and minoxidil to 5 mg daily. The patient was also continued on insulin basal/bolus. For discharge, a plan was made for close outpatient follow-up with the patient administering two injections at home: Victoza and pre-mixed insulin (70-30 novolog, with 30 units in the AM and 20 units at dinner). As the Clinical Care Coordinator, recommended follow-up actions include: (1) ensuring the patient adheres to the diabetic diet, (2) following up on blood pressures given the recent medication changes, (3) monitoring diuretics and volume status, and (4) obtaining follow-up labs (BUN/Cr) at the next appointment to assess the effectiveness of the current regimen and make any necessary adjustments.",custom_multi_hop_query_synthesizer,"**Response to Current Question**

**Specific Adjustments to Medication Regimen for T2DM during Hospitalization:**

Based on the provided documents, the specific adjustments made to the patient's medication regimen to manage poorly-controlled Type 2 Diabetes Mellitus (T2DM) during the recent hospitalization are:

1. **Initial Adjustment**: Administration of **Lantus 30u** on the night of admission (Document 1).
2. **Transition to Home Insulin Regimen**: Transitioned from Lantus to **70/30 Insulin** with a specified dosage of:
	* **30u with breakfast**
	* **20u with lunch** (Document 1 and reinforced in Document 4 as part of the discharge medications).
3. **Continuation of Other Diabetes-Related Medications**:
	* **Victoza (Liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) subcutaneous DAILY** was continued as part of the patient's home medication regimen (Document 2 and Document 4).

**Note on Hyperosmolar Hyperglycemic State (HHS)**: While the question mentions HHS, the documents provided do not explicitly state that the patient was diagnosed with HHS during this hospitalization. The focus is on managing poorly controlled T2DM.

**Follow-up Actions for the Clinical Care Coordinator:**

To ensure the patient's continued care, the Clinical Care Coordinator should:

1. **Verify Medication Adherence**:
	* Confirm the patient understands and is adhering to the new insulin regimen (70/30 Insulin with specified dosages) and the continued use of Victoza.
2. **Schedule Follow-Up Appointments**:
	* Ensure the patient has scheduled and keeps follow-up appointments with their healthcare providers as listed (though specifics are not provided in Document 5).
3. **Monitor for Danger Signs and Weight Changes**:
	* Educate the patient (if not already done) on the ""danger signs"" to watch for (specifics not provided in the documents) and the importance of monitoring weight, with instructions to call the doctor if weight increases or decreases by more than 3 pounds in one day or 5 pounds in one week.
4. **Glycemic Control Monitoring**:
	* Arrange for or recommend regular blood glucose monitoring and HbA1c checks to assess the effectiveness of the current regimen and make adjustments as necessary. The last known HbA1c was 11.4% (Document 1), indicating a need for close monitoring.

**Metadata Consistency**:
- **Patient/Subject ID**: Consistently listed as **13180007** across all documents.
- **Note ID**: Consistently listed as **13180007-DS-19** across all documents.
- **Admission ID**: Consistently listed as **20774429** across all documents.
- **Chart Time and Store Time**: Consistent across all documents, indicating simultaneous or near-simultaneous charting and storage.","['# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'WHAT HAPPENED WHILE I WAS IN THE HOSPITAL?  \n You were given medications to help get the fluid out. Your \nsymptoms got better and were ready to leave the hospital.  \n\n WHAT DO YOU NEED TO DO WHEN YOU ']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
"What is the ussage of Minoxidil in a patient with Hypertension (HTN) and other comorbidities, and what dose ajustments were made?","['08e7114b-32bf-470b-a3c6-d919c6de4e69\n\n# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n# Acute on chronic anemia:\nHb on admission was 7.4. No evidence of bleeding per history or \nexam. Possibly related to worsening of his renal function vs \ndilutional iso heart failure. His Hb was 7.6 on discharge. He \nreceived 3 doses of ferric gluconate 250 mg IV on ___.\n#IDDM\nPoorly controlled. A1c 14.4 in ___ in ___ at ___. \nRepeat A1C ___ was 11.4%. He was given Lantus 30u night of \nadmission, then transitioned to home insulin ___ with 70/30 \n30u with breakfast and 20u with lunch. He was also on ISS while \ninpatient.\nCHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.', '71b11357-64d1-43f3-b5b3-9e2b962adaf4\n\n# Volume overload\n# HFpEF, LVEF 55-60% in ___\nVolume overload on exam. Diuresis began while in ICU, net \nnegative 1.8L prior to transfer. Dry weight appears to be \n154-157. s/p Lasix 80mg x 2 so far. 163.4 lb on ___ A-Strict \nI/Os, daily weights. Continued home carvedilol at increased dose \nas below. He was sent home with PO 60 mg Lasix daily and was net \neven in the hospital. \n# HTN\nBlood pressure medications initially held when he was started on \npropofol. Anti-HTN meds started on day of transfer. Persistently \nhypertensive. Increased carvedilol to 50 mg BID and increased \nminoxidil to 5 mg and continued amlodipine 10 mg QD. Of note, he \nhad been on clonidine and hydralazine but these were stopped by \nPCP just prior to admission. He remained mostly normotensive \nalthough goal SBP <130 and should continue to be goal as an \noutpatient. \n# Normocytic Anemia\nBaseline of ___, secondary to CKD and possible AoCD. Required \n1u pRBC on arrival. Hb stable. \nCHRONIC ISSUES:']","Minoxidil was prescribed for a patient with a history of hypertension, among other conditions (Acute on chronic anemia, IDDM, Hypothyroidism, History of CVA, and later mentioned Volume overload, HFpEF, and Normocytic Anemia). Initially, the patient was on minoxidil 10mg daily. However, during the hospital stay, due to persistently hypertensive readings, the dose of minoxidil was adjusted to 5mg, alongside increases in carvedilol to 50mg BID and continuation of amlodipine 10mg QD, aiming for a goal SBP <130 as an outpatient.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Patient Context:**
* **Patient/Subject ID:** 13180007 (consistent across all documents)
* **Relevant Comorbidities (from various documents):** Hypertension (HTN), Acute on chronic anemia, IDDM (Insulin-Dependent Diabetes Mellitus), Hypothyroidism, History of CVA (Cerebrovascular Accident), among others.

**Usage of Minoxidil:**
* **Indication in the Context of HTN and Other Comorbidities:** Minoxidil is typically used in the management of severe hypertension that is symptomatic or associated with target organ damage and is not manageable with maximal therapeutic doses of a diuretic plus two other antihypertensive drugs. Given the patient's history of hypertension and other cardiovascular comorbidities (e.g., CVA, carotid artery disease), minoxidil is likely being used for its potent antihypertensive effects.

**Dose Adjustments:**
* **Documented Dose:** 10 mg PO DAILY (consistent across Documents 1, 2, and 3, indicating no change in dose across the documented period).
* **Dose Adjustments Made:** **None explicitly mentioned** in the provided documents. The patient was continued on home minoxidil 10 mg daily, suggesting stability in blood pressure management with this medication, at least to the extent that no adjustments were noted during the hospital stay or at discharge.

**Additional Observations:**
- The consistent metadata across all documents confirms that the information pertains to the same patient and hospital admission.
- The lack of explicit mention of dose adjustments for minoxidil, alongside the continuation of the home dose, implies that the current dose was deemed effective or adequate for the patient's blood pressure management during the documented period.","['# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'TRANSITIONAL ISSUES\n===================\n[ ] At discharge his symptoms associated with volume overload \nhad subsided, but he was still slightly volume up on exam with \n1+ edema to ankles bilaterally an', 'Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
"What is the prescribed dosage and administration schedule for Polyethylene Glycol in the provided patient discharge information, and what is the indicated use for this medication?","['784a4f17-941d-40ee-a5aa-7471e6a5f600\n\n70/30 10 Units Lunch \n3.  Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath  \n4.  amLODIPine 10 mg PO DAILY  \n5.  Aspirin 81 mg PO DAILY  \n6.  Atorvastatin 80 mg PO QPM  \n7.  CARVedilol 50 mg PO BID  \n8.  Levothyroxine Sodium 100 mcg PO DAILY  \n9.  Minoxidil 10 mg PO DAILY  \n10.  Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine  \n11.  sevelamer CARBONATE 800 mg PO TID W/MEALS  \n12.  Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY  \n13.  Vitamin D 1000 UNIT PO DAILY  \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPrimary Diagnosis:\n-Acute on chronic diastolic heart failure exacerbation\nSecondary Diagnosis:', '8c579626-76a5-4cd0-9f53-1feadb6904be\n\nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath \n2. amLODIPine 10 mg PO DAILY \n3. Atorvastatin 80 mg PO QPM \n4. CARVedilol 50 mg PO BID \n5. Furosemide 80 mg PO DAILY \n6. 70/30 30 Units Breakfast\n70/30 10 Units Lunch\n7. Levothyroxine Sodium 100 mcg PO DAILY \n8. Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY \n9. Minoxidil 10 mg PO DAILY \n10. Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine \n11. sevelamer CARBONATE 800 mg PO TID W/MEALS \n12. Aspirin 81 mg PO DAILY \n13. Vitamin D 1000 UNIT PO DAILY \n \nDischarge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast']","According to the discharge medications list (not explicitly mentioned but inferred from the context of medications) and the medications on admission list, Polyethylene Glycol is prescribed as follows: **Dosage:** 17 g **Administration Schedule:** PO (orally) DAILY:PRN (as needed) **Indicated Use:** Constipation - First Line treatment.",custom_multi_hop_query_synthesizer,"Based on the provided documents, here is the answer to the question:

**Question:** What is the prescribed dosage and administration schedule for Polyethylene Glycol in the provided patient discharge information, and what is the indicated use for this medication?

**Answer:**

* **Prescribed Dosage:** 17 g
* **Administration Schedule:** PO (orally) DAILY:PRN (as needed)
* **Indicated Use:** Constipation - First Line

**Source Document:** Document 1 (based on content, as this specific information is not found in metadata)

**Relevant Metadata for Context (though not directly answering the question):**

* **Patient/Subject ID:** 13180007 (consistent across all documents)
* **Note ID:** 13180007-DS-19 (consistent across all documents)
* **Admission ID:** 20774429 (consistent across all documents)
* **Chart Time:** 20/06/62 0:00 (consistent across all documents)
* **Store Time:** 21/06/62 9:56 (consistent across all documents)","['Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver', 'DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1', 'WHAT HAPPENED WHILE I WAS IN THE HOSPITAL?  \n You were given medications to help get the fluid out. Your \nsymptoms got better and were ready to leave the hospital.  \n\n WHAT DO YOU NEED TO DO WHEN YOU ', 'Discharge Condition:\nMental Status: Clear and coherent.\nLevel of Consciousness: Alert and interactive.\nActivity Status: Ambulatory - Independent.\n\n \nDischarge Instructions:\n Dear ___,  \n\n It was a ple']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
"What is the role of Aspirin in the medication regimen of patients with chronic conditions, as observed in the provided medical records, and what are the associated health conditions?","['499f5ec0-b3d8-4161-93fa-07c1b6a6de75\n\ncolonoscopy report in our system previously. Iron studies from \n___ with low normal ferritin (53), low iron, low normal \nTIBC - possibly consistent with anemia of chronic disease or \ninflammation, however hard to rule out concomitant iron \ndeficiency.\n# Hypothyroidism: TSH wnl. Continued home levothyroxine.\n# Asthma: Albuterol inhaler prn continued.\nTRANSITIONAL ISSUES:\n- consideration of outpatient colonoscopy referral if not up to \ndate with screening, particularly iso chronic anemia\n- re-check BP at next PCP appointment, decision on further med \ntitration as above (?increase BB, resuming another home agent\n- ?resume Veltassa if K elevated\n- PCP: consider referral to ___ clinic\n \nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Aspirin 81 mg PO DAILY \n2. Atorvastatin 80 mg PO QPM \n3. CloNIDine 0.4 mg PO BID \n4. HydrALAZINE 100 mg PO TID \n5. Levothyroxine Sodium 100 mcg PO DAILY', '784a4f17-941d-40ee-a5aa-7471e6a5f600\n\n70/30 10 Units Lunch \n3.  Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath  \n4.  amLODIPine 10 mg PO DAILY  \n5.  Aspirin 81 mg PO DAILY  \n6.  Atorvastatin 80 mg PO QPM  \n7.  CARVedilol 50 mg PO BID  \n8.  Levothyroxine Sodium 100 mcg PO DAILY  \n9.  Minoxidil 10 mg PO DAILY  \n10.  Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine  \n11.  sevelamer CARBONATE 800 mg PO TID W/MEALS  \n12.  Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY  \n13.  Vitamin D 1000 UNIT PO DAILY  \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPrimary Diagnosis:\n-Acute on chronic diastolic heart failure exacerbation\nSecondary Diagnosis:']","Based on the provided medical context, Aspirin (81 mg PO DAILY) is consistently present in the medication lists. Associated health conditions and considerations include:  - **Chronic Anemia**: Aspirin is mentioned alongside considerations for outpatient colonoscopy referral for screening, particularly in the context of chronic anemia. - **Cardiovascular Health**: The presence of Aspirin, alongside medications like Atorvastatin (for cholesterol), CARVedilol and HydrALAZINE (for blood pressure), and amLODIPine (for hypertension), suggests its role in managing cardiovascular risk. - **Diastolic Heart Failure Exacerbation**: Aspirin is part of the discharge medication list for a patient with a primary diagnosis of acute on chronic diastolic heart failure exacerbation, indicating its continued use in heart failure management. - **General Health Maintenance**: Aspirin's antiplatelet properties are beneficial for overall cardiovascular health, which is a common theme across the observed medical conditions.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Role of Aspirin in the Medication Regimen:**
Based on the provided medical records, Aspirin (specifically, Aspirin 81 mg PO DAILY) appears to be prescribed for its antiplatelet properties, likely for the prevention of cardiovascular events.

**Associated Health Conditions:**
The associated health conditions, as observed in the medical records of **Patient/Subject ID: 13180007** (common across all documents), are:

1. **History of CVA (Cerebrovascular Accident)**: Indicated in Document 1 under ""CHRONIC PROBLEMS"" and further detailed in Document 3 as ""Cerebrovascular disease, status post CVA"".
2. **Carotid Artery Disease**: Mentioned in Document 3 under ""Past Medical History"".
3. **Acute on Chronic Diastolic Heart Failure Exacerbation**: Listed as the Primary Discharge Diagnosis in Document 2.

**Metadata Consistency for Patient/Subject ID:**
- **Patient/Subject ID: 13180007** is consistently mentioned across all documents (Document 1, Document 2, Document 3, Document 4, and Document 5), indicating that all provided medical records pertain to the same patient.
- **Note ID: 13180007-DS-19**, **Admission ID: 20774429**, **Chart Time: 20/06/62 0:00**, and **Store Time: 21/06/62 9:56** are also consistent across all documents, suggesting that these records are part of the same admission episode.","['CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
"What are the trends and implications of CK-MB levels in the provided patient data, considering the fluctuations observed across different time points, and how do these levels correlate with other diagnostic findings such as cardiac silhouette size and pulmonary vascular congestion?","[""2b2ce4e1-1e51-4483-8a53-32a58ee918d2\n\nleft pleural effusion. Borderline size of the cardiac silhouette\nwithout pulmonary edema. No pneumonia, no pneumothorax.  The\nlateral radiograph shows mild flattening of the hemidiaphragms,\npotentially as a consequence of functional obstruction.\nHead CT: 1. No evidence of acute intracranial abnormality.\n2. Unchanged appearance of chronic infarcts within the right\nfrontal lobe and left occipital lobe.\n3. Chronic lacunar infarcts within the right basal ganglia.\n4. Redemonstration of few calcifications within the pons,\nfindings which are unchanged in appearance and likely sequela of\nprior ischemic or inflammatory process.\n___ 11:00AM BLOOD cTropnT-0.04*\n___ 09:00PM BLOOD cTropnT-0.02*\n___ 11:00AM BLOOD %HbA1c-14.4* eAG-367*\n___ 11:00AM BLOOD Lipase-73*\n___ 11:00AM BLOOD CK-MB-4 proBNP-754*\nIMAGING:\n___ CXR -\nComparison to ___.  On today's radiograph, a small \npleural\nleft-sided calcification is seen.  There also is a small left \npleural\neffusion.  Borderline size of the cardiac silhouette without"", 'db1f4cbf-c584-4ec8-b5c0-1cf04afe2fb4\n\n___ 07:44AM BLOOD CK-MB-7 cTropnT-0.03*\n___ 05:00PM BLOOD CK-MB-7 cTropnT-0.03*\n___ 07:00AM BLOOD CK-MB-6 cTropnT-0.02*\nTFTs:\n___ 09:10AM BLOOD TSH-9.6*\n___ 07:44AM BLOOD T4-6.5 T3-118 Free T4-1.0\nIMAGING:\n========\nCXR (___):\nFINDINGS:  \nThe lung volumes are low-normal.  There is no focal \nconsolidation.  There is mild prominence of the bilateral \npulmonary vessels suggestive of volume \noverload.  The heart is top-normal in size.  There is no large \neffusion or a pneumothorax.  There is no acute osseous \nabnormality, chronic left rib \nfractures are noted. \n  \nIMPRESSION:  \nStable top-normal heart size with mild pulmonary vascular \ncongestion. \nTTE (___):\nThe left atrial volume index is normal. There is no evidence for']","Based on the provided context, here are the observations and implications of CK-MB levels in relation to other diagnostic findings:           **CK-MB Levels Over Time:**      - **11:00 AM (initial context node):** CK-MB = 4, indicating a relatively low level of cardiac muscle damage.      - **07:44 AM, 05:00 PM, and 07:00 AM (subsequent context node):** CK-MB levels were consistently higher, at 7 (07:44 AM and 05:00 PM) and slightly lower at 6 (07:00 AM), suggesting an increase in cardiac muscle damage or stress over the initial measurement.           **Correlation with Cardiac Silhouette Size:**      - **Initial Context Node:** Describes a 'borderline size of the cardiac silhouette without pulmonary edema,' which, coupled with a CK-MB of 4, might suggest minimal to no acute cardiac injury at the time of the initial assessment.      - **Subsequent Context Node:** Mentions a 'top-normal heart size' with 'mild pulmonary vascular congestion.' The increased CK-MB levels (6 and 7) here could imply worsening cardiac function or additional cardiac stress, though the heart size is described as only top-normal.           **Implications and Considerations:**      - The fluctuations in CK-MB levels, particularly the increase observed in the subsequent measurements, warrant close monitoring of cardiac function.      - The correlation between CK-MB levels and cardiac silhouette size/pulmonary vascular congestion suggests that as CK-MB increases, there is a noticeable, though mild, impact on cardiac function and pulmonary vascular status.      - Further diagnostic workup, including but not limited to serial CK-MB measurements, detailed cardiac imaging (e.g., more frequent TTE), and clinical assessment, is crucial for accurately determining the prognosis and guiding management.",custom_multi_hop_query_synthesizer,"**Answering the Current Question with Provided Instructions**

**CK-MB Levels Analysis and Correlation with Other Diagnostic Findings**

### **Metadata Overview Relevant to the Question**

* **Patient/Subject ID**: Consistently **13180007** across all documents (1, 2, 3, 4, 5)
* **Note ID**: Consistently **13180007-DS-19** across all documents (1, 2, 3, 4, 5)
* **Admission ID**: Consistently **20774429** across all documents (1, 2, 3, 4, 5)
* **Chart Time** and **Store Time**: While consistent across documents, these do not directly impact the analysis of CK-MB levels.

### **CK-MB Levels Trends and Implications**

* **Document 1 (Content)**: 
	+ **CK-MB Levels Mentioned**: Described as ""flat"" in the context of mild troponin elevation.
	+ **Interpretation Challenge**: Noted as difficult to interpret due to the patient's Chronic Kidney Disease (CKD).
	+ **Comparison**: Troponin elevation is mentioned to be ""at or lower than levels earlier this year.""
* **Other Documents (2, 3, 4, 5)**: 
	+ **CK-MB Levels**: Not explicitly mentioned beyond Document 1.

### **Correlation with Other Diagnostic Findings**

* **Cardiac Silhouette Size**:
	+ Not directly mentioned in any document in a way that correlates with CK-MB levels.
* **Pulmonary Vascular Congestion**:
	+ **Document 2 (Content)**: 
		- **CXR Findings**: Mild pulmonary vascular congestion with small bilateral pleural effusions (left greater than right).
	+ **Correlation with CK-MB**: Given the absence of explicit CK-MB values across most documents, direct correlation with pulmonary vascular congestion findings is not feasible based on the provided information.

### **Implications and Trends**

* **CK-MB Levels**: The flat CK-MB in the context of CKD and mild troponin elevation (which is at or lower than previous levels) suggests a cautious approach in interpreting myocardial injury, leaning towards minimal to no acute myocardial infarction evidence at the time of admission.
* **Diagnostic Findings Correlation**: The presence of pulmonary vascular congestion (Document 2) alongside the clinical presentation (e.g., dyspnea, lower extremity edema) points towards a congestive heart failure exacerbation scenario rather than an acute coronary syndrome, which aligns with the diagnosis of ""Acute on chronic HFpEF"" (Document 5).

**Limitations**:
- Explicit CK-MB values are not provided for a detailed trend analysis.
- Direct correlations with cardiac silhouette size cannot be made due to the lack of relevant data in the documents.","['# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n', 'Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n', 'leaflets (3) are mildly thickened. There is no\naortic valve stenosis. There is no aortic regurgitation. The \nmitral valve leaflets are mildly thickened with\nno mitral valve prolapse. There is trivial ', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver', 'ACUTE PROBLEMS\n==============\n# Acute on chronic HFpEF: \nPatient presented with dyspnea and lower extremity edema and\nfound to be volume overloaded on exam. Warm and wet on exam.\nTrigger for HF exacer']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
"Whats the plan for Asthma management for this patient, espeshally with Albuterol inhaler?","['499f5ec0-b3d8-4161-93fa-07c1b6a6de75\n\ncolonoscopy report in our system previously. Iron studies from \n___ with low normal ferritin (53), low iron, low normal \nTIBC - possibly consistent with anemia of chronic disease or \ninflammation, however hard to rule out concomitant iron \ndeficiency.\n# Hypothyroidism: TSH wnl. Continued home levothyroxine.\n# Asthma: Albuterol inhaler prn continued.\nTRANSITIONAL ISSUES:\n- consideration of outpatient colonoscopy referral if not up to \ndate with screening, particularly iso chronic anemia\n- re-check BP at next PCP appointment, decision on further med \ntitration as above (?increase BB, resuming another home agent\n- ?resume Veltassa if K elevated\n- PCP: consider referral to ___ clinic\n \nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Aspirin 81 mg PO DAILY \n2. Atorvastatin 80 mg PO QPM \n3. CloNIDine 0.4 mg PO BID \n4. HydrALAZINE 100 mg PO TID \n5. Levothyroxine Sodium 100 mcg PO DAILY']","According to the patient's record, for Asthma management, the Albuterol inhaler is to be continued on an as-needed basis (prn). No changes or additional instructions are noted in the provided context beyond this continuation.",custom_multi_hop_query_synthesizer,"**Answer to Current Question**

**Asthma Management Plan with Albuterol Inhaler:**

Based on the provided documents, here is the extracted information related to the plan for Asthma management, specifically with the Albuterol inhaler:

* **Presence of Asthma/COPD or Similar Conditions:** While the documents explicitly mention ""dyspnea"" (shortness of breath) and ""wheeze"" in **Document 1** under ""History of Present Illness,"" there is no clear, direct mention of asthma as a diagnosed condition. However, these symptoms can be associated with asthma or COPD, among other conditions.
  
* **Albuterol Inhaler Prescription:**
	+ **Document 2 (Medications on Admission):** Lists ""1. Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath"" indicating it was part of the patient's pre-admission medication regimen, used as needed (PRN) for shortness of breath.
	+ **Document 4 (Discharge Medications):** Also lists ""3. Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath,"" showing continuity of this medication from admission through discharge.

* **Plan for Asthma Management with Albuterol Inhaler:**
	- **Dosage and Frequency:** 2 puffs, inhale (IH), every 8 hours as needed (Q8H:PRN) for shortness of breath.
	- **Continuity of Care:** The medication is continued from pre-admission, through the hospital stay, to discharge, indicating its importance in managing the patient's respiratory symptoms.
	- **No Explicit Asthma Action Plan:** While the Albuterol inhaler's use is outlined, there is no detailed asthma management plan provided in the documents, such as peak flow monitoring, symptoms to watch for, or steps to take during an exacerbation.

**IDs and Dates (as per instructions):**

- **Patient/Subject ID:** 13180007 (consistent across all documents)
- **Note ID:** 13180007-DS-19 (consistent across all documents)
- **Admission ID:** 20774429 (consistent across all documents)
- **Chart Time:** 20/06/62 0:00 (consistent across all documents, though the format suggests a potential typo, possibly meaning 2022 or another year, given the context)
- **Store Time:** 21/06/62 9:56 (consistent across all documents, with the same date format consideration as above)","['Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'Social History:\n___\nFamily History:\nHis parents have heart disease.  Mother is ___ with heart \nproblems\nand diabetes.  Father, ___, with diabetes.  He has 16 brothers \nand\nsisters.  There is no known ', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
"What are the patient's vital signs (VS) upon discharge, and are there any notable findings in the cardiovascular examination?","['0070a23b-dc9f-483f-a66d-a8d84a4b995b\n\nCARDIOVASCULAR: Regular rate and rhythm with late ___ systolic\nmurmur at RUSB, no rubs or gallops\nLUNGS: clear to auscultation bilaterally without rhonchi,\nwheezes, or crackles\nGI: soft, nontender, without rebounding or guarding, \nnondistended\nwith normal active bowel sounds, no hepatomegaly\nEXTREMITIES: no clubbing, cyanosis, or edema\nGU: no foley\nSKIN: no rashes, petechia, lesions, or echymoses; warm to\npalpation\nNEURO: Alert and interactive to person, ___ (daughters\nstated that this is a hospital before pt named it), ___, but\nthinks that it is ___, cranial nerves II-XII intact, strength \nis\n___ in RUE, RLE, LLE, ___ in LUE elbow flexion/extension and\nhand grip. Gait is WNL, negative Romberg, negative pronator\ndrift.\nPSYCH: normal mood and affect\nDISCHARGE EXAM\nVS: 97.9 PO 151 / 65 64 18 99 RA \nGEN: Alert and interactive, comfortable, no acute distress\nHEENT: PERRL, anicteric, conjunctiva pink, oropharynx without\nlesion or exudate, moist mucus membranes, ears without lesions \nor', '29d118b8-9203-4616-bc9a-07f5566771d6\n\nVS: \n24 HR Data (last updated ___ @ 817)\n    Temp: 98.3 (Tm 98.4), BP: 136/56 (135-164/56-69), HR: 78\n(57-84), RR: 20 (___), O2 sat: 97% (95-97), O2 delivery: RA  \n24 HR Data (last updated ___ @ 817)\n    Temp: 98.3 (Tm 98.4), BP: 136/56 (135-164/56-69), HR: 78\n(57-84), RR: 20 (___), O2 sat: 97% (95-97), O2 delivery: RA  \nFluid Balance (last updated ___ @ 600) \n  Last 8 hours  Total cumulative -405ml\n    IN: Total 120ml, PO Amt 120ml\n    OUT:  Total 525ml, Urine Amt 525ml\n  Last 24 hours  Total cumulative -725ml\n    IN: Total 1000ml, PO Amt 900ml, IV Amt Infused 100ml\n    OUT:  Total 1725ml, Urine Amt 1725ml     \nWEIGHT: 74.3 kg (75.6 kg)\n \nGENERAL: Sitting up in a chair next to bed. NAD.\nNECK: JVP 7-8 cm. \nCARDIAC: Regular rate and rhythm. Normal S1, S2. Right upper\nborder systolic murmur III/VI. \nLUNGS: Respiration is unlabored with no accessory muscle use.\nCTAB. No wheezes/rales/rhonchi. \nABDOMEN: +BS. Distended but soft. Non-tender to palpation.\nEXTREMITIES: Warm. 1+ edema L > RLE.']","Upon discharge, the patient's vital signs (VS) were: Temperature (Temp) = 97.9, Pulse (PO) = 151, Blood Pressure (BP) = 65/64, Respiratory Rate (RR) = 18, Oxygen Saturation (O2 sat) = 99% on Room Air (RA). Notably, the cardiovascular examination revealed a regular rate and rhythm with a late systolic murmur at the Right Upper Sternal Border (RUSB), but no rubs or gallops were detected.",custom_multi_hop_query_synthesizer,"Based on the provided documents, here's the answer to the question following the specified instructions:

**Question:** What are the patient's vital signs (VS) upon discharge, and are there any notable findings in the cardiovascular examination?

**Answer:**

1. **Vital Signs (VS) upon Discharge:**
	* Unfortunately, the exact vital signs upon discharge are not explicitly stated in any of the documents provided. The closest information related to discharge is in **Document 4**, which describes the discharge condition in terms of mental status, level of consciousness, and activity status but does not include traditional vital sign measurements (e.g., Temperature, Heart Rate, Blood Pressure, Respiratory Rate, Oxygen Saturation).
	* **Available Vital Signs from Other Times:**
		+ **Initial VS in the ED (Document 5):** T 98.5, HR 102, BP 178/76, RR 22, SpO2 98% RA
		+ **Vitals on Transfer (Documents 3 & 5):** T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA

2. **Notable Findings in the Cardiovascular Examination:**
	* **Document 1 (DISCHARGE PHYSICAL EXAM):**
		- **CARDIAC:** Regular rate and rhythm. Normal S1, S2. No murmurs, rubs, or gallops.
		- **NECK:** JVP (Jugular Venous Pressure) 12 cm, indicating some elevation which can be associated with fluid overload or heart failure.
		- **EXTREMITIES:** Lower extremity edema to ankles (L>R), suggestive of fluid accumulation, commonly seen in heart failure.
	* **Document 5 (Initial Exam in ED):**
		- **CV:** RRR (Regular Rate and Rhythm), systolic murmur, normal S1, S2.
		- **Notable Labs and Studies:** proBNP 784 (elevated, indicating heart failure), TWI in lateral leads on EKG, and CXR showing mild pulmonary vascular congestion with small bilateral pleural effusions.

**Metadata Consistency for IDs:**
- **Patient/Subject ID:** Consistently **13180007** across all documents.
- **Note ID:** Consistently **13180007-DS-19** across all documents.
- **Admission ID:** Consistently **20774429** across all documents.
- **Chart Time and Store Time:** Consistently **20/06/62 0:00** and **21/06/62 9:56**, respectively, across all documents.","['DISCHARGE PHYSICAL EXAM\n=======================\nGENERAL: NAD. Mood, affect appropriate.  \nHEENT: Normocephalic atraumatic. Sclera anicteric. EOMI.\nConjunctiva were pink. No pallor or cyanosis of the o', 'DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1', 'Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n', 'Discharge Condition:\nMental Status: Clear and coherent.\nLevel of Consciousness: Alert and interactive.\nActivity Status: Ambulatory - Independent.\n\n \nDischarge Instructions:\n Dear ___,  \n\n It was a ple', 'In the ED:  \nInitial VS: T 98.5, HR 102, BP 178/76, RR 22, SpO2 98% RA \n \nExam:\nGeneral- NAD\nHEENT- PERRL, EOMI, normal oropharynx\nLungs- Non-labored breathing, CTAB\nCV- RRR, systolic murmur, normal S']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
"What happen to patient come to ED for asthma but family say no asthma, have weight loss, chills, hand and leg cramping, and history of CVA, what all test and meds patient have in ED?","['33441964-a7d6-441d-ac8e-c600d6bf9f69\n\nED Course:\nExam: no focal neuro deficits. \nVS: T96.1, HR 80, BP 114/50, RR 16, 99% on room air. \nLabs: TropT 0.04, proBNP: 754, Cr 2.3, WBC 5.6, Hgb 10.6\nCultures: urine culture pending. \nMeds: acetaminophen 1g, NS 500mL.\nImaging: CT head: no acute intracranial abnormality. chronic\ninfarcts. \nOn arrival to the floor, pt states that he came to the ED \nbecause\nof his asthma. His daughters are present and state that asthma \nis\nnot, in fact, the reason for his ED presentation. They also\ndescribe anorexia with weight loss. They believe that he looks\nlike he has lost weight, but no clear idea of how much. He\nendorses chills without fevers, which seems to be chronic since\nhis CVA. He has not mentioned chest pain, but has endorsed hand\nand leg cramping. He did have a transient headache which has now\nresolved. \nAt baseline, ___ work full time jobs and have\ntheir own families; pt lives with his wife, who is on HD. ___\ncomes to the house once a week, and pt is followed by RN/BSN \nfrom', ""a6e734ef-1c30-4cb6-ba6d-41227251d4d0\n\nWhen he came home to ___, he apparently thought that he was\nstill in ___, confused his wife for his daughter. On\n___ morning, he fell again. He was confused about the\nconfiguration of the bathroom (no tub in bathroom in PR), so he\ntripped and fell, called his daughter in tears (he often gets\nemotional since his CVA). She booked an appointment for same \nday,\nat which his FSBG>500, HbA1c (point of care, not in OMR) was\n15.0%. He declined to be transferred to the ED. Daughter ___\nwas on vacation from work, and so was able to check on him\nregularly. During these visits, she again established that he is\nnot taking prescribed medications. On the morning of\npresentation, pt's wife called daughter ___, concerned that \npt\nwas increasingly confused. FSBG was >500, and administered\nTresiba 50u at about 8 am. Pt called ___ about 15 minutes\nlater, at which time she again noted confusion and slurred\nspeech, which has intermittently been present since his CVA.\nDecision was made to bring him to the ED. \nOf note, during his last hospitalization ___, he had an\nepisode of dysarthria with confusion and mild expressive and\nreceptive aphasia for which code stroke was called. MRI/MRA \nbrain\nand EEG were unrevealing, with chronic changes and EEG slowing\nonly. He was continued on ASA and atorvastatin.""]","Patient, with history of CVA, presented to ED with claimed asthma, but family denied this, reporting anorexia with weight loss instead. Key findings and actions in ED include:      * **Exam:** No focal neuro deficits.      * **Vital Signs (VS):** T96.1, HR 80, BP 114/50, RR 16, 99% on room air.      * **Labs:** TropT 0.04 (indicating no acute myocardial infarction), proBNP 754 (elevated, suggesting heart failure), Cr 2.3 (elevated, indicating renal impairment), WBC 5.6 (within normal range), Hgb 10.6 (mild anemia). Urine culture pending.      * **Meds Administered in ED:** Acetaminophen 1g, Normal Saline (NS) 500mL.      * **Imaging:** CT head showed no acute intracranial abnormality but chronic infarcts.      * **Symptoms:** Chills without fevers (chronic since CVA), hand and leg cramping, transient headache (now resolved). No chest pain.      * **Pre-ED Context:** Had an episode of confusion, slurred speech, and hyperglycemia (FSBG>500, HbA1c 15.0%) before ED arrival. Was on Tresiba 50u. History of similar neurological episodes, including dysarthria, confusion, and aphasia, during last hospitalization with unrevealing MRI/MRA and EEG, leading to continued ASA and atorvastatin.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and the question, I'll do my best to provide a relevant answer. However, please note that the question seems to describe a different patient scenario than what's presented in the documents. Since the documents don't match the question's scenario (asthma, weight loss, chills, hand and leg cramping, and history of CVA in the context of an ED visit for asthma with family denial), I'll address the question by:

1. **Identifying the mismatch**: The documents provided (1 through 5) describe a patient with conditions like HFpEF, dyspnea, chest pain, and a history of CVA, among others, but do not specifically mention an ED visit for asthma with the additional symptoms listed in the question.

2. **Answering based on the closest relevant information in the documents**:
    - **Patient/Subject ID**: Matches across all documents - **13180007**
    - **Note ID, Admission ID, Chart Time, and Store Time**: Consistent across all documents, but not directly relevant to the question's specifics.
    - **History of CVA**: Mentioned in Documents 2, 3, and 4, aligning with the question's CVA history aspect.
    - **Tests and Meds in the context closest to the question (ED/Initial Assessment)**:
        - **Tests (from Document 1, the closest to an ED assessment)**:
            - EKG: TWI in lateral leads
            - Labs:
                - Hgb 7.4
                - Chem: BUN 39, Cr 2.6
                - proBNP: 784
                - TropT: 0.03
            - Studies:
                - CXR: Mild pulmonary vascular congestion with small bilateral pleural effusions, left greater than right.
        - **Meds (specifically mentioned as received in the ED context, Document 1)**:
            - IV Lasix 80mg

**Important Clarification**: Since the documents do not describe a patient coming to the ED for asthma with the additional symptoms (weight loss, chills, hand and leg cramping) mentioned in the question, the above response provides the closest relevant information based on the history of CVA and the initial ED assessment details available.

**Direct Answer to the Question's Request Based on Available Data**:
- **Patient/Subject ID**: 13180007
- **Tests in ED (closest context)**: EKG, Labs (Hgb, Chem, proBNP, TropT), CXR
- **Meds in ED (as per provided context)**: IV Lasix 80mg","['In the ED:  \nInitial VS: T 98.5, HR 102, BP 178/76, RR 22, SpO2 98% RA \n \nExam:\nGeneral- NAD\nHEENT- PERRL, EOMI, normal oropharynx\nLungs- Non-labored breathing, CTAB\nCV- RRR, systolic murmur, normal S', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver', 'Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n', 'DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
Wha CK-MB level mean for patient wit chest pain but no ischemia sign?,"[""2b2ce4e1-1e51-4483-8a53-32a58ee918d2\n\nleft pleural effusion. Borderline size of the cardiac silhouette\nwithout pulmonary edema. No pneumonia, no pneumothorax.  The\nlateral radiograph shows mild flattening of the hemidiaphragms,\npotentially as a consequence of functional obstruction.\nHead CT: 1. No evidence of acute intracranial abnormality.\n2. Unchanged appearance of chronic infarcts within the right\nfrontal lobe and left occipital lobe.\n3. Chronic lacunar infarcts within the right basal ganglia.\n4. Redemonstration of few calcifications within the pons,\nfindings which are unchanged in appearance and likely sequela of\nprior ischemic or inflammatory process.\n___ 11:00AM BLOOD cTropnT-0.04*\n___ 09:00PM BLOOD cTropnT-0.02*\n___ 11:00AM BLOOD %HbA1c-14.4* eAG-367*\n___ 11:00AM BLOOD Lipase-73*\n___ 11:00AM BLOOD CK-MB-4 proBNP-754*\nIMAGING:\n___ CXR -\nComparison to ___.  On today's radiograph, a small \npleural\nleft-sided calcification is seen.  There also is a small left \npleural\neffusion.  Borderline size of the cardiac silhouette without"", 'd2113a66-fe4f-4869-b3c0-73646862b32b\n\ngluconate (received 3 doses ___. Upon review of recent \noutpatient visit notes, it appears his volume exam is similar to \nbaseline, and patient was asymptomatic during hospital course. \nHe was diuresed effectively with IV Lasix 80. He was \ntransitioned to PO torsemide 100. His BP was well controlled \nwith regimen as described below.\n# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\nat or lower than levels earlier this year. He has denied chest\npain during admission. He does have risk factors for ischemia \nand\nhas not had stress since ___. However, findings and history \nto\ndate are not suggestive of ischemia and he has an ___. TTE did \nnot show evidence of focal wall motion abnormalities or other \nfindings suggestive of ischemia, so further workup was not \npursued. He was continued on ASA and atorvastatin.\n# ___ on CKD:\nCr elevated to 2.6 on admission from baseline of 1.8-2.2. Given\nevidence of congestion elsewhere, concerns for renal congestion\ncausing renal dysfunction. Cr remained stable and was 2.9 on day \nof discharge. He was continued on home sevelamer.']","Patient have flat CK-MB with mild troponin elevation. CK-MB level specifically mentioned as 4. This, combined with other findings, not suggestive of ischemia. Patient continued on ASA and atorvastatin. Note: CK-MB interpretation in context of patient's Chronic Kidney Disease (CKD) should be considered, though direct implications not detailed in provided context.",custom_multi_hop_query_synthesizer,"Based on the provided instructions, here's the response to the current question, incorporating the specified guidelines:

**Current Question:** What CK-MB level means for a patient with chest pain but no ischemia sign?

**Analysis:**

* The question pertains to the patient's medical condition (chest pain and CK-MB levels in the context of no ischemia signs).
* Relevant information is primarily found in **Document 1**, under the ""CONTENT"" section, specifically in the ""# Chest pain:"" subsection.

**Answer:**

* **CK-MB Level Interpretation for No Ischemia Sign:**
	+ According to **Document 1**, the patient presented with ""mild troponin elevation with flat CK-MB.""
	+ **Key Point:** The document explicitly mentions ""flat CK-MB,"" which, in the context of cardiac evaluation, typically suggests that there is no significant elevation in CK-MB (creatine kinase-myocardial band), a marker often associated with myocardial infarction or ischemia.
	+ **Implication for the Patient:** The presence of chest pain coupled with a ""flat CK-MB"" and the overall assessment (""findings and history to date are not suggestive of ischemia"") indicates that the patient's chest pain, in this case, does not appear to be related to an ischemic cardiac event, as supported by the lack of significant CK-MB elevation.

**Metadata Relevance to the Question:**
* **Patient/Subject ID:** 13180007 (consistent across all documents, reinforcing that the analysis pertains to the same patient)
* **Note ID, Admission ID, Chart Time, and Store Time** are consistent across all documents, indicating that all information, including the CK-MB level interpretation, refers to the same patient encounter.

**IDs as per Metadata (for completeness, as instructed):**
* **Patient/Subject ID:** 13180007 (appears in all documents: 1, 2, 3, 4, 5)
* **Note ID:** 13180007-DS-19 (consistent across documents 1 through 5)
* **Admission ID:** 20774429 (consistent across documents 1 through 5)
* **Chart Time:** 20/06/62 0:00 (consistent across documents 1 through 5)
* **Store Time:** 21/06/62 9:56 (consistent across documents 1 through 5)","['# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n', 'Social History:\n___\nFamily History:\nHis parents have heart disease.  Mother is ___ with heart \nproblems\nand diabetes.  Father, ___, with diabetes.  He has 16 brothers \nand\nsisters.  There is no known ', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver', 'Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n', 'or gallops. no thrills or lifts.  \nLUNGS: No chest wall deformities or tenderness. Respiration is\nunlabored with no accessory muscle use. No crackles, wheezes or\nrhonchi.  \nABDOMEN: Soft, non-tender, ']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
"What are the key findings from the patient's Transthoracic Echocardiogram (TTE) regarding ventricular function, valve conditions, and comparisons to prior TTE results, from a medical researcher's analytical perspective?","['6947fbec-1aff-4c0a-8eb5-fe9953adbb08\n\nventricular cavity size with normal free wall motion. The aortic \nsinus diameter is normal for gender with normal ascending aorta \ndiameter for gender. The aortic valve leaflets (3) appear \nstructurally normal. There is no aortic valve stenosis. There is \ntrace aortic regurgitation. The mitral valve leaflets appear \nstructurally normal with no mitral valve prolapse. There is \ntrivial mitral regurgitation. The pulmonic valve leaflets are \nnormal. The tricuspid valve leaflets appear structurally normal. \nThere is physiologic tricuspid regurgitation. The pulmonary \nartery systolic pressure could not be estimated. There is a \ntrivial pericardial effusion.\nIMPRESSION: Mild symmetric left ventricular hypertrophy with \nnormal cavity size and regional/global biventricular systolic \nfunction. No significant mitral regurgitation.\nCompared with the prior TTE ___, the findings are \nsimilar.\nMRI/MRA HEAD AND NECK (___)\nIMPRESSION:\n \n \n1. No hemorrhage or acute infarct.\n2. Chronic infarcts within the subcortical right frontal lobe \nand left\ntemporal and occipital lobes.\n3. Atrophic pons likely a sequela of prior infarcts.', 'db1f4cbf-c584-4ec8-b5c0-1cf04afe2fb4\n\n___ 07:44AM BLOOD CK-MB-7 cTropnT-0.03*\n___ 05:00PM BLOOD CK-MB-7 cTropnT-0.03*\n___ 07:00AM BLOOD CK-MB-6 cTropnT-0.02*\nTFTs:\n___ 09:10AM BLOOD TSH-9.6*\n___ 07:44AM BLOOD T4-6.5 T3-118 Free T4-1.0\nIMAGING:\n========\nCXR (___):\nFINDINGS:  \nThe lung volumes are low-normal.  There is no focal \nconsolidation.  There is mild prominence of the bilateral \npulmonary vessels suggestive of volume \noverload.  The heart is top-normal in size.  There is no large \neffusion or a pneumothorax.  There is no acute osseous \nabnormality, chronic left rib \nfractures are noted. \n  \nIMPRESSION:  \nStable top-normal heart size with mild pulmonary vascular \ncongestion. \nTTE (___):\nThe left atrial volume index is normal. There is no evidence for']","Based on the provided TTE findings, the key observations include:  1. **Mild symmetric left ventricular hypertrophy** with normal cavity size. 2. **Normal regional/global biventricular systolic function**. 3. **Structurally normal valve leaflets** for aortic, mitral, pulmonic, and tricuspid valves. 4. **Trace aortic regurgitation** and **trivial mitral regurgitation** with **physiologic tricuspid regurgitation**. 5. A **trivial pericardial effusion** was noted. 6. **Comparison to prior TTE** shows similar findings, indicating stability in the observed conditions. These findings suggest a relatively stable cardiac condition with some minor abnormalities, but no significant deterioration or new major issues compared to the previous TTE.",custom_multi_hop_query_synthesizer,"**Analytical Response**

**Patient/Subject ID:** 13180007 (consistent across all documents: **Document 1**, **Document 2**, **Document 3**, **Document 4**, and **Document 5**)
**Note ID:** 13180007-DS-19 (consistent across all documents)
**Admission ID:** 20774429 (consistent across all documents)
**Chart Time:** 20/06/62 0:00 (consistent across all documents)
**Store Time:** 21/06/62 9:56 (consistent across all documents)

**Key Findings from Transthoracic Echocardiogram (TTE):**

### **Ventricular Function:**
- **Left Ventricular (LV) Function:**
	+ **LV Hypertrophy:** Mild symmetric LV hypertrophy with a normal cavity size (**Document 4**).
	+ **LV Systolic Function:** Normal regional and global LV systolic function (**Document 4**).
	+ **LV Ejection Fraction (LVEF):** Visually estimated LVEF is 65% (**Document 4**).
	+ **Diastolic Function:** Evidence for diastolic dysfunction (grade indeterminate) with increased left ventricular filling pressure (PCWP > 18 mmHg) (**Document 4**).
- **Right Ventricular (RV) Function:**
	+ **RV Cavity Size:** Normal (**Document 4**).
	+ **RV Free Wall Motion:** Normal (**Document 4**).

### **Valve Conditions:**
- **Aortic Valve:**
	+ **Leaflets:** Mildly thickened (**Document 3** and **Document 4**).
	+ **Stenosis/Regurgitation:** No aortic valve stenosis or regurgitation (**Document 3** and **Document 4**).
- **Mitral Valve:**
	+ **Leaflets:** Mildly thickened (**Document 3** and **Document 4**).
	+ **Prolapse/Regurgitation:** No mitral valve prolapse, trivial mitral regurgitation (**Document 3**).
- **Tricuspid Valve:**
	+ **Leaflets:** Structurally normal (**Document 3**).
	+ **Regurgitation:** Physiologic tricuspid regurgitation (**Document 3**).
- **Pulmonic Valve:**
	+ **Leaflets:** Normal (**Document 3**).

### **Comparisons to Prior TTE Results:**
- **No direct comparisons to prior TTE results are provided in the documents**. All TTE findings are reported without reference to previous studies for direct comparison.

### **Additional Notable Findings:**
- **Pericardial Effusion:** Small pericardial effusion without frank tamponade (**Document 3**).
- **Estimated Pulmonary Artery Systolic Pressure:** Normal (**Document 3**).","['Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n', 'In the ED:  \nInitial VS: T 98.5, HR 102, BP 178/76, RR 22, SpO2 98% RA \n \nExam:\nGeneral- NAD\nHEENT- PERRL, EOMI, normal oropharynx\nLungs- Non-labored breathing, CTAB\nCV- RRR, systolic murmur, normal S', 'leaflets (3) are mildly thickened. There is no\naortic valve stenosis. There is no aortic regurgitation. The \nmitral valve leaflets are mildly thickened with\nno mitral valve prolapse. There is trivial ', '___\nCONCLUSION:\nThe left atrial volume index is normal. The estimated right \natrial pressure is ___ mmHg. There is mild\nsymmetric left ventricular hypertrophy with a normal cavity \nsize. There is norm', '# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
"What are the key considerations and current plans for managing the patient's cardiovascular health, particularly regarding the known inducible ischemia in the LCX distribution, in the context of their complex medical history including CKD and recent medication adjustments?","['3854e9c9-f299-4327-94b1-3dc260a4fc6f\n\nLying HR: 68 RR: 20 O2 sat: 98% O2 delivery: 3LNC Dyspnea: 3\nRASS: 0 Pain Score: ___ \n \n  Of note, since ___, he has had known inducible ischemia on\nLCX distribution from stress test. The risks (including dialysis\nafter contrast load) and benefits were discussed with primary\ncardiologist Dr. ___. Coronary angiogram was deferred. \n  He also had a recent admission to the heart failure service\nwith uptitration of blood pressure control agents. Coronary\nangiogram was deferred at that time. ACEi was stopped (prior\nlisinopril 40mg) given worsened CKD vs ___.  Low dose lisinopril\nwas reinitiated at last visit with Dr. ___. \n  Multiple notes in OMR describe issues with ensuring consistent\nsupply of medications. The patient and his family confirm this.\nHowever, they state recently no change in medications, ___ comes\nonce per week.  He describes his diet as healthy but family\nconcerned about salt intake. No h/o arrhythmia, no palpitations. \n On the floor, he reports ongoing mild wheeze, improving\nshortness of breath, no current chest pain. \nREVIEW OF SYSTEMS:  \nPositive per HPI.', '4b3d7a96-6534-434e-8295-b8356c5ca64d\n\nbasal/bolus four times daily regimen. However, this is not a \nsustainable regimen for patient on discharge. Discussed \npossibility of switching to 70/30 mix BID, however currently \npatient cannot be guaranteed to eat regular meal after each \ninsulin injection therefore currently not a tenable plan. In the \nfuture, if patient able to be placed in a day program, \npotentially could switch to this but for now will we continued \nhis prior home regimen (EXCEPT for Jardiance, which was \ndiscontinued due to contraindication with chronic kidney \ndisease) on discharge, with very close ___ follow-up and ___ \nservices to help increase compliance. With regards to his more \nsubacute mental status decompensation, would benefit from \nreferral for outpatient neurocognitive evaluation.\n# Hx of CAD: \n# Hx of ischemic CVA:\nStress test in ___ with area of inducible ischemia in LCx \ndistribution, in setting of multiple risk factors. Has been \nmedically optimized by prescribed medications, but as above it \nseems that pt has been taking these medications. TnT 0.04->0.02 \nin setting of CKD stage III-IV. Continued home aspirin, \natorvastatin, and carvedilol. Note that he was once on \nlisinopril (most recently filled in ___ for 2.5mg dose) \nhowever seems that this has since been discontinued.\n# CKD stage III:']","The patient has known inducible ischemia in the LCX distribution from a previous stress test, alongside multiple risk factors. Management considerations include:         - **Coronary Angiogram Deferral**: Recently deferred due to risks, including dialysis after contrast load, as discussed with Dr. ___.        - **Medication Adjustments**:           - **ACEi (Lisinopril)**: Initially stopped due to worsened CKD, then reinitiated at a low dose.          - **Continued Medications**: Home aspirin, atorvastatin, and carvedilol are continued.          - **Discontinued**: Jardiance, due to contraindication with chronic kidney disease.        - **Future Plans**: Potential switch to a more sustainable insulin regimen (e.g., 70/30 mix BID) if the patient can be placed in a day program, emphasizing close follow-up and compliance services upon discharge.        - **Additional Recommendations**: Outpatient neurocognitive evaluation for subacute mental status decompensation.",custom_multi_hop_query_synthesizer,"Based on the provided documents, here's a structured answer to the question, following the given instructions:

**Key Considerations for Managing Cardiovascular Health:**

1. **Known History of Inducible Ischemia in LCX Distribution:** *No explicit mention* of inducible ischemia in the LCX distribution is found in the provided documents (1 through 5). This information might be absent or documented elsewhere.
2. **CKD (Chronic Kidney Disease):**
	* **Consideration:** Elevated Cr levels (admission: 2.6, discharge: 2.9) indicate CKD, which can impact cardiovascular health and medication choices.
	* **Current Plan:** Continued on home sevelamer (Document 1, # ___ on CKD).
3. **Recent Medication Adjustments for Cardiovascular Health:**
	* **ASA (Aspirin) and Atorvastatin:** Continued for cardiovascular protection (Documents 1, 4; # Chest pain and #History of CVA, respectively).
	* **Amlodipine, Coreg (Carvedilol), and Minoxidil:** Continued for hypertension management (Document 2, # Hypertension).
	* **Torsemide (Transitioned from IV Lasix):** For managing volume overload in the context of HFpEF (Document 3, # Acute on chronic HFpEF).

**Observations from Metadata:**

* **Patient/Subject ID:** Consistently **13180007** across all documents (1 through 5).
* **Note ID and Admission ID:** Consistently **13180007-DS-19** and **20774429**, respectively, across all documents, indicating these documents pertain to the same hospital admission.
* **Chart Time and Store Time:** Identical across all documents, suggesting simultaneous or near-simultaneous charting and storage.

**Answer to the Question:**
Given the information provided, the key considerations for managing the patient's cardiovascular health, in the context of CKD and recent medication adjustments, focus on:

1. Ongoing management of CKD with sevelamer.
2. Continued use of ASA, atorvastatin, amlodipine, Coreg, and minoxidil for cardiovascular and hypertension management.
3. Management of HFpEF with torsemide, as adjusted from IV Lasix.

**Limitation:**
The question regarding ""known inducible ischemia in the LCX distribution"" cannot be addressed with the provided documents, as this specific condition is not mentioned.","['# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', 'ACUTE PROBLEMS\n==============\n# Acute on chronic HFpEF: \nPatient presented with dyspnea and lower extremity edema and\nfound to be volume overloaded on exam. Warm and wet on exam.\nTrigger for HF exacer', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
What is the prescribed dosage of hydralazine for a patient with acute on chronic heart failure and hypertension?,"['5d1619ab-197a-416d-b0af-616eff82199c\n\n#*60 Tablet Refills:*0 \n12.  HydrALAZINE 100 mg PO TID \nRX *hydralazine 100 mg 1 tablet(s) by mouth three times a day \nDisp #*90 Tablet Refills:*0 \n13.  Levothyroxine Sodium 100 mcg PO DAILY \nRX *levothyroxine 100 mcg 1 tablet(s) by mouth once a day Disp \n#*30 Tablet Refills:*0 \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPRIMARY DIAGNOSIS\n==================\nAcute on chronic heart failure with preserved ejection fraction\nSECONDARY DIAGNOSES\n====================\nAcute kidney injury\nCoronary artery disease\nType 2 Diabetes Mellitus\nHyperkalemia', '71b11357-64d1-43f3-b5b3-9e2b962adaf4\n\n# Volume overload\n# HFpEF, LVEF 55-60% in ___\nVolume overload on exam. Diuresis began while in ICU, net \nnegative 1.8L prior to transfer. Dry weight appears to be \n154-157. s/p Lasix 80mg x 2 so far. 163.4 lb on ___ A-Strict \nI/Os, daily weights. Continued home carvedilol at increased dose \nas below. He was sent home with PO 60 mg Lasix daily and was net \neven in the hospital. \n# HTN\nBlood pressure medications initially held when he was started on \npropofol. Anti-HTN meds started on day of transfer. Persistently \nhypertensive. Increased carvedilol to 50 mg BID and increased \nminoxidil to 5 mg and continued amlodipine 10 mg QD. Of note, he \nhad been on clonidine and hydralazine but these were stopped by \nPCP just prior to admission. He remained mostly normotensive \nalthough goal SBP <130 and should continue to be goal as an \noutpatient. \n# Normocytic Anemia\nBaseline of ___, secondary to CKD and possible AoCD. Required \n1u pRBC on arrival. Hb stable. \nCHRONIC ISSUES:']","According to the provided medical context, the patient was previously on hydralazine but it was stopped by the PCP just prior to admission. However, a past prescription for hydralazine is mentioned in one of the discharge medications lists as: '12. HydrALAZINE 100 mg PO TID' which translates to 'hydralazine 100 mg, 1 tablet by mouth three times a day'. Please note, this might not reflect the current treatment plan as the medication was stopped prior to the described hospital stay.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, here is the response to the current question:

**Current Question:** What is the prescribed dosage of hydralazine for a patient with acute on chronic heart failure and hypertension?

**Answer:**
* **Dosage of Hydralazine:** NOT MENTIONED in any of the provided documents (1 through 5).
* **Alternative Medication for Hypertension:** 
	+ Document 3 (CHRONIC PROBLEMS) and Document 4 (Hypertension section) mention the patient is continued on home **amlodipine 10 mg PO DAILY**, **CARVedilol (Coreg) 50 mg PO BID**, and **minoxidil 10 mg PO DAILY** for hypertension, but no hydralazine is listed.
	+ Document 2 (Discharge Medications) also lists the patient's discharge medications, which include **amLODIPine 10 mg PO DAILY**, **CARVedilol 50 mg PO BID**, and **Minoxidil 10 mg PO DAILY**, but again, no hydralazine is mentioned.

**Metadata Relevance to the Question:**
* None of the metadata fields (Patient/Subject ID, Note ID, Admission ID, Chart Time, Store Time) in any document (all share the same IDs) provide information about the prescribed dosage of hydralazine, as hydralazine is not mentioned in the content of the documents. 
* **Shared IDs across documents:** Yes, all documents share the same Patient/Subject ID (**13180007**), Note ID (**13180007-DS-19**), and Admission ID (**20774429**), indicating they pertain to the same patient and admission.","['ACUTE PROBLEMS\n==============\n# Acute on chronic HFpEF: \nPatient presented with dyspnea and lower extremity edema and\nfound to be volume overloaded on exam. Warm and wet on exam.\nTrigger for HF exacer', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
"What are the key considerations for a Clinical Care Coordinator managing a patient with Mild Aortic Regurgitation (Mild AR) alongside other cardiac risk factors and extensive intracranial atherosclerosis, in terms of preventing repeated hospital admissions and managing home medications?","['07c9a41e-be29-4f49-810c-9cfabe64e237\n\nInterventions: \n3L LR, Vanc/Cefepime/Flagyl, insulin gtt, Propofol (changed to\nmidazolam for hypotension), fentanyl \nVS Prior to Transfer: temp 96.2, HR 61, BP 109/54, RR 24, O2 sat\n99% Intubation \nROS: Positives as per HPI; otherwise negative.  \n \n \nPast Medical History:\n1. CARDIAC RISK FACTORS  \n- Type 2 Diabetes Mellitus\n- Hypertension  \n- Dyslipidemia  \n- Coronary artery disease\n2. CARDIAC HISTORY  \n- Secondum ASD\n- Mild AR\n3. OTHER PAST MEDICAL HISTORY  \n- Extensive intracranial atherosclerosis, worse in the right\nMCA territory.\n- Cerebrovascular disease, status post CVA in ___\n- Asthma\n- OSteoarthritis', '2fefbd11-fef9-45c9-8e5f-7c57ff45ef50\n\nCase Management, ___, as outpatient. ___ and\n___ both feel that their father needs increased services at\nhome to prevent repeated admissions. They are both providing as\nmuch support as they can, in the setting of having their own \nfull\ntime jobs and families. ___ expresses concern that his home\nmedications will be resumed/uptitrated without the understanding\nthat he is not, in fact, taking them as prescribed; she\nrecognizes that this could result in major adverse events, if \nall\nhome medications were to be resumed at the same time in the\nhospital.\n \nPast Medical History:\n1. CARDIAC RISK FACTORS  \n- Type 2 Diabetes Mellitus\n- Hypertension  \n- Dyslipidemia  \n- Coronary artery disease\n2. CARDIAC HISTORY  \n- Secondum ASD\n- Mild AR\n3. OTHER PAST MEDICAL HISTORY  \n- Extensive intracranial atherosclerosis, worse in the right\nMCA territory.']","Based on the provided context, key considerations for managing such a patient include:  1. **Close Monitoring of Cardiac Condition**: Given the patient's history of Mild AR, Secondary ASD, Type 2 Diabetes Mellitus, Hypertension, Dyslipidemia, and Coronary Artery Disease, careful monitoring of cardiac health is crucial. 2. **Management of Intracranial Atherosclerosis**: The patient's extensive intracranial atherosclerosis, particularly worse in the right MCA territory, and history of CVA, necessitate careful management to prevent further cerebrovascular events. 3. **Preventing Repeated Admissions**: Increasing home services, as suggested by the patient's family, could help in preventing repeated hospital admissions by providing adequate support and monitoring. 4. **Safe Management of Home Medications**: It is critical to understand the patient's adherence to prescribed medications before resuming or uptitrating them post-hospitalization to avoid major adverse events. A tailored approach to medication management, possibly including education on proper medication use, is essential.",custom_multi_hop_query_synthesizer,"**Key Considerations for Clinical Care Coordinator**

**Patient Identifier:** 
* **Patient/Subject ID:** 13180007 (consistent across all documents: 1, 2, 3, 4, 5)
* **Note ID:** 13180007-DS-19 (consistent across all documents)
* **Admission ID:** 20774429 (consistent across all documents)

**Clinical Considerations for Managing Mild Aortic Regurgitation (Mild AR) and Other Conditions:**

1. **Comprehensive Medication Management:**
	* **Current Home Medications (from Document 1 & updated in Document 3):**
		+ Albuterol Inhaler
		+ Amlodipine 10 mg
		+ Aspirin 81 mg
		+ Atorvastatin 80 mg
		+ Carvedilol 50 mg BID
		+ Levothyroxine Sodium 100 mcg
		+ Minoxidil 10 mg
		+ Polyethylene Glycol 17 g (PRN)
		+ Sevelamer Carbonate 800 mg TID
		+ Victoza (Liraglutide) 0.6 mg/0.1 mL (DAILY)
		+ Vitamin D 1000 UNIT
		+ **Updated/Added on Discharge (Document 3):** Torsemide 100 mg (replacing Furosemide from Document 1)
	* **Monitor and Adjust:** Regular review of medications, especially in light of multiple conditions (HFpEF, CKD, DM, Hypertension, Carotid Artery Disease, and Mild AR). Consideration for medication adjustments to prevent hospital readmissions.

2. **Disease Management:**
	* **Heart Failure with preserved Ejection Fraction (HFpEF):** Emphasize weight monitoring (provide a scale if needed), symptom reporting (e.g., worsening edema, dyspnea), and adherence to diuretics (now Torsemide 100 mg).
	* **Mild Aortic Regurgitation (Mild AR):** Regular cardiac follow-ups for monitoring AR progression. Educate on recognizing signs of worsening AR.
	* **Extensive Intracranial Atherosclerosis:** Neurological follow-ups for monitoring disease progression and managing stroke risk.
	* **Diabetes Management:** Given the poorly controlled IDDM (A1c 14.4, later 11.4%), intensify diabetes education, and consider adjusting the insulin regimen (currently 70/30 with meals) under medical supervision.

3. **Preventing Repeated Hospital Admissions:**
	* **Enhanced Home Monitoring:** Ensure the patient has a weight scale and understands its use. Regular phone or telehealth check-ins to monitor for worsening symptoms.
	* **Symptom Management Education:** Educate the patient and caregivers on recognizing early signs of decompensation (e.g., increased edema, shortness of breath, chest discomfort) and when to seek immediate medical attention.
	* **Multidisciplinary Care Team Involvement:** Coordinate with cardiologists, neurologists, endocrinologists, and primary care physicians for comprehensive care.

4. **Transition of Care:**
	* **Discharge Follow-Up:** Schedule follow-up appointments with relevant specialists and primary care within a short timeframe post-discharge.
	* **Home Health Services (as indicated in Document 3 - Discharge Disposition: Home With Service):** Ensure these services are utilized effectively for medication management, wound care (if applicable), and monitoring of the patient's condition.","['CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', 'Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
What are the key findings from the patient's Transthoracic Echocardiogram (TTE) regarding left ventricular function and structure?,"['81401d7e-0074-4c95-b4cf-e031f6b09906\n\nFindings are compatible with moderate pulmonary edema with a \nmoderate left\npleural effusion.  Underlying bibasilar atelectasis and/or \npneumonia in the\nappropriate clinical setting should also be considered.\nCT HEAD WO CON (___)\nIMPRESSION: \n \nArea of low-density left occipital ___ represent subacute \ninfarct, if there are clinical symptoms, consider brain MRI \nwithout contrast. Small chronic lacunar infarct right basal \nganglia. Few calcifications at the pons, nonspecific, may be \nsequela of prior\ninflammatory or ischemic process, cavernoma cannot be excluded.\nTTE (___)\n---------------\nCONCLUSION: The left atrial volume index is mildly increased. \nThere is mild symmetric left ventricular hypertrophy with a \nnormal cavity size. There is normal regional and global left \nventricular systolic function. The visually estimated left \nventricular ejection fraction is 55-60%. There is no resting \nleft ventricular outflow tract gradient. Normal right', 'd2113a66-fe4f-4869-b3c0-73646862b32b\n\ngluconate (received 3 doses ___. Upon review of recent \noutpatient visit notes, it appears his volume exam is similar to \nbaseline, and patient was asymptomatic during hospital course. \nHe was diuresed effectively with IV Lasix 80. He was \ntransitioned to PO torsemide 100. His BP was well controlled \nwith regimen as described below.\n# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\nat or lower than levels earlier this year. He has denied chest\npain during admission. He does have risk factors for ischemia \nand\nhas not had stress since ___. However, findings and history \nto\ndate are not suggestive of ischemia and he has an ___. TTE did \nnot show evidence of focal wall motion abnormalities or other \nfindings suggestive of ischemia, so further workup was not \npursued. He was continued on ASA and atorvastatin.\n# ___ on CKD:\nCr elevated to 2.6 on admission from baseline of 1.8-2.2. Given\nevidence of congestion elsewhere, concerns for renal congestion\ncausing renal dysfunction. Cr remained stable and was 2.9 on day \nof discharge. He was continued on home sevelamer.']","According to the TTE findings, the patient has:               1. **Mildly increased left atrial volume index**.              2. **Mild symmetric left ventricular hypertrophy** with a normal cavity size.              3. **Normal regional and global left ventricular systolic function**.              4. A **visually estimated left ventricular ejection fraction of 55-60%**.              5. **No resting left ventricular outflow tract gradient**.              Additionally, the TTE did not show evidence of focal wall motion abnormalities or other findings suggestive of ischemia.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Key Findings from Transthoracic Echocardiogram (TTE) regarding Left Ventricular Function and Structure:**

Based on the analysis of **Documents 1, 2, and 3** (which all share the same **Patient/Subject ID: 13180007**, **Note ID: 13180007-DS-19**, and **Admission ID: 20774429** as per their METADATA), the key TTE findings related to left ventricular function and structure are:

1. **Left Ventricular Ejection Fraction (LVEF):** Visually estimated LVEF is **65%**, indicating normal left ventricular systolic function. (**Document 1** and mentioned in **Document 3** for context)
2. **Left Ventricular Structure:**
	* **Hypertrophy:** There is **mild symmetric left ventricular hypertrophy**. (**Document 1**)
	* **Cavity Size:** The left ventricular cavity size is **normal**. (**Document 1**)
3. **Diastolic Function:**
	* **Diastolic Dysfunction:** Echocardiographic evidence suggests **diastolic dysfunction (grade indeterminate)**. (**Document 1**)
	* **Left Ventricular Filling Pressure:** Tissue Doppler indicates **increased left ventricular filling pressure (PCWP greater than 18 mmHg)**. (**Document 1**)

**Metadata Consistency Note:**
- **Patient/Subject ID**, **Note ID**, **Admission ID**, **Chart Time**, and **Store Time** are consistent across **Documents 1, 2, 3, 4, and 5**, confirming these findings pertain to the same patient encounter.","['___\nCONCLUSION:\nThe left atrial volume index is normal. The estimated right \natrial pressure is ___ mmHg. There is mild\nsymmetric left ventricular hypertrophy with a normal cavity \nsize. There is norm', 'leaflets (3) are mildly thickened. There is no\naortic valve stenosis. There is no aortic regurgitation. The \nmitral valve leaflets are mildly thickened with\nno mitral valve prolapse. There is trivial ', 'ACUTE PROBLEMS\n==============\n# Acute on chronic HFpEF: \nPatient presented with dyspnea and lower extremity edema and\nfound to be volume overloaded on exam. Warm and wet on exam.\nTrigger for HF exacer', '# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n', 'In the ED:  \nInitial VS: T 98.5, HR 102, BP 178/76, RR 22, SpO2 98% RA \n \nExam:\nGeneral- NAD\nHEENT- PERRL, EOMI, normal oropharynx\nLungs- Non-labored breathing, CTAB\nCV- RRR, systolic murmur, normal S']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
"What is the prescribed dosage and administration schedule for HydrALAZINE in the provided medical discharge instructions, and what are the primary and secondary diagnoses associated with its prescription?","['058d90f2-3d7b-4d29-bca6-e70e3cb19e4d\n\n4.  HydrALAZINE 100 mg PO TID \nRX *hydralazine 100 mg 1 tablet(s) by mouth three times daily \nDisp #*90 Tablet Refills:*0 \n5.  Glargine 30 Units Breakfast \n6.  Albuterol Inhaler 2 PUFF IH Q4H  \n7.  amLODIPine 10 mg PO DAILY  \n8.  Atorvastatin 80 mg PO QPM  \n9.  CloNIDine 0.2 mg PO BID  \n10.  Gabapentin 400 mg PO TID  \n11.  Levothyroxine Sodium 100 mcg PO DAILY  \n12.  MetFORMIN (Glucophage) 850 mg PO TID  \n13.  Vitamin D ___ UNIT PO WEEKLY  \n14. HELD- Lisinopril 40 mg PO DAILY  This medication was held. \nDo not restart Lisinopril until told to do so by your doctor\n15.Outpatient Lab Work\nChem-7 to be draw ___\nICD 10: I50.3: Diastolic (congestive) heart failure\nFax results to: ___ ATTN: ___\n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___', '5d1619ab-197a-416d-b0af-616eff82199c\n\n#*60 Tablet Refills:*0 \n12.  HydrALAZINE 100 mg PO TID \nRX *hydralazine 100 mg 1 tablet(s) by mouth three times a day \nDisp #*90 Tablet Refills:*0 \n13.  Levothyroxine Sodium 100 mcg PO DAILY \nRX *levothyroxine 100 mcg 1 tablet(s) by mouth once a day Disp \n#*30 Tablet Refills:*0 \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPRIMARY DIAGNOSIS\n==================\nAcute on chronic heart failure with preserved ejection fraction\nSECONDARY DIAGNOSES\n====================\nAcute kidney injury\nCoronary artery disease\nType 2 Diabetes Mellitus\nHyperkalemia']","According to the discharge instructions, HydrALAZINE is prescribed as follows: 100 mg PO (by mouth) TID (three times a day). This medication regimen is associated with the following diagnoses: **PRIMARY DIAGNOSIS** - Acute on chronic heart failure with preserved ejection fraction, and **SECONDARY DIAGNOSES** - Acute kidney injury, Coronary artery disease, Type 2 Diabetes Mellitus, and Hyperkalemia. The prescription details are consistent across both provided medical records (Disp #*90 Tablet Refills:*0 in one record and implied in the other with #*60 Tablet Refills:*0 for a different medication, suggesting a similar dispensing approach might be intended for HydrALAZINE despite the specific refill number not being directly mentioned in the second record for HydrALAZINE).",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

* **Prescribed Dosage and Administration Schedule for HydrALAZINE:**
	+ **Dosage:** Not mentioned
	+ **Administration Schedule:** Not mentioned
	+ **Reason:** HydrALAZINE is not mentioned at all in the provided medical discharge instructions (Documents 1 through 5).

* **Primary and Secondary Diagnoses Associated with HydrALAZINE's Prescription:**
	+ **Primary Diagnosis:** Not applicable (since HydrALAZINE is not prescribed)
	+ **Secondary Diagnoses:** Not applicable (since HydrALAZINE is not prescribed)

**Additional Information (as per the instructions for reporting IDs and dates):**

* **Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, Document 2, Document 3, Document 4, Document 5)
* **Note ID:** 13180007-DS-19 (consistent across all documents: Document 1, Document 2, Document 3, Document 4, Document 5)
* **Admission ID:** 20774429 (consistent across all documents: Document 1, Document 2, Document 3, Document 4, Document 5)
* **Chart Time and Store Time:** Consistent across all documents (20/06/62 0:00 for Chart Time and 21/06/62 9:56 for Store Time), but not directly relevant to the question about HydrALAZINE.

**Primary and Secondary Diagnoses for the Patient (from Document 1, for context):**

* **Primary Diagnosis:** Acute on chronic diastolic heart failure exacerbation
* **Secondary Diagnoses:**
	1. Acute kidney injury
	2. Acute on chronic anemia
	3. Type 2 diabetes mellitus","['Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1', 'Discharge Condition:\nMental Status: Clear and coherent.\nLevel of Consciousness: Alert and interactive.\nActivity Status: Ambulatory - Independent.\n\n \nDischarge Instructions:\n Dear ___,  \n\n It was a ple', 'TRANSITIONAL ISSUES\n===================\n[ ] At discharge his symptoms associated with volume overload \nhad subsided, but he was still slightly volume up on exam with \n1+ edema to ankles bilaterally an']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
"What me worry bout wen patient hav small left pleural effusion, borderline cardiac silhouette, and chronic infarcts in brain CT, but no acute intracranial abnormality? Should i look into somethin else wit dis patient?","[""2b2ce4e1-1e51-4483-8a53-32a58ee918d2\n\nleft pleural effusion. Borderline size of the cardiac silhouette\nwithout pulmonary edema. No pneumonia, no pneumothorax.  The\nlateral radiograph shows mild flattening of the hemidiaphragms,\npotentially as a consequence of functional obstruction.\nHead CT: 1. No evidence of acute intracranial abnormality.\n2. Unchanged appearance of chronic infarcts within the right\nfrontal lobe and left occipital lobe.\n3. Chronic lacunar infarcts within the right basal ganglia.\n4. Redemonstration of few calcifications within the pons,\nfindings which are unchanged in appearance and likely sequela of\nprior ischemic or inflammatory process.\n___ 11:00AM BLOOD cTropnT-0.04*\n___ 09:00PM BLOOD cTropnT-0.02*\n___ 11:00AM BLOOD %HbA1c-14.4* eAG-367*\n___ 11:00AM BLOOD Lipase-73*\n___ 11:00AM BLOOD CK-MB-4 proBNP-754*\nIMAGING:\n___ CXR -\nComparison to ___.  On today's radiograph, a small \npleural\nleft-sided calcification is seen.  There also is a small left \npleural\neffusion.  Borderline size of the cardiac silhouette without"", 'a0523bf3-a15e-4abc-bd78-1c98b6c5dc7e\n\nedema.  No\nevidence of displaced fracture.\nCT head ___:\nThere is no evidence of infarction, hemorrhage, edema,or midline \nshift.  There\nis prominence of the ventricles and sulci suggestive of \ninvolutional changes.\n \nThere is no evidence of fracture.  Opacification of the mastoid \nair cells. \nThe visualized portion of the paranasal sinuses, mastoid air \ncells, and middle\near cavities are clear.  The visualized portion of the orbits \nare\nunremarkable.\nCT abd/pelvis ___:\n1. Bilateral lower lobe opacities, concerning for aspiration or \npneumonia.\n2. No acute finding in the abdomen or pelvis.\nCT C spine ___:\nNG tube and endotracheal tube are noted.  Alignment is normal. \nNo fractures\nare identified. There is no evidence of high-grade spinal canal']","Based on provided CT scans and blood work, key concerns for the patient include:      1. **Small left pleural effusion and borderline size of the cardiac silhouette** observed in the chest X-ray (CXR), suggesting potential cardiac or pulmonary issues, but **no pneumonia or pneumothorax**.     2. **Chronic infarcts** within the right frontal lobe, left occipital lobe, and right basal ganglia, as well as **calcifications in the pons**, indicating past ischemic or inflammatory processes, but **no evidence of acute intracranial abnormality** on the Head CT.     3. **Elevated %HbA1c (14.4)** and **eAG (367)**, indicating poorly controlled diabetes.     4. **proBNP of 754**, which may suggest heart failure or other cardiac conditions.     **Recommendation**: Further investigation into the patient's cardiac health (given the borderline cardiac silhouette and proBNP levels) and management of diabetes are warranted. Monitoring for any signs of neurological deterioration, despite the current lack of acute intracranial abnormalities, is also advisable.",custom_multi_hop_query_synthesizer,"Based on the provided instructions, I'll address the question while following the guidelines.

**Question Analysis**

* The question pertains to a patient's condition, specifically mentioning:
	1. Small left pleural effusion
	2. Borderline cardiac silhouette
	3. Chronic infarcts in brain CT
	4. No acute intracranial abnormality
* The question asks what to worry about with these conditions and if something else should be looked into for this patient.

**Metadata Review (as per instructions)**

* **Patient/Subject ID**: 13180007 (consistent across all documents)
* **Note ID**: 13180007-DS-19 (consistent across all documents)
* **Admission ID**: 20774429 (consistent across all documents)
* **Chart Time** and **Store Time** are also consistent, indicating these documents pertain to the same admission period.

**Content Review for Relevant Information**

* **Small pleural effusion**: Document 1 (CONTENT) mentions ""small bilateral pleural effusions, left greater than right"" in the CXR findings, aligning with the question's concern.
* **Borderline cardiac silhouette**: Not explicitly mentioned in the provided documents. **Action Suggested**: Review additional imaging reports (e.g., CXR detailed report) not included in the provided documents.
* **Chronic infarcts in brain CT**: Document 1 (CONTENT) mentions ""Cerebrovascular disease, status post CVA in ___"" and ""Extensive intracranial atherosclerosis,"" indicating a history of cerebral vascular events. However, the specific mention of ""chronic infarcts in brain CT"" is not found in the provided documents. **Action Suggested**: Review neuroimaging reports (e.g., CT/MRI scans) not included in the provided documents.
* **No acute intracranial abnormality**: While not explicitly stated in the provided documents, the absence of any mention of acute intracranial issues in the context of the provided information might imply this. However, **confirmation from direct neuroimaging reports is recommended**.

**What to Worry About and Next Steps**

Given the information and the gaps identified:

1. **Cardiac Function**: Given the pleural effusion and the patient's complex medical history (e.g., hypertension, dyslipidemia, diabetes mellitus type 2, cerebrovascular disease), monitoring cardiac function closely is crucial. The mention of a ""stiff left ventricle"" and ""small pericardial effusion"" in Document 2 suggests potential cardiac involvement.
   
2. **Renal Function**: The elevated Cr levels (Document 3) indicate a need to monitor renal function, potentially attributing the elevation to renal congestion.

3. **Neurological Status**: While chronic infarcts are hinted at through the patient's history, ensuring no new or acute neurological deficits is important. A detailed neurological examination and review of recent brain imaging (if available) would be prudent.

4. **Multidisciplinary Care**: Given the patient's complex, multifaceted medical history, coordinating care among cardiology, nephrology, neurology, and primary care teams is essential for comprehensive management.

**Recommendations for Further Review**

- **Imaging Reports**:
	* Detailed CXR report for borderline cardiac silhouette
	* Recent brain CT/MRI for chronic infarcts and to confirm no acute abnormalities
- **Specialized Consults**:
	* Cardiology for further cardiac evaluation
	* Nephrology for renal function management
	* Neurology for neurological status assessment
- **Medication Review**: Ensure all medications (listed in Document 4) are optimized for the patient's current condition, particularly those affecting cardiac and renal function.","['Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n', 'leaflets (3) are mildly thickened. There is no\naortic valve stenosis. There is no aortic regurgitation. The \nmitral valve leaflets are mildly thickened with\nno mitral valve prolapse. There is trivial ', '# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'In the ED:  \nInitial VS: T 98.5, HR 102, BP 178/76, RR 22, SpO2 98% RA \n \nExam:\nGeneral- NAD\nHEENT- PERRL, EOMI, normal oropharynx\nLungs- Non-labored breathing, CTAB\nCV- RRR, systolic murmur, normal S']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
"What medikashuns shud patient wit Type 2 Diabetes Mellitus, heart failure, and acute kidney injury take when goin home from hospital, espeshally for diabetis?","['281ec1ee-1c32-43a3-8667-6c9eaa2f4734\n\nEKG:  SR, NL axis, NIs, TWIs laterally (c/w prior) \nLabs/studies notable for:  proBNP: 1140, Cr 1.9\nPatient was given:  IV Furosemide 10mg\nOn the floor...  \n---------------\nStates that he feels better than he did when he came to the\nhospital. No SOB, CP, or palpitations. Only complaint is the\nburning/itching in his lower extremities. \n \nPast Medical History:\n1. CARDIAC RISK FACTORS  \n- Type 2 Diabetes Mellitus\n- Hypertension  \n- Dyslipidemia  \n- Coronary artery disease\n2. CARDIAC HISTORY  \n- Secondum ASD\n- Mild AR\n3. OTHER PAST MEDICAL HISTORY  \n- Extensive intracranial atherosclerosis, worse in the right\nMCA territory.\n- Cerebrovascular disease, status post CVA in ___\n- Asthma\n- OSteoarthritis', '5d1619ab-197a-416d-b0af-616eff82199c\n\n#*60 Tablet Refills:*0 \n12.  HydrALAZINE 100 mg PO TID \nRX *hydralazine 100 mg 1 tablet(s) by mouth three times a day \nDisp #*90 Tablet Refills:*0 \n13.  Levothyroxine Sodium 100 mcg PO DAILY \nRX *levothyroxine 100 mcg 1 tablet(s) by mouth once a day Disp \n#*30 Tablet Refills:*0 \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPRIMARY DIAGNOSIS\n==================\nAcute on chronic heart failure with preserved ejection fraction\nSECONDARY DIAGNOSES\n====================\nAcute kidney injury\nCoronary artery disease\nType 2 Diabetes Mellitus\nHyperkalemia']","Based on provided context, for a patient with Type 2 Diabetes Mellitus discharged home, the specified medications do not directly target diabetes management at home. However, medications listed in the context that the patient was on or discharged with, which might be relevant or need monitoring in the context of their diabetes and other conditions, include:  - **HydrALAZINE 100 mg PO TID** (primarily for hypertension, a cardiac risk factor for diabetes patients) - **Levothyroxine Sodium 100 mcg PO DAILY** (for thyroid conditions, not directly related to diabetes but important for overall metabolic health) - **IV Furosemide 10mg** was administered in the hospital (for acute kidney injury and heart failure, not a home medication in this context but important for managing conditions that impact diabetes care).  **Direct Diabetes Management Medication:** Not specified in the discharge or hospital administration context provided. Typically, a patient with Type 2 Diabetes Mellitus would be on medications such as Metformin, Sulfonylureas, or other classes depending on their specific condition and health status, but these are not mentioned in the given context.",custom_multi_hop_query_synthesizer,"Based on the provided documents, I'll answer your question following the instructed guidelines.

**Patient Context:**
Before diving into the medications, let's establish the patient's context based on the documents:

- **Patient/Subject ID:** 13180007 (consistent across all documents: Document 1, 2, 3, 4, 5)
- **Conditions Relevant to Your Question:**
  - Type 2 Diabetes Mellitus (mentioned in Document 1 under ""Discharge Diagnosis"" > ""Secondary Diagnosis"")
  - Heart Failure (implied through ""Acute on chronic diastolic heart failure exacerbation"" in Document 1 and history of HFpEF in Documents 3 and 5)
  - Acute Kidney Injury (mentioned in Document 1 under ""Discharge Diagnosis"" > ""Secondary Diagnosis"")

**Medications for the Specified Conditions upon Discharge (especially for Diabetes):**

Based on **Document 1: Discharge Medications**, which directly addresses medications upon discharge, and cross-referenced with other documents for comprehensive understanding:

- **For Type 2 Diabetes Mellitus:**
  1. **70/30 Insulin**:
     - 30 Units with Breakfast
     - 10 Units with Lunch
  2. **Victoza (Liraglutide)**: 0.6 mg/0.1 mL (18 mg/3 mL) subcutaneous DAILY

- **For Heart Failure:**
  Note: Specific medications for heart failure are not exclusively listed under a ""Heart Failure"" section, but the following are relevant based on the patient's overall medication list and conditions:
  1. **Torsemide 100 mg PO DAILY** (a diuretic, which is crucial in managing fluid overload associated with heart failure)
  2. **Carvedilol 50 mg PO BID** (a beta-blocker commonly used in heart failure management)
  3. **Minoxidil 10 mg PO DAILY** (while primarily for hypertension, it can have implications in heart failure management due to its vasodilatory effects)

- **For Acute Kidney Injury (AKI):**
  No medications are specifically highlighted in the documents as being for AKI upon discharge. Management of AKI often involves careful fluid management and adjustment of medications to avoid further renal insult. The patient's discharge medications seem to be tailored with this in mind (e.g., diuretic use as mentioned for heart failure), but there's no direct mention of medications specifically for AKI.

**Additional Notes:**

- **Consistency in IDs:** The Patient/Subject ID, Note ID, and Admission ID are consistent across all provided documents, reinforcing the context that these documents pertain to the same patient event.
- **Medication List Accuracy:** Document 4 mentions that ""The Preadmission Medication list is accurate and complete,"" but for discharge medications, **Document 1** is the authoritative source based on the question's context.","['Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
"Whats the deal with the Asprin perscription for a patient with a history of CAD and CKD stage III, shouldnt they be on somethin els?","['4b3d7a96-6534-434e-8295-b8356c5ca64d\n\nbasal/bolus four times daily regimen. However, this is not a \nsustainable regimen for patient on discharge. Discussed \npossibility of switching to 70/30 mix BID, however currently \npatient cannot be guaranteed to eat regular meal after each \ninsulin injection therefore currently not a tenable plan. In the \nfuture, if patient able to be placed in a day program, \npotentially could switch to this but for now will we continued \nhis prior home regimen (EXCEPT for Jardiance, which was \ndiscontinued due to contraindication with chronic kidney \ndisease) on discharge, with very close ___ follow-up and ___ \nservices to help increase compliance. With regards to his more \nsubacute mental status decompensation, would benefit from \nreferral for outpatient neurocognitive evaluation.\n# Hx of CAD: \n# Hx of ischemic CVA:\nStress test in ___ with area of inducible ischemia in LCx \ndistribution, in setting of multiple risk factors. Has been \nmedically optimized by prescribed medications, but as above it \nseems that pt has been taking these medications. TnT 0.04->0.02 \nin setting of CKD stage III-IV. Continued home aspirin, \natorvastatin, and carvedilol. Note that he was once on \nlisinopril (most recently filled in ___ for 2.5mg dose) \nhowever seems that this has since been discontinued.\n# CKD stage III:', 'cd30826d-ad9e-4a08-8b63-15e1e3bbfe0c\n\nYou were admitted to the hospital because:\n================================\n-You had worsening shortness of breath, with increased leg \nswelling and weight gain.\nDuring your stay:\n============\n-You had too much volume onboard so you were given IV diuretic \nmedications,. You improved significantly.\nAfter your discharge:\n================\n-Please continue taking all medications as prescribed (see \nbelow).\n-Please stop taking Lisinopril and metoprolol.\n-Please continue taking insulin according to the regimen you \nwere following before this admission.\n-New medications:\n  - Aspirin 81mg once daily\n  - Carvedilol 25mg twice daily\n  - Furosemide 40mg twice daily\n  - Hydralazine 100mg three times daily\n-Please attend any upcoming outpatient appointments you have \n(see below).\nWe wish you the very best!']","According to the patient's care plan, **Aspirin** is indeed continued at home, alongside **atorvastatin** and **carvedilol**, despite the patient's history of CAD (with a past stress test showing inducible ischemia in LCx distribution) and CKD stage III. This decision was made as part of medically optimizing the patient, with close follow-up planned. Specifically, the patient is to take **Aspirin 81mg once daily** as prescribed upon discharge, with no indication in the provided context to switch to an alternative due to these conditions.",custom_multi_hop_query_synthesizer,"Based on the provided instructions, I'll address the question to the best of my abilities. However, I must clarify a few assumptions since the question introduces information not explicitly mentioned in the documents (e.g., CAD and CKD stage III) but inferred from the content.

**Assumptions for Clarification:**

1. **CAD (Coronary Artery Disease) History:** While Document 1 mentions ""No known history of CAD,"" this contradicts the question's premise. For the sake of answering, let's assume the patient might have developed or been newly diagnosed with CAD, not reflected in these documents.
   
2. **CKD Stage III:** The documents mention CKD (Chronic Kidney Disease) but do not specify the stage. Assuming CKD Stage III based on the question.

**Addressing the Question:**

Given the patient's **assumed** condition (CAD and CKD Stage III) and the **actual** information from the documents:

- **Patient/Subject ID:** 13180007 (consistent across all documents)
- **Relevant Medication Mentioned:** Aspirin (81 mg PO DAILY) in Document 2, also mentioned in the context of a history of CVA (Cerebrovascular Accident) in Documents 2 and implied in the management of other conditions across documents.

**Analysis on Aspirin Prescription:**

- **For CAD:** Aspirin is commonly used for primary and secondary prevention of cardiovascular events in patients with CAD. However, the documents do not explicitly confirm CAD, so this assumption may not directly apply.
  
- **For CKD Stage III:** The use of aspirin in CKD patients is more nuanced, balancing cardiovascular protection against the risk of bleeding, especially in those with more advanced kidney disease. Guidelines often recommend individualized decision-making, considering the patient's overall cardiovascular risk, bleeding risk, and kidney function.

**Conclusion Based on Provided Documents and Assumptions:**

1. **ID Confirmation:** Patient/Subject ID is consistently **13180007** across all documents.
2. **Aspirin Prescription:** Given in the context of CVA history and possibly for cardiovascular protection, but the documents do not explicitly address CAD or provide a detailed rationale for aspirin use in the context of CKD.
3. **Should They Be on Something Else?** Without explicit confirmation of CAD and given the CKD, an alternative or adjunct to aspirin might be considered (e.g., other antiplatelets, depending on the patient's specific risk profile). However, based solely on the provided documents, there's no clear indication to deviate from the current aspirin prescription without further clinical context or updated diagnoses.

**Recommendation for Clinical Practice (outside the document analysis scope but for completeness):**

- Review the patient's updated medical history, including any newly diagnosed CAD and the current stage of CKD.
- Assess the patient's overall cardiovascular risk and bleeding risk.
- Consider consulting current clinical guidelines (e.g., AHA, ADA, KDIGO) for managing patients with CAD and CKD Stage III.
- Individualize the patient's treatment plan, which may include but is not limited to, adjusting antiplatelet therapy, optimizing kidney protective measures, and closely monitoring both cardiovascular and renal health.","['# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', 'ACUTE PROBLEMS\n==============\n# Acute on chronic HFpEF: \nPatient presented with dyspnea and lower extremity edema and\nfound to be volume overloaded on exam. Warm and wet on exam.\nTrigger for HF exacer']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
What is the prescribed administration schedule for Albuterol Inhaler upon hospital admission for a patient experiencing shortness of breath?,['8c579626-76a5-4cd0-9f53-1feadb6904be\n\nMedications on Admission:\nThe Preadmission Medication list is accurate and complete.\n1. Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath \n2. amLODIPine 10 mg PO DAILY \n3. Atorvastatin 80 mg PO QPM \n4. CARVedilol 50 mg PO BID \n5. Furosemide 80 mg PO DAILY \n6. 70/30 30 Units Breakfast\n70/30 10 Units Lunch\n7. Levothyroxine Sodium 100 mcg PO DAILY \n8. Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY \n9. Minoxidil 10 mg PO DAILY \n10. Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine \n11. sevelamer CARBONATE 800 mg PO TID W/MEALS \n12. Aspirin 81 mg PO DAILY \n13. Vitamin D 1000 UNIT PO DAILY \n \nDischarge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast'],"According to the preadmission medication list, Albuterol Inhaler is prescribed as 2 puffs, inhaled (IH) every 8 hours as needed (Q8H:PRN) specifically for shortness of breath.",custom_multi_hop_query_synthesizer,"Based on the provided documents, to answer the question about the prescribed administration schedule for Albuterol Inhaler upon hospital admission for a patient experiencing shortness of breath, we'll analyze the relevant information:

**Question:** What is the prescribed administration schedule for Albuterol Inhaler upon hospital admission for a patient experiencing shortness of breath?

**Relevant Documents for Answer:**
- **Document 1:** Contains discharge medications, which may not directly reflect admission prescriptions but can indicate ongoing treatment.
- **Document 3:** Lists medications on admission, providing a direct answer to the question about hospital admission prescriptions.

**Analysis from Document 3 (Medications on Admission):**
1. **Medication Name:** Albuterol Inhaler
2. **Dosage:** 2 PUFF
3. **Route:** IH (Inhalation)
4. **Frequency:** Q8H:PRN (Every 8 Hours, as needed)
5. **Indication (as per question context):** shortness of breath

**Answer:**
- **Medication:** Albuterol Inhaler
- **Administration Schedule upon Hospital Admission for shortness of breath:** 2 PUFF IH Q8H:PRN (2 puffs by inhalation every 8 hours, as needed for shortness of breath)

**Metadata Relevance to the Question:** None directly, as the question pertains to medication administration schedule, not patient IDs, dates, or other metadata values. However, for completeness regarding the patient context:
- **Patient/Subject ID:** 13180007 (consistent across all documents)
- **Note ID, Admission ID, Chart Time, and Store Time** are also consistent but not relevant to the specific question about Albuterol Inhaler's administration schedule.","['Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1', 'Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
"What adjustments were made to the patient's medication regimen for managing Type 2 Diabetes Mellitus (T2DM) and Hypertension, and what follow-up actions were recommended upon discharge?","['386e4975-89d1-411a-99a3-9d225138df6c\n\n[] Ensure that patient was able to adhere to a diabetic diet\nPCP:\n[] Had elevated SBP in 130s-150s. Increased minoxidil to 5mg and \ncarvedilol to 50 mg BID. Please follow-up on blood pressures. \n[] Follow up on diuretics and volume status. Please get \nfollow-up labs BUN/Cr at follow-up appointment.\nNew meds: 70-30 novolog (30 units in AM, 20 units at dinner)\nStopped meds: none\nChanged meds: Carvedilol 50 mg twice a day, increased minoxidil \n5 mg daily \nACUTE ISSUES: \n=============== \n# HHS\n# T2DM\nPatient has history of poorly-controlled DM w/ A1c ~14. Based on \nlabs, determined to be in HHS likely precipitated by med \nnon-adherence or difficulty understanding multi-step process. No \nclear infection was identified. Of note, he tends to have high \ninsulin requirements. Pt was continued on insulin basal/bolus \nwhile inpatient. There was significant efforts to have him bring \nin home Victoza but he only had a half dose so he was continued \non basal/bolus course and made a plan for close outpatient \nfollow up and home 2 injections (Victoza and pre-mixed insulin).']","Adjustments made to the patient's medication regimen include: increasing minoxidil to 5mg daily and carvedilol to 50mg twice a day (BID) to manage elevated Systolic Blood Pressure (SBP); continuation of basal/bolus insulin due to high insulin requirements and the patient's difficulty with multi-step medication processes. Specifically for T2DM, the patient was started on 70-30 novolog (30 units in the morning, 20 units at dinner). Upon discharge, recommended follow-up actions include: monitoring blood pressures, assessing diuretics and volume status, and obtaining follow-up labs for BUN/Cr at the next appointment. Additionally, plans were made for close outpatient follow-up and administering two injections at home (Victoza and pre-mixed insulin).",custom_multi_hop_query_synthesizer,"**Adjustments to Medication Regimen and Follow-up Actions for T2DM and Hypertension**

### **Type 2 Diabetes Mellitus (T2DM) Adjustments and Follow-up:**

* **Medication Adjustments:**
	+ **Document 1 (Discharge Medications):** 
		- Insulin regimen: 70/30 30 Units with Breakfast, 10 Units with Lunch
		- **Note:** Transitioned from inpatient Lantus 30u (night of admission) to the above home insulin regimen (**Document 4**)
	+ **No adjustments mentioned in metadata for T2DM**
* **Follow-up Actions:**
	+ **Document 3 (Patient Instructions):** 
		- Follow up with doctors as listed (specific doctors not listed in provided documents)
		- **No specific T2DM follow-up labs or appointments mentioned in the provided documents**

### **Hypertension Adjustments and Follow-up:**

* **Medication Adjustments:**
	+ **Document 1 (Discharge Medications) & Document 4 (Hypertension):**
		- **Amlodipine:** Continued on home amlodipine 10 mg PO DAILY
		- **Carvedilol (Coreg):** Continued on home Carvedilol 50 mg PO BID
		- **Minoxidil:** Continued on home Minoxidil 10 mg PO DAILY
	+ **Document 1 (Discharge Medications) - New/Adjusted for Overall Condition:**
		- **Torsemide:** Discharged on Torsemide 100 mg PO DAILY for active diuresis (addresses volume overload, which can be related to hypertension management)
* **Follow-up Actions:**
	+ **Document 3 (Patient Instructions):** 
		- Weigh yourself daily; report weight increases >3 pounds in one day or >5 pounds in one week
		- Follow up with doctors as listed (specific doctors not listed in provided documents)
	+ **Document 5 (Transitional Issues):**
		- **Lab Follow-up:** Not specifically for hypertension, but mentioned for overall condition - follow-up labs should be drawn (date not specified)

### **Shared IDs and Dates:**
- **Patient/Subject ID:** 13180007 (consistent across all documents)
- **Note ID:** 13180007-DS-19 (consistent across all documents)
- **Admission ID:** 20774429 (consistent across all documents)
- **Chart Time & Store Time:** Consistent across all documents (20/06/62 0:00 and 21/06/62 9:56, respectively)","['Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', 'WHAT HAPPENED WHILE I WAS IN THE HOSPITAL?  \n You were given medications to help get the fluid out. Your \nsymptoms got better and were ready to leave the hospital.  \n\n WHAT DO YOU NEED TO DO WHEN YOU ', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', 'TRANSITIONAL ISSUES\n===================\n[ ] At discharge his symptoms associated with volume overload \nhad subsided, but he was still slightly volume up on exam with \n1+ edema to ankles bilaterally an']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
"What are the current management strategies for a patient with Coronary Artery Disease (CAD) presenting with inducible ischemia and a recent Non-ST Elevation Myocardial Infarction (NSTEMI), given the presence of chronic kidney disease (CKD)?","['2574c42a-a6ef-418e-ac90-a21855611d18\n\npulmonary edema. No pneumonia, no pneumothorax.  The lateral \nradiograph shows mild flattening of the hemidiaphragms, \npotentially as a consequence of functional obstruction.\n___ CT HEAD -\n1. No evidence of acute intracranial abnormality.\n2. Unchanged appearance of chronic infarcts within the right \nfrontal lobe and left occipital lobe.\n3. Chronic lacunar infarcts within the right basal ganglia.\n4. Re-demonstration of few calcifications within the pons, \nfindings which are unchanged in appearance and likely sequela of \nprior ischemic or inflammatory process.\nMICRO:\n___ 3:38 pm URINE\n                            **FINAL REPORT ___\n   URINE CULTURE (Final ___:    < 10,000 CFU/mL. \n \nBrief Hospital Course:\nMr. ___ is a ___ ___ speaking male with a \nPMH of prior CVA ___, residual emotional lability, \ndysarthria), HFpEF, uncontrolled DM2, HTN, CAD, CKD, \n?hypothyroidism, asthma, mild cognitive impairment who presented', '5afc91e0-6481-46b3-aa3c-473b2c2e6895\n\n#Community acquired pneumonia\nCough, worsened SOB, hypoxemia (although alternate explanation) \nbut no leukocytosis or fevers; influenza negative. Legionella \nand strep were negative. Patient was given a 5-day course of \nceftriaxone and azithromycin. \n#Hypertension\nGoal <130/80. As patient is on several anti-hypertensives with \nstill an elevated blood pressure, he underwent a secondary \nhypertension workup. His last renal ultrasound in ___ was \nwithin normal limits. He was placed on continuous O2 monitoring \novernight, and patient did not desaturate. His aldosterone to \nrenin ratio was 0.13, indicating no primary hyperaldosteronism. \n24 hour urine metanephrines and catecholamines were within \nnormal limits.\n#CAD w/ inducible ischemia\n#NSTEMI\nTroponin peaked at 0.02, thought to be type 2 due to volume \noverload. Continued aspirin, atorvastatin, carvedilol. The \ndecision was made to hold off on coronary angiogram due to \nkidney function and the suspicion that this was type 2.\n#H/o CVA\nPatient had an episode while in hospital with dysarthria,']","According to the provided context, for a patient with CAD, inducible ischemia, and recent NSTEMI (troponin peaked at 0.02, suspected as type 2 due to volume overload), the management includes:  - Continuation of aspirin, atorvastatin, and carvedilol.  - A decision was made to hold off on the coronary angiogram due to compromised kidney function and the suspicion of a type 2 myocardial infarction.  Additionally, the patients hypertension is being managed with multiple anti-hypertensives, aiming for <130/80, and a secondary hypertension workup was conducted, which included an aldosterone to renin ratio and 24-hour urine metanephrines and catecholamines, all within normal limits.",custom_multi_hop_query_synthesizer,"Based on the provided instructions and documents, here's the response to the question:

**Question:** What are the current management strategies for a patient with Coronary Artery Disease (CAD) presenting with inducible ischemia and a recent Non-ST Elevation Myocardial Infarction (NSTEMI), given the presence of chronic kidney disease (CKD)?

**Response Analysis:**

1. **Patient/Subject ID:** 13180007 (consistent across all documents)
2. **Relevance to CAD, NSTEMI, and CKD:**
   - **CAD with Inducible Ischemia and NSTEMI:** The documents do not explicitly mention a recent NSTEMI or inducible ischemia. Document 1 discusses chest pain with mild troponin elevation but suggests this is difficult to interpret due to CKD and does not definitively indicate a recent NSTEMI or inducible ischemia.
   - **CKD:** Acknowledged in all documents, with Document 1 specifically discussing the challenge of interpreting troponin elevation in the context of CKD.

3. **Management Strategies for Assumed CAD/Ischemia in the Context of CKD (based on provided documents, noting the absence of explicit NSTEMI or inducible ischemia mentions):**
   - **Medications:**
     - **ASA (Aspirin):** Continued (Document 1 and implied in Document 5 as part of the patient's regimen for a history of CVA).
     - **Atorvastatin:** Continued (Document 1 and listed in Document 5).
     - **No specific anti-ischemic or CAD management adjustments for CKD are detailed beyond the above, which are more for prevention and general cardiovascular health.**
   - **Diagnostic/Therapeutic Interventions:**
     - **TTE (Transthoracic Echocardiogram):** Performed, showing no focal wall motion abnormalities suggestive of ischemia (Document 1).
     - **Stress Test:** Mentioned as not having been done since an unspecified time (Document 1), but no recent results or plans for one are discussed in the context of the current admission.
     - **Management of CKD:**
       - **Sevelamer:** Continued for CKD management (Documents 1 and 5).
       - **Monitoring of Renal Function:** Implied through the discussion of creatinine levels (Document 1).

**Conclusion:**
Given the documents do not explicitly confirm a recent NSTEMI or inducible ischemia, and prioritizing the metadata and content provided:
- The patient's management strategy, as it relates to the assumed context (CAD/Ischemia with CKD), focuses on continuation of preventive cardiovascular medications (ASA, atorvastatin) and management of CKD (sevelamer, monitoring).
- **No specific treatment for a recent NSTEMI or inducible ischemia is outlined in the documents**, highlighting a potential gap in addressing the question's full scope based on the provided information.

**IDs and Dates (as per instructions):**
- **Patient/Subject ID:** 13180007 (consistent across Documents 1-5)
- **Note ID:** 13180007-DS-19 (consistent across Documents 1-5)
- **Admission ID:** 20774429 (consistent across Documents 1-5)
- **Chart Time:** 20/06/62 0:00 (consistent across Documents 1-5)
- **Store Time:** 21/06/62 9:56 (consistent across Documents 1-5)","['# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n', '# Hypertension:\nHistory of hypertension, currently well controlled. He was warm \non exam. He was continued on home amlodipine 10, Coreg 50 BID \nand minoxidil 10 daily.\n\n# Acute on chronic anemia:\nHb o', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver', 'ACUTE PROBLEMS\n==============\n# Acute on chronic HFpEF: \nPatient presented with dyspnea and lower extremity edema and\nfound to be volume overloaded on exam. Warm and wet on exam.\nTrigger for HF exacer', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
"What is the prescribed dosage and administration schedule for sevelamer CARBONATE in the provided patient discharge information, and how might it relate to the patient's diagnosed conditions, particularly those affecting kidney function (e.g., CKD)?","['080dba33-29e9-4409-89cb-54a03af0e470\n\n8.  Levothyroxine Sodium 100 mcg PO DAILY  \n9.  Minoxidil 10 mg PO DAILY  \n10.  Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine  \n11.  sevelamer CARBONATE 800 mg PO TID W/MEALS  \n12.  Torsemide 100 mg PO DAILY  \n13.  Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY  \n14.  Vitamin D 1000 UNIT PO DAILY  \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPRIMARY DIAGNSOIS:\n==================\nAcute Hypoxemic Respiratory Failure\nAcute on Chronic Diastolic Heart Failure\nHyperglycemia, Type 2 Diabetes \n___ on CKD \nSECONDARY DIAGNOSIS:', '784a4f17-941d-40ee-a5aa-7471e6a5f600\n\n70/30 10 Units Lunch \n3.  Albuterol Inhaler 2 PUFF IH Q8H:PRN shortness of breath  \n4.  amLODIPine 10 mg PO DAILY  \n5.  Aspirin 81 mg PO DAILY  \n6.  Atorvastatin 80 mg PO QPM  \n7.  CARVedilol 50 mg PO BID  \n8.  Levothyroxine Sodium 100 mcg PO DAILY  \n9.  Minoxidil 10 mg PO DAILY  \n10.  Polyethylene Glycol 17 g PO DAILY:PRN Constipation - First \nLine  \n11.  sevelamer CARBONATE 800 mg PO TID W/MEALS  \n12.  Victoza 2-Pak (liraglutide) 0.6 mg/0.1 mL (18 mg/3 mL) \nsubcutaneous DAILY  \n13.  Vitamin D 1000 UNIT PO DAILY  \n \nDischarge Disposition:\nHome With Service\n \nFacility:\n___\n \nDischarge Diagnosis:\nPrimary Diagnosis:\n-Acute on chronic diastolic heart failure exacerbation\nSecondary Diagnosis:']","According to the discharge medication lists (nodes: 080dba33-29e9-4409-89cb-54a03af0e470 and 784a4f17-941d-40ee-a5aa-7471e6a5f600), the prescribed dosage for sevelamer CARBONATE is 800 mg, administered orally three times a day (PO TID) with meals. Sevelamer carbonate is often used to treat high phosphate levels in patients with chronic kidney disease (CKD). Given the patient's secondary diagnosis includes '___ on CKD' in one discharge summary and no explicit mention in the other, but both indicating the presence of kidney issues through CKD, the sevelamer carbonate is likely prescribed to manage hyperphosphatemia associated with CKD, thereby supporting the patient's renal health alongside other treatments for diagnosed conditions like Acute on Chronic Diastolic Heart Failure and Type 2 Diabetes.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Prescribed Dosage and Administration Schedule for Sevelamer CARBONATE:**

* **Dosage:** 800 mg
* **Administration Schedule:** PO (orally) TID (three times a day) W/MEALS (with meals)

**Source Documents:**
- **Document 1: Discharge Medications** (Content)
- **Document 3: Chronic Problems** (Content, under ""Medications on Admission"", though the context implies continuation of this medication upon discharge, as supported by Document 1)

**Relation to Diagnosed Conditions, Particularly Those Affecting Kidney Function (e.g., CKD):**

* **CKD (Chronic Kidney Disease):** Sevelamer carbonate is commonly prescribed to patients with CKD to control phosphorus levels in the blood. Elevated phosphorus (hyperphosphatemia) is a complication of CKD, as the kidneys are less effective at removing excess phosphorus. In **Document 4** (Content, under ""# ___ on CKD""), the patient's elevated creatinine (Cr) levels are discussed, indicating impaired kidney function. The prescription of sevelamer carbonate is likely aimed at managing the patient's phosphorus levels, though the specific phosphorus levels are not provided in the documents. **Document 4** also mentions the patient's phosphorus level as ""Phos-6.0*"" in the lab results, indicating an elevated level, which supports the rationale for sevelamer carbonate treatment.

**Metadata Relevance:**
- The same **Patient/Subject ID (13180007)**, **Note ID (13180007-DS-19)**, and **Admission ID (20774429)** are consistently mentioned across all documents (Document 1 through Document 5), confirming that all information pertains to the same patient and admission.","['Discharge Medications:\n1.  Torsemide 100 mg PO DAILY \nRX *torsemide 20 mg 5 tablet(s) by mouth once a day Disp #*70 \nTablet Refills:*0 \n2.  70/30 30 Units Breakfast\n70/30 10 Units Lunch \n3.  Albuterol', 'DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1', 'CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', '# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n', 'TRANSITIONAL ISSUES\n===================\n[ ] At discharge his symptoms associated with volume overload \nhad subsided, but he was still slightly volume up on exam with \n1+ edema to ankles bilaterally an']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
"What is the significance of continuing ASA (Aspirin) in the patient's treatment plan, given their medical history and recent hospitalization?","[""a6e734ef-1c30-4cb6-ba6d-41227251d4d0\n\nWhen he came home to ___, he apparently thought that he was\nstill in ___, confused his wife for his daughter. On\n___ morning, he fell again. He was confused about the\nconfiguration of the bathroom (no tub in bathroom in PR), so he\ntripped and fell, called his daughter in tears (he often gets\nemotional since his CVA). She booked an appointment for same \nday,\nat which his FSBG>500, HbA1c (point of care, not in OMR) was\n15.0%. He declined to be transferred to the ED. Daughter ___\nwas on vacation from work, and so was able to check on him\nregularly. During these visits, she again established that he is\nnot taking prescribed medications. On the morning of\npresentation, pt's wife called daughter ___, concerned that \npt\nwas increasingly confused. FSBG was >500, and administered\nTresiba 50u at about 8 am. Pt called ___ about 15 minutes\nlater, at which time she again noted confusion and slurred\nspeech, which has intermittently been present since his CVA.\nDecision was made to bring him to the ED. \nOf note, during his last hospitalization ___, he had an\nepisode of dysarthria with confusion and mild expressive and\nreceptive aphasia for which code stroke was called. MRI/MRA \nbrain\nand EEG were unrevealing, with chronic changes and EEG slowing\nonly. He was continued on ASA and atorvastatin."", 'd2113a66-fe4f-4869-b3c0-73646862b32b\n\ngluconate (received 3 doses ___. Upon review of recent \noutpatient visit notes, it appears his volume exam is similar to \nbaseline, and patient was asymptomatic during hospital course. \nHe was diuresed effectively with IV Lasix 80. He was \ntransitioned to PO torsemide 100. His BP was well controlled \nwith regimen as described below.\n# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\nat or lower than levels earlier this year. He has denied chest\npain during admission. He does have risk factors for ischemia \nand\nhas not had stress since ___. However, findings and history \nto\ndate are not suggestive of ischemia and he has an ___. TTE did \nnot show evidence of focal wall motion abnormalities or other \nfindings suggestive of ischemia, so further workup was not \npursued. He was continued on ASA and atorvastatin.\n# ___ on CKD:\nCr elevated to 2.6 on admission from baseline of 1.8-2.2. Given\nevidence of congestion elsewhere, concerns for renal congestion\ncausing renal dysfunction. Cr remained stable and was 2.9 on day \nof discharge. He was continued on home sevelamer.']","The patient was continued on ASA (Aspirin) and atorvastatin, indicating that these medications are crucial for managing the patient's condition. Given the patient's history of CVA (Cerebrovascular Accident) with episodes of dysarthria, confusion, and aphasia, ASA is likely prescribed for its antiplatelet effects to prevent further cerebrovascular events. Additionally, the patient has risk factors for ischemia, although recent findings were not suggestive of ischemia. ASA's continuation suggests its importance in primary or secondary prevention of cardiovascular events, aligning with the patient's overall cardiovascular and cerebrovascular risk management.",custom_multi_hop_query_synthesizer,"**Answer to the Current Question**

**Significance of Continuing ASA (Aspirin) in the Patient's Treatment Plan:**

Based on the provided documents, the significance of continuing ASA (Aspirin) in the patient's treatment plan can be inferred from their medical history and the context of their recent hospitalization.

1. **Medical History Context:**
	* **Document 1 (CONTENT, #History of CVA)**: The patient has a history of Cerebrovascular Accident (CVA), commonly known as a stroke. Aspirin is often prescribed long-term after a CVA to reduce the risk of further ischemic events.
	* **Document 3 (CONTENT, Past Medical History)**: The patient also has a history of carotid artery disease and extensive intracranial atherosclerosis, which increases the risk of ischemic events. Aspirin's antiplatelet effect is beneficial in managing these conditions.
2. **Recent Hospitalization Context:**
	* **Document 2 (CONTENT, # Chest pain)**: Although the patient presented with chest pain, the findings were not suggestive of ischemia, and further workup was not pursued. However, given the patient's risk factors for ischemia (as mentioned in the document), continuing ASA is prudent for primary and secondary prevention of cardiovascular events.
	* **Document 4 (CONTENT, Brief Hospital Course SUMMARY)**: The patient was admitted for Heart Failure with preserved Ejection Fraction (HFpEF) exacerbation. While ASA is not directly treating HFpEF, its continuation is justified by the patient's broader cardiovascular disease profile.

**Conclusion:**
Continuing ASA (Aspirin) in the patient's treatment plan is significant for the primary and secondary prevention of ischemic cardiovascular events, given their history of CVA, carotid artery disease, intracranial atherosclerosis, and risk factors for ischemia, despite the recent hospitalization being primarily for HFpEF exacerbation.

**ID Values as per Metadata (for completeness, as per instruction 3):**
- **Patient/Subject ID**: 13180007 (consistent across all documents)
- **Note ID**: 13180007-DS-19 (consistent across all documents)
- **Admission ID**: 20774429 (consistent across all documents)","['CHRONIC PROBLEMS\n================\n#Hypothyroidism\nHe was continued on home levothyroxine 100mcg daily.\n\n#History of CVA\nHe was continued on home aspirin and atorvastatin 80.\n \nMedications on Admission', '# Chest pain: \nNo known history of CAD. Presented with chest pain and mild\ntroponin elevation with flat CK-MB. As noted above, troponin\nelevation difficult to interpret in setting of CKD, and appears\n', 'Studies notable for:  \n-CXR:  Mild pulmonary vascular congestion with small bilateral\npleural effusions, left greater than right. \n\nVitals on transfer: T 97.3, HR 88, BP 120/54, RR 18, SpO2 98% RA \n\n\n', 'DISCHARGE LABS\n==============\n\n___ 06:35AM BLOOD WBC-5.4 RBC-2.92* Hgb-7.6* Hct-24.3* \nMCV-83 MCH-26.0 MCHC-31.3* RDW-15.9* RDWSD-47.8* Plt ___\n___ 06:35AM BLOOD Glucose-164* UreaN-51* Creat-2.9* Na-1', 'Name:  ___              Unit No:   ___\n \nAdmission Date:  ___              Discharge Date:   ___\n \nDate of Birth:  ___             Sex:   M\n \nService: MEDICINE\n \nAllergies: \nNo Known Allergies / Adver']","[{'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}, {'note_id': '13180007-DS-19', 'subject_id': '13180007', 'hadm_id': '20774429', 'charttime': '20/06/62 0:00', 'storetime': '21/06/62 9:56'}]"
